<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2025-11-03 09:16:44 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis.
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. G. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature medicine, Nature Network Boston</td>
          <td>79</td>
          <td>47</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, S. Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>131</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Z. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, Joan Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>51</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aea7049b4e71c37e1947582309f6a97454e33576" target='_blank'>
              Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours.
              </a>
            </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, Jessica Le Berichel, Maximilian M Schaefer, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Assaf Magen, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Kaili Fan, Dughan Ahimovic, Michael J. Bale, K. Nie, Grace Chung, D. D’souza, K. Angeliadis, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, Jason D. Buenrostro, S. Josefowicz, A. Tsankov, T. Marron, Sai Ma, Brian D Brown, Miram Merad
          </td>
          <td>2025-09-10</td>
          <td>Nature</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="Chronic graft-versus-host disease (cGVHD) frequently follows allogeneic hematopoietic stem cell transplantation and impacts the mucosa. This atlas study highlights the role of exhausted-like effector CD8+ T cells (TEXEF) in oral mucosal cGVHD pathogenesis. Biopsies from the oral mucosa were collected at oral cGVHD onset or at six months post-transplant and analyzed using single-cell RNA sequencing and other modalities. At cGVHD onset, in addition to changes in the myeloid compartment, two distinct populations of CD8+T cells with a TEXEF phenotype were prevalent: an inflammatory CD8T cell cluster (CD8T_4) expressing CCL4, CD69, and TNFSF9, and an exhausted CD8T cell cluster (CD8T_5) characterized by the expression of CXCL13, HIF1A, and HLA-DRA, both correlated with clinical disease severity. Pseudo-time analysis suggests a transition from the inflammatory pre-exhausted CD8T_4 cluster to the cytolytic, terminally exhausted CD8T_5 cluster. The CXCL9-CXCR3 interactions among CD8+ T cells, fibroblasts and myeloid cells are implicated in tissue damage. Onset of cGVHD despite frequent oral mucosal FOXP3⁺ regulatory CD4⁺T cells suggests potential impaired Treg function or CD8+T cell dysfunction. These findings highlight TEXEF cells as key contributors to oral cGVHD pathology and potential therapeutic targets for mitigating sustained tissue injury in cGVHD.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6d284cca909c27cba4b0530f9740be31da2b9880" target='_blank'>
              Exhausted-like effector CD8 T cells mediate immune-stromal interactions at mucosal Chronic Graft-versus-Host Disease onset
              </a>
            </td>
          <td>
            A. C. Costa-da-Silva, Rubina Sharma, M. Aure, D. Martin, Noemi Kedei, Damilola F. Killanin, A. Javaid, Francis A Boksa, Drashty P Mody, J. Nguyen, S. Ganesan, Joshua T. Dodge, Clara H. Kim, Marie Kao-Hsieh, David E. Kleiner, C. Kanakry, S. Pavletic, J. W. Mays
          </td>
          <td>2025-09-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>73</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1c809269d9254558fb4308ec6c19a38c6246f527" target='_blank'>
              STING activation reshapes the tumor microenvironment leading to tumor regression in osteosarcoma
              </a>
            </td>
          <td>
            Elizabeth P Young, , Alex G Lee, Douglass Morris, Jessica Tsui, Marcus R. Breese, Juan Antonio, Camara Serrano, Courtney R Schott, Clare L. Abram, Stanley G. Leung, L. Sayles, Aafrin M. Pettiwala, Vanessa S Gutierrez Vera, Clifford A. Lowell, Alexis J. Combes, T. A. McEachron, A. Sweet-Cordero
          </td>
          <td>2025-10-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/db216fc3d5be7dbd3db4a74639b3258d970f9b5a" target='_blank'>
              Reinvigoration of translational activity in dysfunctional T cells initiates the early intratumoral response to PD-1 blockade
              </a>
            </td>
          <td>
            Paulien Kaptein, Nadine Slingerland, A. M. van der Leun, Eline Runderkamp, Roos A. Wagensveld, S. Michael Chin, Janniek R. Mors, M. Machuca-Ostos, Timm M. Reissig, K. Moynihan, I. Djuretic, Y. A. Yeung, T. Schumacher, D. Thommen
          </td>
          <td>2025-09-27</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="ABSTRACT Lymphotoxin β receptor (LTβR/TNFRSF3) signaling plays a crucial role in immune defense. Notably, LTβR-deficient (LTβR-/-) mice exhibit severe defects in innate and adaptive immunity against various pathogens and succumb to Toxoplasma gondii infection. Here, we investigated the bone marrow (BM) and peritoneal cavity (PerC) compartments of LTβR-/- mice during T. gondii infection, demonstrating perturbed B-cell and T-cell subpopulations in the absence of LTβR signaling. T. gondii infection disrupted BM lymphopoiesis, depleting early and mature B cells in WT mice, whereas mature B cells remained present in LTβR-/- BM. LTβR-/- BM also exhibited reduced MHCII+ monocytes and a plasma cell compartment skewed toward IgM+ rather than IgA+ cells. In addition, BM Tcell subsets were altered, exhibiting decreased double-negative (CD4-/CD8-) and increased CD4+ and CD8+ T-cell frequencies. Analysis of the BM transcriptome revealed diminished interferon responses but an upregulated TNFα-NF-κB signaling signature in uninfected and infected LTβR-/- mice, potentially compensating for the absence of LTβR signaling. LTβR-/- mice displayed an altered B-1a to B-1b ratio and a predominant presence of neutrophils in the PerC. In summary, we identified novel immunological alterations in the BM and PerC compartments of LTβR-/- mice, which suggest new roles for LTβR signaling in B- and T-cell homeostasis, migration, and pathogen defense.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5f45e29b5cb5a70cb38b7791d56ec73e803082c" target='_blank'>
              Lymphotoxin beta receptor-/- mice display altered B- and T-cell subpopulations in the bone marrow and peritoneal cavity after Toxoplasma gondii infection
              </a>
            </td>
          <td>
            M. Helle, Ursula R Sorg, Johannes Ptok, Rachel E Thomas, Katharina Pracht, Patrick Petzsch, Alain de Bruin, Hans-Martin Jäck, K. Köhrer, D. Degrandi, K. Pfeffer
          </td>
          <td>2025-09-09</td>
          <td>Infection and Immunity</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Abstract Background Chimeric antigen receptor (CAR) T cells targeting CD19 induce durable responses in B-cell acute lymphoblastic leukemia (B-ALL). However, the contribution of the tumor microenvironment to the therapeutic response after CAR T-cell treatment remains incompletely understood. Methods We performed single-cell RNA sequencing and spectral flow cytometry-based analyses of bone marrow-resident immune cells from B-ALL patients before and after CAR T-cell treatment. Results We observed profound changes in the microenvironment in response to CAR T-cell-mediated inflammation, including an increase in myeloid cells. Significant induction of the interferon response, hypoxia, and TGF-β signaling was accompanied by expansion of myeloid-derived suppressor cells (MDSCs) and endogenous exhausted CD8+ T cells. PD-1 expression in endogenous T cells post-treatment was associated with a lack of durable response in the cohort of patients analyzed. Further, we revealed that HIF-1α, VEGF, and TGFBR2 are key players in the intercellular communication between CAR T cells and the immune niche, potentially driving widespread T-cell dysfunction. Infusion of anti-CD19 CAR T cells led to increased accumulation of human MDSCs, exacerbation of a hypoxic environment and T-cell exhaustion in hematopoietic stem/progenitor cell-humanized mice bearing a human tumor. Conclusions In conclusion, CAR T-cell-mediated myeloid activation is associated with pathways of immune dysregulation that may antagonize the effects of therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e17ba18b5c3d494ffd54cbb6fc378f9f236571c2" target='_blank'>
              Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance
              </a>
            </td>
          <td>
            Marianna Ponzo, Lorenzo Drufuca, C. Buracchi, Marco M. Sindoni, Silvia Nucera, C. Bugarin, Ramona Bason, G. Rossetti, R. Bonnal, Cristian Meli, B. Rambaldi, F. Lussana, Silvia Ferrari, Alex Moretti, G. Dastoli, Giulia Risca, C. Pellegrino, M. Manz, Stefania Galimberti, A. Rambaldi, G. Gaipa, A. Biondi, Massimiliano Pagani, Chiara F Magnani
          </td>
          <td>2025-10-23</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Background Metastatic lung carcinoma poses considerable treatment difficulties. It exhibits cellular characteristics that differ from those of early-stage cancer. Immunotherapy demonstrates enhanced hope for patients with advanced and metastatic lung cancer. Tumor-associated macrophages (TAMs) may be a contributing factor that diminishes the effectiveness of immunotherapy. Secreted phosphoprotein 1 (SPP1)+ TAMs are considered to possess immunosuppressive characteristics, as their interaction with CD8+ T lymphocytes results in the exhaustion of these cells. Methods We analyzed single-cell RNA sequencing datasets of lung cancer metastases in order to examine the development of brain metastatic tumors. Furthermore, the cell–cell interactions between SPP1+ TAM cells and CD8+ T cells within primary and brain metastatic cancers were systematically compared. Additionally, we utilized a flow cytometer and immunofluorescence to demonstrate how SPP1 affects the function of CD8+ T cells. In vitro, we generated SPP1-overexpressing macrophages and performed qPCR, Western blot, and co-culture assays with or without anti-SPP1 or anti-A2AR treatment to evaluate immunosuppressive effects. Results The results demonstrated that the proportions of immune cells in metastatic brain tissues are lower, while the infiltration of macrophages is higher. SPP1+ TAMs contribute to immune suppression in lung cancer by limiting the activation of CD8+ T cells and cytokine production. Anti-SPP1 treatment positively impacts CD8+ T cell function, counteracting SPP1-induced dysfunction and facilitating the production of cytokines. SPP1 overexpression in macrophages enhanced their immunosuppressive phenotype by upregulating CD73 and cytokines such as IL-10 and TGF-β, leading to impaired CD8⁺ T cell function via A2AR signaling; notably, neutralization of SPP1 or A2AR successfully restored CD8⁺ T cell activity. Conclusions Our findings characterize the immunological environment of both primary and metastatic lung cancer, highlighting SPP1-mediated immune suppression as a potential therapeutic target to restore T cell responses. Preclinical data demonstrate that Anti-SPP1 antibodies can reverse T cell exhaustion and enhance immune responses in lung cancer. Supplementary Information The online version contains supplementary material available at 10.1007/s00262-025-04180-3.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/659292b315a12f27348d32dba8f9ec9a4a03cedd" target='_blank'>
              Single-cell transcriptomic analyses provide insights into SPP1+ TAM-mediated immune suppression and CD8+ T cell dysfunction in lung cancer
              </a>
            </td>
          <td>
            Rahma Taher Almgrami, Tengyue Zhang, Qitai Zhao, Mingming You, Jinyan Liu, Yi Zhang
          </td>
          <td>2025-09-29</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1ff24f2e8ab0ac14f953e55e0ecee156943f456a" target='_blank'>
              Longitudinal profiling of tumor-reactive T cells during TIL therapy in metastatic melanoma
              </a>
            </td>
          <td>
            M. Sandholzer, Clara Serger, Alessia G. Liner, Sarp Uzun, David König, H. Thut, R. Ritschard, Jonas D. Fürst, Andreas Zingg, N. Rodrigues Mantuano, B. Kasenda, K. Glatz, E. Kappos, Matthias Matter, A. Holbro, F. Stenner, J. Passweg, Nina Khanna, L. Jeker, Mascha Binder, A. Zippelius, Heinz Läubli
          </td>
          <td>2025-09-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/952046f90f3d6fd3b65c4bc71397ef55777b1e4f" target='_blank'>
              Albumin-STING Nanoagonist Reprograms HSPCs to Antitumor Neutrophils Enhancing MHC I–Mediated CD8⁺ T Cell Immunity
              </a>
            </td>
          <td>
            Jinsong Tao, Hong-Yi Zhao, Chengyi Li, Hanning Wen, Fang Ke, Qiuxia Li, Miao He, Bo Wen, Zhongwei Liu, Wei Gao, Duxin Sun
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc9320984fb7ca80afa8b2d49d724dd86390a378" target='_blank'>
              Transposable Elements and Homotypic Niches Drive Immune Dynamics and Resistance in Melanoma Epigenetic-based immunotherapy
              </a>
            </td>
          <td>
            Erika Ciervo, Francesco Ceccarelli, A. D. Di Giacomo, Piera Grisolia, A. Covre, Z. M. Besharat, Antonio De Falco, F. Caruso, Luigi Laezza, Luigi Ferraro, Gloria Mas Martin, M. F. Lofiego, Tommaso Sani, E. Ferretti, Yan Guo, Sean B. Holden, R. Mortarini, A. Anichini, M. Maio, T. Noviello, M. Ceccarelli
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="Abstract Background LKB1 (STK11)-deficient tumors exhibit an immunosuppressive microenvironment that limits the efficacy of immunotherapies such as anti-programmed cell death protein 1 (PD-1) antibodies. However, the underlying mechanisms driving immune evasion remain unclear. Dendritic cells (DCs), especially conventional DC 1 (cDC1), play a crucial role in antigen presentation and CD8+ T-cell activation, yet their dysfunction in LKB1-deficient tumors has not been well characterized. Methods Tumor-intrinsic LKB1 deficiency was modeled by subcutaneous inoculation of CRISPR/Cas9-engineered Stk11-knockout tumor cell lines into syngeneic mice. DC infiltration and function were assessed through a series of flow cytometry-based in vivo and in vitro assays, including analyses of infiltration, migration, antigen uptake, maturation, and CD8+ T-cell priming. Naïve CD8+ T-cell activation by cDC1s was evaluated via adoptive transfer of CD45.1+ OT-I T cells. Secretome proteomics and functional rescue experiments identified anterior gradient 2 (AGR2) as a key immunosuppressive mediator, and arginase 1 (ARG1) was validated as its functional interactor through liquid chromatography-tandem mass spectrometry (LC-MS/MS), co-immunoprecipitation, and imaging flow cytometry. Upstream regulation of AGR2 was investigated by AMPKα/FOXA1 silencing and chromatin immunoprecipitation (ChIP) quantitative PCR, revealing a tumor-intrinsic AMPKα–FOXA1–AGR2 axis driving DC dysfunction. Results LKB1-deficient tumors exhibited significantly reduced cDC1 infiltration, and cDC1s were functionally impaired in antigen uptake, migration, and naïve CD8+ T-cell priming. AGR2, a secreted protein transcriptionally upregulated via the tumor-intrinsic AMPKα–FOXA1 pathway, was identified as a key mediator of DC dysfunction. Mechanistically, AGR2 interacted with ARG1, stabilizing its expression and promoting ARG1 accumulation in DCs. Restoring DC infiltration and activity through FLT3L-driven expansion and tumor-antigen–specific DC supplementation significantly enhanced the efficacy of anti-PD-1 treatment in LKB1-deficient lung adenocarcinoma models. Conclusion Our study identifies profound DC dysfunction—characterized by impaired antigen uptake, migration, and naïve CD8+ T-cell priming—as a key mechanism of immune evasion in LKB1-deficient tumors. This dysfunction is driven by tumor-secreted AGR2, which stabilizes ARG1 in DCs and suppresses CD8+ T-cell activation. Targeting the AMPKα–FOXA1–AGR2–ARG1 axis or restoring DC competence offers a promising strategy to enhance immunotherapy efficacy in LKB1-deficient subtype.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e07849093d53dea4843df9f47992371aef80f74" target='_blank'>
              Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer
              </a>
            </td>
          <td>
            Yuxin Yao, Yuejun Luo, Zhanyu Wang, Enzhi Yin, Chengming Liu, Sufei Zheng, Xinfeng Wang, Xiaoya Tang, Nan Sun, Jie He
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5941ecec7872e6e7a4fe85dc2f11895a3625725" target='_blank'>
              PD-1 signaling is essential for the early accumulation of HBV-specific CD8+ T cells during HBV infection
              </a>
            </td>
          <td>
            Xiaoqing Zeng, Wen Pan, Ziwei Li, Zhaoli Liu, Hongming Huang, Xuecheng Yang, K. Sutter, Mengji Lu, Ulf Dittmer, Gennadiy Zelinskyy, Xin Zheng, Dongliang Yang, P. Kennedy, Yanqin Du, Jia Liu
          </td>
          <td>2025-09-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Introduction A comprehensive characterization of immune cells within the tumor microenvironment (TME) of cervical squamous cell carcinoma (CSCC) is essential to advance understanding of tumor biology and guide immunotherapy development. Methods Using single-cell RNA sequencing, we analyzed 14,441 immune cells isolated from tumor tissues and paratumor tissues of three CSCC patients. By integrating data on tumor suppressors, oncogenic factors, cytokines, and chemokines, we performed differential gene expression analyses across immune populations. Results This analysis identified nine major immune cell subsets, including CD8+ T cells, regulatory T cells (Tregs), natural killer/T cells (NK/T cells), B cells, plasmacytoid dendritic cells (pDCs), and macrophages. Notably, elevated CCR7 expression in exhausted CD8+ T cells was associated with improved prognosis, suggesting it as a preliminary candidate for an immunoregulatory target that warrants further investigation. Additionally, CCL5 levels were elevated in Tregs, indicating a possible involvement in their recruitment to the tumor site that requires further validation. Furthermore, differential gene expression analysis identified candidate genes for further mechanistic investigation. Discussion This systematic comparison of the TME between tumor and paratumor tissues reveals dynamic changes in the immune landscape, providing insights and suggesting potential targets for further study to enhance understanding and treatment of CSCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/37a843f84193a8f20739341bcfd74ef25632d521" target='_blank'>
              Profiling of immune cell subsets and functional characteristics of cervical cancer based on single cell RNA sequencing
              </a>
            </td>
          <td>
            Yue Yuan, Dejun Sun, Mingyue Yang, Ying Xia, Chunli Yuan, Xiaosong Wang
          </td>
          <td>2025-09-25</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b829e516ebd849b779eb9a27bfa0536b868f851" target='_blank'>
              Regulatory T cells inhibit CD8+ TRM-like cells during the early stages of tumor immune escape
              </a>
            </td>
          <td>
            Jason B. Williams, Shishir M. Pant, Alexander L. Kley, Bharat A. Rajmalani, Clarence Yapp, Jiang Zhang, Kyle Deans, E. Rotrosen, Angelika Sales, Peter K. Soger, Thomas S. Kupper
          </td>
          <td>2025-10-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb6cd3cc9c09de4de9afc685bf10e2503b30b407" target='_blank'>
              Identifying Distinct Molecular Response of CAR-T cells to Solid Tumors by Synthetic Single-Cell Transcriptomic Analyses
              </a>
            </td>
          <td>
            Yi Hui Luo, Elisabetta Forte, Yoshiaki Tanaka
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="The immunosuppressive tumor microenvironment (TME) drives radioresistance, but the role of γδ T cells in regulating radiosensitivity remains incompletely understood. In this study, we found that γδ T cell infiltration in the TME substantially increased after radiotherapy and contributed to radioresistance. Depletion of γδ T cells enhanced radiosensitivity. Single-cell RNA sequencing revealed that γδ T cells in the post-radiotherapy TME were characterized by the expression of Zbtb16, Il23r, and Il17a, and served as the primary source of IL-17A. These γδ T cells promoted radioresistance by recruiting myeloid-derived suppressor cells and suppressing T cell activation. Mechanistically, radiotherapy-induced tumor cell-derived microparticles containing dsDNA activated the cGAS-STING/NF-κB signaling pathway in macrophages, upregulating the expression of the chemokine CCL20, which was critical for γδ T cell recruitment. Targeting γδ T cells and IL-17A enhanced radiosensitivity and improved the efficacy of radiotherapy combined with anti-PD-1 immunotherapy, providing potential therapeutic strategies to overcome radioresistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b1efdac109d7acd0476c2a995db227fa1bebc94" target='_blank'>
              IL-17-producing γδ T cells in the tumor microenvironment promote radioresistance in mice.
              </a>
            </td>
          <td>
            Yue Deng, Xixi Liu, Xiao Yang, Wenwen Wei, Jiacheng Wang, Zheng Yang, Yajie Sun, Yan Hu, Haibo Zhang, Yijun Wang, Zhanjie Zhang, Lu Wen, Fang Huang, Kunyu Yang, Chao Wan
          </td>
          <td>2025-10-07</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Neutrophils, a first-line defender, has a multifaceted presence in chronic inflammation, autoimmune pathology, and tumor progression. The microenvironmental cues facilitate functional plasticity and phenotypic heterogeneity to neutrophils that enable both their protective and pathogenic roles. Autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and juvenile idiopathic arthritis (JIA) display the presence of dysregulated subsets of neutrophil, such as low-density granulocytes (LDGs) that promote proinflammation and contribute to tissue damage via NETosis and type I interferon-mediated signaling. In cancer, particularly tumors, they exhibit tumor-associated neutrophils (TANs) which may polarize either towards anti-tumorigenic ‘N1’ or pro-tumorigenic ‘N2’ phenotypes based on available modulators such as TGF-β and leucine-driven epigenetic modifications. The development in neutrophil biology has introduced several novel therapeutic strategies that allow NET targeting, inhibition of chemokine receptors like CXCR2, and exploration of neutrophil-derived biomarkers for diagnosis and disease monitoring. Such findings encourage the importance of neutrophils as both effectors and therapeutic targets in inflammatory and neoplastic conditions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/297b618276da8a976275300915cf5f9bf45c76b8" target='_blank'>
              Roles of Neutrophils in Autoimmune Diseases and Cancers
              </a>
            </td>
          <td>
            Anjali Bhargav, Vinay Kumar, N. Rai
          </td>
          <td>2025-09-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5268b5f8f5e67d2ca0369f9fa75cc7835efa85a7" target='_blank'>
              Anti-CD206 CAR T Cell Treatment Restores Fibrosis-Induced Loss of Dermal White Adipose Tissue
              </a>
            </td>
          <td>
            Chanhyuk Park, , Helen C. Jarnagin, Rajan Bhandari, Jason Gunn, Joana M. Murad-Mabaera, Noelle N Kosarek, Fred W. Kolling, Owen M. Wilkins, Yina H. Huang, Michael Whitfield, Patricia A. Pioli
          </td>
          <td>2025-10-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b846de35114daacf2b8cb62d0ddc0dc54e1e9471" target='_blank'>
              Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy
              </a>
            </td>
          <td>
            Lior Goldberg, Eric R Haas, Jiaqi Wu, Bryan Garcia, Ryan Urak, Vibhuti Vyas, Ruby Espinosa, Tamara Munoz, Shirley Bierkatz, K. Pathak, Nathaniel P. Hansen, P. Pirrotte, Jyotsana Singhal, J. Figarola, Ricardo Zerda Noriega, Zhuo Li, Dasol Wi, Erin Tanaka, Ramon I. Klein Geltink, Min-Hsuan Chen, Xiwei Wu, J. Wagner, Jinny A Paul, Mary C. Clark, Dat Ngo, Ibrahim Aldoss, Stephen J. Forman, Xiuli Wang
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our understanding of multiple myeloma (MM) pathogenesis and supports the development of novel therapeutic strategies. In this analysis, single-cell RNA sequencing, surface protein profiling, and B lymphocyte antigen receptor profiling of unsorted, whole bone marrow (BM) mononuclear cell samples was used to study molecular changes in tumor cells and the tumor microenvironment (TME). A cell atlas of the BM microenvironment was generated from 123 subjects including healthy volunteers and patients with monoclonal gammopathy of unknown significance (MGUS), smoldering MM (SMM), and MM. These analyses revealed commonalities in molecular pathways, including MYC signaling, E2F targets and interferon alpha response, that were altered during disease progression. Evidence of early dysregulation of the immune system in MGUS and SMM, which increases and impacts many cell types as the disease progresses, was found. In parallel with disease progression, population shifts in CD8 + T cells, macrophages, and classical dendritic cells were observed, and the resulting differences in CD8 + T cells and macrophages were associated with poor overall survival outcomes. Potential ligand-receptor interactions that may play a role during the transition from precursor stages to MM were identified, along with potential biomarkers of disease progression, some of which may represent novel therapeutic targets. MIF, IL15, CD320, HGF and FAM3C were detected as potential regulators of the TME by plasma cells, while SERPINA1 and BAFF (TNFSF13B) were found to have the highest potential to contribute to the downstream changes observed between precursor stage and MM cells. These findings demonstrate that myeloma tumorigenesis is associated with dysregulation of molecular pathways driven by gradually occurring immunophenotypic changes in the tumor and TME. Trial registration: This project has been registered at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with protocol number NOPRODMMY0001 and EudraCT Number 2018-004443-23 on 12 December 2018.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/98a4e027d57002b46ccf88e1aa10930bce31da48" target='_blank'>
              Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma
              </a>
            </td>
          <td>
            Isabelle Bergiers, M. C. Köse, Sheri Skerget, Milan Malfait, N. Fourneau, Jenna-Claire Ellis, Greet Vanhoof, Tina Smets, Bie Verbist, Dries De Maeyer, Jeroen Van Houdt, Koen Van der Borght, Raluca Verona, Bradley Heidrich, William Kurth, Michel Delforge, Nathalie Meuleman, Jan Van Droogenbroeck, P. Vlummens, Christoph J Heuck, Yves Beguin, Nizar J. Bahlis, T. Casneuf, J. Caers
          </td>
          <td>2025-10-01</td>
          <td>PLOS Genetics</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Abstract Background Patients with colon cancer liver metastases (CCLM) frequently exhibit poor responses to immunotherapy, a phenomenon attributed in part to an immune desert tumor microenvironment. This study aimed to comprehensively characterize the immune landscape in primary colon cancers and their matched liver metastases via single-cell transcriptome analysis, with the goal of identifying potential immunotherapeutic targets. Methods Tumor specimens from patients with CCLM were subjected to single-cell RNA sequencing. Immune subpopulations were profiled with emphasis on exhausted T cells (Tex)—including both CD8+ and CD4+ ANK3+ subsets—as well as on a distinct stress response T-cell subset (TSTR) defined by high HSPA1A/HSPA1B expression. In parallel, we performed assessments of the phenotype and prognostic impact of SPP1high myeloid cells, along with in vitro assays to examine their role in modulating T-cell number and function. Results Liver metastatic lesions exhibited a significantly elevated infiltration of Tex compared with primary tumors. Notably, Tex cells exhibited upregulated expression of exhaustion-related marker genes such as ANK3, ZBTB20, ETV6, and CAMK4, which were markedly downregulated in TSTR cells. TSTR was identified as an intermediate developmental state between effector and exhausted T cells in patients with CCLM, suggesting that TSTR cells represent a distinct state from exhausted T cells. Furthermore, myeloid cells expressing high levels of secreted phosphoprotein 1 (SPP1), along with apolipoprotein C-I and apolipoprotein E, were associated with poor prognosis in patients with CCLM. In vitro studies revealed that Macro_SPP1high cells diminished T-cell populations and triggered a stress response state in both CD4+ and CD8+ T cells via the SPP1/CD44/PI3K/AKT signaling pathway in a CD44-dependent manner. Importantly, combination treatment with anti-SPP1 and anti-programmed cell death protein-1 antibodies significantly inhibited liver metastasis growth, enhanced dendritic cell maturation, decreased M2-polarized macrophages, and restored T-cell infiltration and function. Conclusions These findings reveal a previously unrecognized relationship between Macro_SPP1high cells and HSPA1Ahigh/HSPA1Bhigh T cells in driving CCLM progression, suggesting a potential synergistic therapeutic approach that could boost immune checkpoint treatment efficacy in patients with CCLM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/70332185d211e11f66dfe54e607751159e5a3aea" target='_blank'>
              SPP1high macrophage-induced T-cell stress promotes colon cancer liver metastasis through SPP1/CD44/PI3K/AKT signaling
              </a>
            </td>
          <td>
            Dongbing Ding, Weibo Li, Jiannan Ren, Yiquan Li, Guangchun Jiang, Rongpu Liang, He Huang, Jiarong You, Yuan Wang, Bo Wei
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="The infiltration of myeloid-derived suppressor cells (MDSCs) is critical for the establishment of immunosuppressive tumor microenvironment (TME), yet no approved therapies specifically block it. Here, we employed a gene signature-based drug screening approach to identify potential agents for reversing MDSC-mediated immunosuppression in triple-negative breast cancer (TNBC). Transcriptomic analysis of 73,326 tumor samples and 190,588 single cells revealed C-X-C motif ligand 1 (CXCL1) and CXCL2 as the key gene signature of MDSC infiltration. Combining this gene signature with high-throughput sequencing-based high-throughput screening (HTS2), we identified ponatinib as a potential inhibitor of MDSC infiltration. By employing multiple preclinical models, we demonstrated that ponatinib blocks MDSC infiltration and reverses the immunosuppressive TME, thus inhibiting TNBC growth in a TME-dependent manner, and significantly enhances anti-programmed cell death-ligand 1 (PD-L1) immunotherapy efficacy. Mechanistically, ponatinib directly inhibits p38α kinase activity, reducing signal transducer and activator of transcription 1 (STAT1) phosphorylation at Ser727 and suppressing CXCL1 and CXCL2 expression in cancer cells, thereby blocking MDSC infiltration. Our findings establish ponatinib as a novel inhibitor of MDSC-mediated immunosuppressive TME and underscore its therapeutic potential in combination with immune checkpoint blockade for TNBC treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc90db7dd199fb8de970dffa7d826b02f123cd75" target='_blank'>
              Gene Signature-Based Drug Screening Reveals Ponatinib Enhances Immunotherapy Efficacy in Triple-Negative Breast Cancer by Reversing MDSC-Mediated Immunosuppressive Tumor Microenvironment
              </a>
            </td>
          <td>
            Qianyu Wang, Shasha Li, Yuan Wu, Xiankuo Yu, Yifei Dai, Yumei Wang, Lu Li, Ming Yang, Kequan Lin, Wei Shao, Haiyan Wang, Huili Wang, Guanbin Zhang, Dong Wang
          </td>
          <td>2025-09-10</td>
          <td>Research</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/652af720fe035d258a47aa0abc6ca14da634c448" target='_blank'>
              Cytotoxic Vδ2+ T cell subsets expand in response to malaria in human tonsil and spleen organoids
              </a>
            </td>
          <td>
            K. Press, Florian Bach, Elsa Sola, Kylie Camanag, Nicholas L Dooley, Anselma Ivanawati, Damian Oyong, Mayimuna Nalubega, Abel Kakuru, Sedrack Matsiko, Nankya Felistas Namirimu, Kenneth Musinguzi, Annet Nalwoga, Evelyn Nansubuga, Johnie Ategeka, Ebusu Charles, Odongo Bakar, Chloe Kashiwagi, Xuhuai Ji, Molly Miranda, Joselyn Tachiwa-Appiah, Kareena Sandhu, Lilit Kamalyan, K. van der Ploeg, Michelle J. Boyle, Lisa E. Wagar, Mark M Davis, P. Jagannathan
          </td>
          <td>2025-09-27</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e0439a6de8243c20d60a46c125842a0d34a0ceda" target='_blank'>
              RELB Reprograms Exhausted Tumor-Infiltrating Lymphocytes for Improved Adoptive Cell Therapy
              </a>
            </td>
          <td>
            Christian D. McRoberts Amador, Rachel E. Conover, Michael C. Brown, Liliana S. Lyniv, P. Noldner, Ying Zhou, Aretha R. Gao, Sean R. McCutcheon, S. Antonia, Charles A. Gersbach
          </td>
          <td>2025-10-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="The immune ecosystem is central to maintaining effective defensive responses. However, it remains largely understudied how immune cells in the peripheral blood interact with circulating tumor cells (CTCs) in metastasis. Here, blood analysis of patients with advanced breast cancer revealed that over 75% of CTC-positive blood specimens contained heterotypic CTC clusters with CD45+ white blood cells (WBCs), which correlates with breast cancer subtypes, racial groups, and decreased survival. CTC-WBC clusters included overrepresented T cells and underrepresented neutrophils. Specifically, a rare subset of CD4 and CD8 double-positive T (DPT) cells was 140-fold enriched in CTC clusters versus their frequency in WBCs. DPT cells shared properties with CD4+ and CD8+ T cells but exhibited unique features of T cell exhaustion and immune suppression. Mechanistically, the integrin heterodimer α4β1, also named very late antigen 4 (VLA-4), in DPT cells and its ligand, VCAM1, in tumor cells are essential mediators of DPT-CTC clusters. Neoadjuvant administration of anti-VLA-4 neutralizing antibodies markedly blocked CTC–DPT clusters, inhibited metastasis, and extended mouse survival. These findings highlight a pivotal role of rare DPT cells in fostering cancer dissemination through CTC clustering. It lays a foundation for developing innovative biomarker-guided therapeutic strategies to prevent and target cancer metastasis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4b3207b5d57cd5e8be09dffff60afa2174fc6551" target='_blank'>
              Double-positive T cells form heterotypic clusters with circulating tumor cells to foster cancer metastasis
              </a>
            </td>
          <td>
            David Scholten, Lamiaa El-Shennawy, Yuzhi Jia, Youbin Zhang, Elizabeth Hyun, C. Reduzzi, Andrew D. Hoffmann, Hannah F Almubarak, Fangjia Tong, Nurmaa K Dashzeveg, Yuanfei Sun, Joshua R. Squires, Janice Lu, Leonidas C Platanias, C. Wasserfall, W. Gradishar, M. Cristofanilli, Deyu Fang, Huiping Liu
          </td>
          <td>2025-09-16</td>
          <td>The Journal of Clinical Investigation</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Massive immune cell infiltration and persistent inflammation in the central nervous system (CNS) are key hallmarks of multiple sclerosis. Here, we report a myeloid-derived suppressor cell (MDSC)–based therapeutic strategy, named CNS Immune Targeting Enabled by MDSCs (CITED), which uses surface-decorated MDSCs carrying rapamycin nanoparticles (NPs) for targeted multimodal immune reprogramming in CNS. We show that NP decoration enhances MDSC immunomodulatory function, facilitates their trafficking to inflamed CNS regions, and increases NP accumulation within CNS. In an experimental autoimmune encephalomyelitis model, CITED exhibited robust therapeutic efficacy, resulting in reduced disease progression, improved motor function, and diminished myelin damage. Mechanistic studies reveal that CITED exerts its therapeutic effects by targeted reprogramming of both innate and adaptive immune responses in CNS. Specifically, CITED inhibits immune cell infiltration, rebalances CD4 T cell phenotypes, and promotes the polarization of myeloid cells toward anti-inflammatory phenotypes. Collectively, CITED could provide a broadly effective approach for targeted immune restoration in multiple sclerosis and potentially other autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8f24c23e0ed496fd13e4cd70e0bb4daac42d668" target='_blank'>
              Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis
              </a>
            </td>
          <td>
            Endong Zhang, H. Algarni, Luyu Zhang, Chih-Jia Chao, Shan He, Aditi Upadhye, Qing Bao, Dahee Jung, Shubhi Srivastava, Edidiong Michael Udofa, Philana Phan, Dejan S Nikolic, Steve Seung-Young Lee, Jalees Rehman, Zongmin Zhao
          </td>
          <td>2025-10-15</td>
          <td>Science Advances</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Pancreatic ductal adenocarcinoma (PDAC), the most common malignant type of pancreatic cancer, is characterized by a dense desmoplastic stroma, low neoantigen burden, and a highly immunosuppressive tumor microenvironment (TME), which severely limit cytotoxic T-cell infiltration and the efficacy of immune therapies. Here, we present a novel strategy harnessing acute transplant rejection mechanisms by employing a recombinant oncolytic rVMG vector engineered to express the murine H-2Kk MHC class I alloantigen (rVMG-H-2Kk), thereby inducing tumor-specific antigenic mismatch responses. In vitro, rVMG-H-2Kk exhibited strong replication and cytolytic activity while inducing cell surface expression of both H-2Kk and endogenous H-2Kb, in addition to upregulation of antigen presentation genes (β2-microglobulin, Tap1, and Tapbp). In two independent immunocompetent PDAC models, intratumoral and systemic delivery of rVMG-H-2Kk delayed tumor progression and prolonged survival. Multiplex immunohistochemistry and immunophenotyping revealed substantial TME remodeling, marked by increased effector T-cell infiltration, regulatory T-cell depletion, and reduced fibrosis. Spatial transcriptomics further showed compartment-specific immune activation and epithelial metabolic reprogramming, corroborating with enhanced tumor immunogenicity. Despite these effects, rVMG-H-2Kk also induced compensatory immunosuppressive pathways, including upregulation of antiviral response genes and immune checkpoint receptors such as PDL-2. Importantly, combination therapy with rVMG-H-2Kk and murine checkpoint blockade (anti-PD-1 and anti-CTLA-4) drastically improved survival than checkpoint blockade alone. Strikingly, surviving mice resisted tumor rechallenge, indicating the establishment of durable antitumor memory. Collectively, these findings establish rVMG-H-2Kk as a novel immunotherapeutic platform capable of converting immune-cold tumors into immune-hot, sensitizing tumors to immune checkpoint inhibitors, and establishing durable antitumor immunity in PDAC. One Sentence Summary Oncolytic virus-based delivery of an alloantigen improves antitumor immunity and synergizes with immune checkpoint inhibitors in pancreatic cancer. Significance statement Delivery of murine alloantigens via an engineered oncolytic vesiculovirus, combined with immune checkpoint blockade, overcomes immunosuppressive barriers and establishes durable antitumor immunity in PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/144175af3ddbf48d09d3cc3b2903ab4c80fcc958" target='_blank'>
              Pancreatic tumor microenvironment reprogramming via alloantigenexpressing virotherapy elicits tumor rejection and improves immunotherapy response
              </a>
            </td>
          <td>
            M. Tesfay, Aleksandra Cios, Zetao Cheng, K. U. Ferdous, Randal S. Shelton, Bahaa Mustafa, Natalie M. Elliott, Elizabeth A. Raupach, Camila C Simoes, I. Miousse, Alicja Urbaniak, Michael A. Bauer, Eric R. Siegel, Steven R Post, J. C. Chamcheu, Rang Govindarajan, V. Grdzelishvili, Martin J Cannon, M. Fernandez-Zapico, Alexei G. Basnakian, C. Chabu, Omeed Moaven, M. Borad, B. Nagalo
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>62</td>
        </tr>

        <tr id="Epigenetic scarring of terminally dysfunctional (TDysf) CD8+ T cells hinders long-term protection and response to immune checkpoint blockade during chronic infections and cancer. We developed a faithful in vitro model for CD8+ T cell terminal dysfunction as a platform to advance T cell immunotherapy. Using TCR-transgenic CD8+ T cells, we found that 1-week peptide stimulation, mimicking conditions in previous models, failed to induce a stable exhaustion program. In contrast, prolonged stimulation for 2–3 weeks induced T cell dysfunction but triggered activation-induced cell death, precluding long-term investigation of exhaustion programs. To better mimic in vivo exhaustion, we provided post-effector, chronic TGF-β1 signals, enabling survival of chronically stimulated CD8+ T cells for over 3 weeks. These conditions induced a state of terminal dysfunction, marked by a stable loss of effector, cytotoxicity, and memory programs, along with mitochondrial stress and impaired protein translation. Importantly, transcriptomic and epigenetic analyses verified the development of terminal exhaustion-specific signatures in TDysf cells. Adoptive transfer of TDysf cells revealed their inability to recall effector functions or proliferate after acute lymphocytic choriomeningitis virus rechallenge. This tractable model system enables investigation of molecular pathways driving T cell terminal dysfunction and discovery of therapeutic targets for cancer or chronic infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc4dbe9ec01dc079f493706a4c9a1123f839c591" target='_blank'>
              Faithful modeling of terminal CD8+T cell dysfunction and epigenetic stabilization in vitro
              </a>
            </td>
          <td>
            Amira Yousif, Abbey A. Saadey, Ava Lowin, Asmaa M. Yousif, Ankita Saini, Madeline R. Allison, Kelley Ptak, Eugene M Oltz, Hazem E. Ghoneim
          </td>
          <td>2025-10-08</td>
          <td>JCI Insight</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Neutrophils are integral components of the bone marrow and stromal cell network. They express the immune checkpoint molecule PD-L1 and can induce T cell exhaustion, thereby promoting immunosuppression. In this study, we investigated whether tumor-derived Cldn7 deficiency could recruit polymorphonuclear neutrophils (PMNs), induce their metabolic reprogramming, and consequently drive their transition toward a pro-tumor phenotype, leading to the establishment of an immunosuppressive tumor microenvironment (TME). Using single-cell RNA sequencing, clinical sample validation, and both in vivo and in vitro experiments, we found that Cldn7 deficiency in colorectal cancer (CRC) results in a tumor microenvironment characterized by significantly increased infiltration of CD11b⁺ Ly6G⁺ neutrophils. This is accompanied by neutrophil metabolic reprogramming that facilitates their phenotypic shift toward a tumor-promoting state, which in turn suppresses the cytotoxic function of CD8⁺ T cells and contributes to the formation of an immunosuppressive TME, thereby accelerating CRC progression. Mechanistically, Cldn7 deficiency indirectly activates the NF-κB signaling pathway, leading to elevated secretion of chemokines such as CXCL1 that are responsible for PMN recruitment. Inhibition of the NF-κB/CXCL1 axis reduces PMN infiltration, decreases PD-L1 expression on neutrophils, suppresses neutrophil glycolysis and histone lactylation, reverses the exhausted phenotype of CD8⁺ T cells, thereby mitigating the immunosuppressive microenvironment. Furthermore, overexpression of Cldn7 enhances the efficacy of immune checkpoint blockade (ICB) therapy.Collectively, our findings indicate that Cldn7 deficiency not only contributes to immune evasion and malignant progression in CRC but also plays a critical role in immune modulation. Targeting PMN metabolic reprogramming and immunosuppressive function associated with Cldn7 loss may offer a promising strategy to improve the therapeutic efficacy of immunotherapy in CRC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57fa7d965f4e46d2deb56381980d3616631c7424" target='_blank'>
              Claudin-7 deficiency induces metabolic reprogramming of neutrophils in the colorectal cancer microenvironment
              </a>
            </td>
          <td>
            Xiaoqing Liang, Dajin Yuan, Songyun Zhao, Jianbo Zhou, Kun Wang, Xiaoli Liu, Yin Liu, Huimin Li, Mengdi Hao, Wenbin Huang, Wenjie Li, Lei Ding
          </td>
          <td>2025-10-16</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/739a87fd565af12d2e067e28eb04d43a769bbc0a" target='_blank'>
              Skin-derived G-CSF activates pathological granulopoiesis upon psoriasis
              </a>
            </td>
          <td>
            Tomson Kosasih, Tatsuya Morishima, Sohyeon Lee, Jungyeon Yoon, Kanako Wakahashi, Pilhan Kim, Aiko Sada, Hitoshi Takizawa
          </td>
          <td>2025-10-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3d8175d96b7c6cd7d7b5ae734fb75666b210772" target='_blank'>
              Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models
              </a>
            </td>
          <td>
            Markella Zannikou, Joseph T. Duffy, Daniel Procissi, H. Najem, Rebecca Levine, Aditi Thakur, D. Hambardzumyan, Catalina Lee-Chang, Lara Leoni, C. Horbinski, D. Simberg, Bin Zhang, A. Heimberger, J. Miska, Irina V Balyasnikova
          </td>
          <td>2025-10-01</td>
          <td>Journal for ImmunoTherapy of Cancer</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Background Immune checkpoint inhibitors have traditionally been understood to exert their effects primarily within the tumor microenvironment, particularly targeting CD8 + T cells. However, recent studies have highlighted a pivotal role of tumor-draining lymph nodes in mediating responses to immune checkpoint inhibitor therapy. This study aimed to elucidate the specific mechanisms by which tumor-draining lymph nodes respond to immune checkpoint inhibitor therapy and regulate the tumor microenvironment in human colorectal cancer. Methods We performed single-cell RNA sequencing and T cell receptor sequencing on tumor-draining lymph nodes and tumor tissues from patients with colorectal cancer. Through in-depth analysis of the single-cell data, we established the connection between TDLNs and tumor, and explored the impact of immune checkpoint inhibitor therapy on the immune microenvironment of tumor-draining lymph nodes. In addition, we conducted animal experiments to validate these findings. Results Our findings revealed that immune checkpoint inhibitor treatment induced the expansion of tumor-specific CD8 + effector memory T cells within tumor-draining lymph nodes, which may serve as a source for the progenitor-exhausted CD8 + T cells in the tumor microenvironment. Moreover, conventional dendritic cells type 1 and macrophages within tumor-draining lymph nodes facilitated this process. We also observed that immune checkpoint inhibitor therapy promoted the expansion of tumor-specific CD4 + follicular helper T cells in tumor-draining lymph nodes, which may explain the increase of CD4 + follicular helper T cells in the tumor microenvironment after immune checkpoint inhibitor therapy. These hypotheses were corroborated through experiments in mice. Conclusions Our findings delineate the critical regulatory function of tumor-draining lymph nodes in modulating the tumor microenvironment during Immune checkpoint inhibitor therapy. Supplementary Information The online version contains supplementary material available at 10.1007/s00262-025-04187-w.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b9de1a203560b665a61560f8094ade12f18f1b7" target='_blank'>
              Tumor-draining lymph nodes respond to immune checkpoint inhibition and orchestrate tumor immune remodeling
              </a>
            </td>
          <td>
            Jinzhu Zhang, Jian Ma, Yaru Niu, Jialiang Liu, Zhexue Wang, Jinyu Guo, Yongsheng Meng, Ruifang Sun, Zhen Zhang, Haiyi Liu, Juan Xu, L. Zan, Xu Guan, Xishan Wang
          </td>
          <td>2025-10-06</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Lung cancer remains the leading cause of cancer-related mortality worldwide, with its progression shaped not only by tumor-intrinsic factors but also by a complex and immunosuppressive tumor microenvironment (TME). Within this niche, diverse immune populations—including CD8+ cytotoxic T cells, CD4+ helper T cell subsets (Th1, Th17, Tregs), B cells, natural killer (NK) cells, tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs)—collectively regulate immune surveillance and tumor escape. While effector lymphocytes mediate antitumor responses, their function is often attenuated by TAM- and MDSC-driven immunosuppression via cytokines (IL-10, TGF-β), metabolic disruption, and immune checkpoint expression. High densities of M2-polarized TAMs and MDSCs correlate with poor prognosis and resistance to therapy. Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have improved outcomes in lung cancer, yet therapeutic efficacy remains limited by the immunosuppressive TME. This review outlines the functional roles of key immune cell subsets in lung cancer and highlights emerging strategies to reprogram the TME and enhance immunotherapeutic responsiveness.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec07b573d2c713f5c6d11528b863b0a4240be315" target='_blank'>
              Reprogramming the immune microenvironment in lung cancer
              </a>
            </td>
          <td>
            Kai Chen, Linqi Luo, Yong Li, Ge Yang
          </td>
          <td>2025-09-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2c146d74e58561771a7d91f4ca1977ff7215575" target='_blank'>
              Efineptakin alfa (NT-I7) improves overall survival and induces tertiary lymphoid structures in murine lung tumors
              </a>
            </td>
          <td>
            Trang Dinh, Judong Lee, Sidra Islam, Namita Nanda, Dijana Bjelivuk, Dathan Andrews, Jiasen Zhang, N. Mani, Jin Zhou, Alexandra A. Wolfarth, Donghoon Choi, Rafi Ahmed, Joseph Skitzki, Deyu Fang, Weihong Guo, Zhenghe Wang, Rebecca C. Obeng
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Abstract Background Numerous studies have demonstrated the promising efficacy of granulocyte colony‐stimulating factor (G‐CSF) in the treatment of couples with unexplained recurrent pregnancy loss (URPL) during early pregnancy. While neutrophils are recognised as the main effectors mediating immunoregulation, their G‐CSF‐mobilised phenotype and mechanisms regulating maternal–fetal immunity remain unclear. Methods Single‐cell RNA sequencing (scRNA‐seq) and single‐cell T‐cell receptor sequencing (scTCR‐seq) were conducted to uncover the immune reconstitution dynamics of peripheral blood under G‐CSF stimulation. Integrative analysis of transcriptomic‐proteomic profiles with functional validation revealed a unique immunomodulatory neutrophil population. Further, we used spatial transcriptomics, flow cytometry and immunohistochemistry to explore the spatial distribution characteristics of this population at the maternal–fetal interface, and validated its therapeutic efficacy in animal models. Results G‐CSF‐mobilised peripheral blood (G‐PB) displayed immune hyporesponsiveness. Unique neutrophils expressing high levels of CD177 and the S100A gene family expanded substantially in response to G‐CSF. These neutrophils exhibited a comparatively immature morphology and impaired T‐cell responses via contact‐dependent arginase 1 release, as well as upregulation of T‐cell immune checkpoints. A reduction of CD177+S100Ahi neutrophils was observed in both peripheral blood and decidua of URPL patients relative to healthy pregnant women. Functional validation in abortion‐prone murine models confirmed that exogenous supplementation of G‐CSF or adoptive transfer of CD177+S100Ahi neutrophils could successfully improve the pregnancy outcomes. Conclusion G‐CSF played a crucial regulatory role in improving pregnancy outcomes by selectively expanding CD177⁺S100Ahi neutrophils with polymorphonuclear myeloid‐derived suppressor cells (PMN‐MDSCs) properties, providing a solid theoretical foundation for the treatment of patients with URPL using G‐CSF. Key points G‐CSF induces peripheral blood immune hyporesponsiveness in patients with UPRL. First to characterize G‐CSF mobilised CD177+S100Ahi neutrophils displayed PMN‐MDSCs properties. Both CD177+S100Ahi‐LDNs and CD177+S100Ahi‐NDNs induce T cell hyporesponsiveness through coordinated activation of the ARG1/L‐Arg metabolic axis and synergistic upregulation of immune checkpoint molecules. CD177+S100Ahi neutrophils are diminished in the peripheral blood and decidua of patients with UPRL.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6e8e769871352922cc92c745bad2ac8d159aa41" target='_blank'>
              Granulocyte colony‐stimulating factor induced T‐cell hyporesponsiveness via modulation of CD177+S100Ahi neutrophils in unexplained recurrent pregnancy loss
              </a>
            </td>
          <td>
            Ping-Fen Li, Xue Zhang, Peng-Sheng Zheng
          </td>
          <td>2025-10-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Esophageal squamous cell carcinoma (ESCC) is commonly diagnosed at an advanced stage, where conventional chemoradiotherapy offers only limited clinical benefit. Immune checkpoint inhibitors targeting the tumor microenvironment (TME) have demonstrated substantial therapeutic potential; however, reliable biomarkers for predicting therapeutic outcomes remain unclear.Single-cell RNA sequencing dataset for ESCC was obtained from the GEO database and analyzed using the Seurat R package to evaluate gene expression in tumor and adjacent tissues. Additionally, flow cytometry was used to assess immune cell subsets in peripheral blood samples from patients undergoing immunotherapy. Statistical analyses, including survival analysis and the Kruskal-Wallis test, were conducted to investigate the association between immune cell subsets and treatment efficacy.In tumor tissues, immune subsets were significantly enriched compared with adjacent tissues, including CD8+ T cells with exhaustion (CD39, TIM3, PD-1) or activation/tissue residency (CD137, CD103) features; CD4+ T cells with activation (CD134, CD137) or regulatory (FOXP3) phenotypes; and dendritic cells expressing TIM3 or CD103. In peripheral blood, a median change in TIM3+ CD8+ T cells of 3.35% was observed following immunotherapy. Patients with changes exceeding this threshold experienced shorter progression-free survival (PFS) compared to those with lower changes (5.0 vs. 8.5 months, P = 0.024). Furthermore, TIM3+ CD8+ T cell changes were markedly reduced in patients achieving complete or partial responses compared to those with progressive disease.TIM3+ CD8+ T cells are a promising predictive biomarker for immunotherapy outcomes in ESCC. These findings highlight their potential to guide personalized treatment strategies in clinical practice.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77197e0a364b3fcb759f2e0c19cc56cbf8817972" target='_blank'>
              Correlation of immune cell subsets in the tumor microenvironment and peripheral blood with immunotherapy response in esophageal squamous cell carcinoma
              </a>
            </td>
          <td>
            Wei Chen, Lian Gong, Yahu Li, Mengyao Wu, Min Tao
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/31031a58b5867a2e511ab4f057111637ee377752" target='_blank'>
              LRH-1 is a novel regulator of neutrophil-driven immune responses within the tumor microenvironment
              </a>
            </td>
          <td>
            Yu Wang, Bryan Duong, Sam Keeley, Natalia Krawczynska, Shruti V. Bendre, Claire P. Schane, Erin Weisser, Nadia Cobo Vuilleumier, Lara I. Kockaya, Yifan Fei, A. Das Gupta, H. E. Vidana Gamage, Adam T. Nelczyk, Sisi He, Hannah Kim, Jenny Drnevich, Benoit R Gauthier, Erik R. Nelson
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ac1a5e9156da35067055050deefa4d847ef10215" target='_blank'>
              Macrophage-derived WNT regulates tumor immune microenvironment to reduce colitis-associated colon cancer
              </a>
            </td>
          <td>
            P. Bhanja, R. Chugh, Shujah Rehman, Stacey Krepel, Amrita Mitra, Pooja Gupta, Ximena Diaz Olea, Harsh Pathak, Anup Kasi, Subhrajit Saha
          </td>
          <td>2025-09-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/276902406914fa26315122d32de7c8926d35072f" target='_blank'>
              Interferon Restores Antigen Presentation and Sensitizes Medulloblastoma to T Cell Killing
              </a>
            </td>
          <td>
            Tanja Eisemann, M. Masihi, Theophilos Tzaridis, Veronika Pister, Isaac Youm, Kendall R. Chambers, Aditi Dutta, Alexander T Wenzel, Koei Chin, Scott L. Pomeroy, Jill P. Mesirov, E. Fraenkel, Anindya Bagchi, Lukas Chavez, Robert J Wechsler-Reya
          </td>
          <td>2025-10-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Tertiary lymphoid structures (TLSs) in the tumor microenvironment (TME) act as local hubs for antigen presentation and lymphocyte activation, reinforcing antitumor immunity. They act as ectopic, lymph node-like niches that orchestrate local antitumor immunity through well-defined B-cell follicles, T-cell zones, follicular dendritic cells (FDCs), and high endothelial venules (HEVs). Although various cancer treatment methods can impact TLSs, thereby changing the state of the TME, the dynamic changes in TLSs caused by treatment and the mechanisms therein have not been comprehensively summarized to date. This review highlights the mechanisms of different cancer treatment effects on TLSs dynamic change, including the number and functionality of TLSs within tumors. We also summarize the value of TLSs in predicting prognosis and therapeutic effect, as well as the deficiencies in current research and future development directions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4b10ea5ef7732254210365008058829408071ec8" target='_blank'>
              Dynamic remodeling of tertiary lymphoid structures in response to cancer therapy: a recent review
              </a>
            </td>
          <td>
            Chongyu Tan, Jinliang Huang, Ning Gao, Bingquan Wu, Matsika Juliet, Jiatong Xiao, Jiao Hu, Ping Liu, Jinbo Chen
          </td>
          <td>2025-09-29</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Background Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous and aggressive hematologic malignancy, with the activated B-cell-like (ABC) subtype displaying particularly poor prognosis due to inherent treatment resistance and elevated recurrence rates. Despite advances in targeted therapies and immunotherapies, a significant proportion of patients experience relapse or refractory disease, highlighting the urgent need for novel biomarkers and innovative therapeutic strategies to improve clinical outcomes. Methods A multi-dimensional analysis of SH3BP5 expression was performed across DLBCL subtypes, integrating transcriptomic, proteomic, and clinical datasets to assess its correlation with immune infiltration, tumor metabolism, and patient prognosis. Single-cell RNA sequencing data were employed to examine the tumor microenvironment (TME) with higher resolution. Further analysis of the association between SH3BP5 and immune checkpoint gene expression was conducted to explore its potential role in immunotherapy response. Functional in vitro assays were carried out to assess the impact of SH3BP5 knockdown on DLBCL cell proliferation and apoptosis. Results The analysis revealed that SH3BP5 is preferentially overexpressed in the ABC subtype of DLBCL across multiple datasets and validated cohorts, and its high expression is significantly associated with poor overall survival. Single-cell transcriptomic profiling demonstrated that SH3BP5 is mainly expressed in malignant B cells and inversely correlated with immune cell infiltration, particularly CD8 + T cells. Mechanistically, pathway enrichment and metabolic assays indicated that SH3BP5 is linked to mitochondrial metabolic reprogramming, promoting oxidative phosphorylation (OXPHOS) and potentially contributing to reduced responsiveness to immune checkpoint inhibitors (ICIs). Functional studies showed that SH3BP5 knockdown significantly suppressed DLBCL cell proliferation, induced apoptosis, and reduced tumor cell viability in vitro. Conclusion This study suggests that SH3BP5 may serve as a prognostic biomarker and a potential therapeutic target in DLBCL, particularly within the ABC subtype. By delineating its associations with immune evasion and metabolic reprogramming, these findings provide a mechanistic basis for further exploration of SH3BP5-targeted interventions to help overcome therapy resistance. Future studies in larger clinical cohorts and functional models are warranted to validate these results and assess the potential of integrating SH3BP5 expression profiling into precision medicine strategies for DLBCL. Trial registration The study was registered in the Chinese Clinical Trial Registry (ChiCTR2200060430; http://www.chictr.org.cn/) on June 1, 2022. Supplementary Information The online version contains supplementary material available at 10.1186/s12967-025-06951-z.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d27222190fd1301e27cfd9869b08b07fc58aa185" target='_blank'>
              SH3BP5-driven metabolic-immune crosstalk in DLBCL: a prognostic biomarker and therapeutic target for reshaping immunosuppressive microenvironment
              </a>
            </td>
          <td>
            Tong Wu, Yi Yang, Yuan Zong, Jiawen Zhao, Xiaoyu Zhao, Lei Li, Yiming Gao, Ning Li, Liting Jiang, Yinyin Xie
          </td>
          <td>2025-09-24</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d6db7c438373e1be32f3e8f8962c7eb002d2e0ff" target='_blank'>
              Single-cell profiling reveals that dynamic lung immune responses distinguish protection from susceptibility to tuberculosis
              </a>
            </td>
          <td>
            Fergal J. Duffy, M. L. Neal, Courtney R. Plumlee, Sarah Cohen, B. Gern, A. Diercks, Michael Y Gerner, K. Urdahl, J. Aitchison
          </td>
          <td>2025-10-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6a9f3325348d0e9acac4d1170eb3ed6e4599ca92" target='_blank'>
              Co-Stimulatory Blockade Prevents Intragraft Accrual of Class-Switched, Activated B Cells Despite Failing to Prevent T-Cell Mediated Rejection
              </a>
            </td>
          <td>
            J. T. Caldwell, Tiffany Shi, Ashley R. Burg, Ashley Koby, Krishna M. Roskin, Anna L. Peters, E. DePasquale, E. Woodle, D. Hildeman
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Background Relapsed and refractory multiple myeloma (RRMM) remains a major clinical challenge, as most patients eventually relapse following standard treatments and are left with limited therapeutic options. Although b-cell maturation antigen (BCMA) CAR-T cell therapy has recently shown remarkable efficacy in select patients, broader implementation is hindered by its reliance on autologous cells, prolonged manufacturing timelines, high costs, and severe immune-related toxicities. These challenges have prompted an urgent demand for safer, more accessible, and rapidly applicable immunotherapeutic alternatives. Methods CBMC (cord blood mononuclear cells) were cultured with irradiated BMMC (bone marrow mononuclear cells) from RRMM patients in the presence of defined cytokines, aiming to develop a new therapeutic immune cell product for RRMM. Their phenotypic and functional characteristics, including non-MHC-restricted and MHC-restricted cytotoxicity mechanisms, were analyzed using surface marker profiling, cytokine secretion assays, in vitro cytotoxicity assays, functional and blocking assays. Antitumor activity was evaluated in xenograft mouse models using MM.1 S and RPMI-8226 cells. Results We successfully generated CD8+ NKT-like cells through tumor priming, which exhibited potent cytotoxicity and elevated cytokine production against multiple myeloma cell lines and primary RRMM samples. Mechanistically, tumor-priming CD8+ NKT-like cells (TPNC) cytotoxicity was mediated by both non-MHC–restricted pathways involving LFA-1 and DNAM-1, and MHC-restricted, TCR-mediated recognition. TPNC efficiently formed immune synapses, rapidly polarized cytotoxic granules, and engaged in serial killing. In xenograft models, TPNC significantly suppressed tumor progression, prolonged survival, and persisted in circulation without observable toxicity. Based on these findings, we extended the tumor-priming strategy to acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), successfully generating TPNC with robust cytotoxic activity. In ALL samples, TPNC exhibited cytotoxicity comparable to anti-CD19 CAR-NK cells. Conclusions TPNC represents a novel cytotoxic lymphocyte product generated through tumor-driven priming. Their dual recognition capacity, functional versatility, and favorable safety profile highlight their potential as a scalable and personalized immunotherapy platform for hematologic malignancies. Supplementary Information The online version contains supplementary material available at 10.1186/s40164-025-00707-7.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/93312d628496ab87e87c047dff1fc445e08f269c" target='_blank'>
              Tumor-priming CD8+ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma
              </a>
            </td>
          <td>
            Juheon Lee, E. Choi, Bohwa Han, Jeongmin Kim, Dana Jung, Kyeong-Hee Kim, Sung Yong Oh, Sung-Hyun Kim, Kyungsoo Ha, Ji-Hoon Kim, Ji Hyun Lee, Duck Cho, Junsang Doh, Seok-Ho Kim
          </td>
          <td>2025-09-29</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/414b17ddf14219ad322717a5070ccfe55d235131" target='_blank'>
              ZEB1 promotes chemo-immune resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16.
              </a>
            </td>
          <td>
            Shaobo Zhang, Yumeng Hu, Zhijun Zhou, Gaoyuan Lv, Chenze Zhang, Yuanyuan Guo, Fangxia Wang, Yuxin Ye, Haoran Qi, Hui Zhang, Wenming Wu, Min Li, Mingyang Liu
          </td>
          <td>2025-09-09</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Background and objective Tumor antigen–escape variants undermine immunotherapy by subverting lymphocyte effector functions and reshaping tumor–immune dynamics. It is essential to delineate functional interplay within immune networks during tumor progression. We investigated whether homeostatic crosstalk between CD8+T cells and natural killer (NK) cells preempts tumor antigen–escape. Methods Adoptive CD8+T cell transfers were administered before (D–7, homeostatic pre-priming) or after (D+1) tumor establishment in Rag1−/− and Rag1−/−γc−/− mice. Antigen presentation, immune activation, proliferation, cytotoxicity, and memory were quantified by flow cytometry, live bioluminescence and confocal imaging. Monoculture, co-culture, and a 3D silica nanofiber carpet mimicking basement-membrane-like topography modeled intercellular interactions. Signaling arrays and motion metrics (Speed-Distance Index, deceleration) were conducted. Human ligand–receptor pairs engaged in CD8+T–NK crosstalk were probed in silico. Results and discussion Pre-tumor D–7 CD8+T cell transfer completely suppressed antigen–escape tumors with NK cells as major effectors showing elevated CD25, CD69, CD107a, and GzmB, marking activated and effector phenotype, and promoting central-memory CD62L⁺CD44⁺CD8⁺TCM precursors. By contrast, post-tumor D+1–transferred CD8+T cells allowed emergence of tumor variants resistant to antigen-specific cytolysis as assessed on day 25, despite those T cells retaining higher intrinsic cytotoxic capacity than the D–7 T cell cohort. Mechanistically, CD8+T and NK cells formed stable contacts through pseudopodial intercellular nanotubes enabling bidirectional membrane exchange and signaling via STAT, Akt, and mTOR pathways, augmenting NK effector function and promoting CD8+TCM differentiation. In silico analysis identified human ligand–receptor pairs engaged in CD8+T–NK adhesion, stimulatory and regulatory axes, including CD200–CD200R, PD-L1–PD-1, and CD18/CD11a–DNAM-1 (CD226). Together, data support a three-phase model of preemptive immunosurveillance initiated by early CD8⁺T–NK crosstalk. Conclusion Homeostatic conditioning and effector cooperativity between CD8+T and NK cells protect against tumor immune escape. The findings uncover a mechanistic axis of preemptive immunosurveillance that lays the foundation for next-generation preventive immunotherapies to control antigen–escape tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7da5a7fdb4ec2b2b9a760d690ae1d6009548f667" target='_blank'>
              CD8+ T–NK cell crosstalk establishes preemptive immunosurveillance to eliminate antigen–escape tumors
              </a>
            </td>
          <td>
            R. Uzhachenko, Salvador González Ochoa, T. Kanagasabai, H. Rajakaruna, Menaka C Thounaojam, M. T. D. de Aquino, Tanu Rana, L. Costa, A. Terekhov, William H. Hofmeister, Thomas J. Sayers, Claude Boyer, Alla Ivanova, J. S. Goodwin, A. Schmitt-Verhulst, A. Shanker
          </td>
          <td>2025-09-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ee5dbb33a6a382fa70961ac781d31dc13ae0aa3f" target='_blank'>
              Tumor cell dissemination is facilitated through regulatory T cell-driven extracellular matrix remodeling
              </a>
            </td>
          <td>
            Ailen D. Garcia-Santillan, Jessanne Y. Lichtenberg, He Shen, , Sandra Makar, Jonathan Barra, Nicholas M. Clark, Wei Du, , Ashley D. Hadjis, Taylor Calicchia, Mikhail G. Dozmorov, J. Bravo-Cordero, Amy L. Olex, Priscilla Y. Hwang, Paula D. Bos
          </td>
          <td>2025-10-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/15ffe224afe018a4f7b0a537cc1b027c3c818db6" target='_blank'>
              An autologous human iPSC-derived 3D organoid infection model for preclinical testing of antiviral T cells
              </a>
            </td>
          <td>
            Ugarit Daher, V. Fernandez-Vallone, Morris Baumgardt, Benedikt Obermayer, Niklas Wiese, Achim Klaus Kirsch, Tanja Fisch, A. Löwa, Michael Schmueck-Henneresse, A. Hocke, L. Amini, Harald Stachelscheid
          </td>
          <td>2025-09-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a4abcaf5776ad97c1813abd2abb8852a605b524d" target='_blank'>
              Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapies
              </a>
            </td>
          <td>
            A. Carturan, Mathew G. Angelos, P. Guruprasad, , R. Pajarillo, Andrew Lee, Yunlin Zhang, Yi-Hao Chiang, Wei Xie, Jesse L. Rodriguez, Jaryse Harris, Pooja Devi, Olabisi I. Afolayan-Oloye, Jason Xu, Jonathan Sussman, Omar Elghawy, Austin Yang, Adam Barsouk, J. Cho, Carolyn E. Shaw, Ekta Singh, O. Ugwuanyi, D. Espie, L. Paruzzo, Federico Stella, Shan Liu, Siena Nason, Antonio Imparato, Antonia Rotolo, Jean Lemoine, David M. Barrett, A. Posey, A. Rook, Vinodh Pillai, Adam Bagg, S. Pileri, Dongfang Liu, Kai Tan, S. Schuster, D. Teachey, P. Porazzi, M. Ruella
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>66</td>
        </tr>

        <tr id="Abstract Myeloid cells are a diverse group of immune cell types with systemic and organ-specific functions. Myeloid cells are frequently found in the tumor microenvironment and their infiltration correlates with survival and response to treatment. High myeloid infiltration is typically a poor prognostic factor, and the immune suppressive and prometastatic roles of myeloid cells are well established. However, there is an increasing appreciation of the antitumor functions performed by myeloid cells, which include direct tumor cell killing, phagocytosis, antigen presentation and T and natural killer cell recruitment. Moreover, advances in immune phenotyping have uncovered myeloid subsets with positive prognostic significance, including subsets correlating with higher response rates to immunotherapy. This review summarizes recent progress in mapping and dissecting the opposing effects of myeloid cells on cancer progression and immunotherapy response. The overall impact of myeloid cells is context-dependent, and combination therapies are needed to leverage the antitumor potential of these cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3823ee46218e3233f5b48e60b02f6fa9d09ba69f" target='_blank'>
              Positive and negative roles of myeloid cells in cancer immunotherapy
              </a>
            </td>
          <td>
            Jaroslav Zak, Judith A. Varner
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ed2e2b6e5867f00f570022e3faf5971a5955554" target='_blank'>
              Highly multiplexed imaging recovers immune and metabolic niches in multiple myeloma associated with disease progression and bone involvement
              </a>
            </td>
          <td>
            Ingrid Aass Roseth, Lukas Hatscher, Chiara Schiller, Håkon Skjalg Selland Johnstuen, T. Slørdahl, Håkon Hov, D. Schapiro, T. Standal
          </td>
          <td>2025-09-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Non-small cell lung cancer (NSCLC) exhibits profound immune dysregulation, driven in part by the opposing roles of regulatory T cells (Tregs) and T helper 17 (Th17) cells. Tregs facilitate tumor progression through immune suppression, angiogenesis, and checkpoint engagement, while Th17 cells display dual effects depending on the tumor microenvironment, either promoting anti-tumor responses or enhancing malignancy. Importantly, plasticity between these subsets, orchestrated by cytokines such as TGF-β, IL-6, and IL-1β, allows dynamic interconversion that shapes immune outcomes. This review comprehensively summarizes the differentiation, molecular mechanisms, and functions of Tregs and Th17 cells in NSCLC. We highlight recent advances in targeting the Th17/Treg axis via immune checkpoint inhibitors, Treg depletion, and metabolic reprogramming. Understanding this immunological balance offers promising avenues for restoring anti-tumor immunity and improving therapeutic efficacy in NSCLC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc2fe215418a201aa8b5de519c7cfb5b11dfb23a" target='_blank'>
              Rewiring immune suppression in NSCLC: Roles and plasticity of Tregs and Th17 cells
              </a>
            </td>
          <td>
            Shasha Zhu, Ning Zhou, Qingling Li, Xiaoxing Liu
          </td>
          <td>2025-10-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="T cell responses are generally curtailed by suppressive mechanisms within the tumor microenvironment (TME) that prevent T cell infiltration and function. Consequently, T cell-based therapies for solid tumors have yielded limited and often non-durable clinical responses. Tumors develop a hostile TME, where tumor-associated macrophages (TAMs) that initially support T cells are converted into immune suppressive TAMs that facilitate tumor evasion from T cell control. In fact, immune suppressive TAMs represent a dominant fraction of immune cells within the TME and their presence is associated with poor prognosis and resistance to immunotherapy. Often in close contact with effector T cells, TAMs directly suppress CD8+ T cells through mechanisms involving metabolic mediators, co-signaling receptors, their ligands and/or cytokines. Here, we revisit molecular interactions behind TAM-mediated suppression of T cell responses and address the potential targeting of such molecules and pathways to re-boost anti-tumor T cell immunity. This perspective, focusing on molecular interactions between TAM and T cells, may aid the improvement of T cell-based therapies for solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c01dfbcf193a83248342e1e2c8db14cdc37f598" target='_blank'>
              Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy
              </a>
            </td>
          <td>
            R. M. Coelho, R. Debets, Dora Hammerl
          </td>
          <td>2025-10-16</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="The release of danger-associated molecular patterns (DAMPs) such as ATP from stressed or damaged cells is a key initiator of sterile inflammation. In autoimmune diseases, extracellular ATP acts as a potent pro-inflammatory signal by activating the purinergic receptor P2X7, which is expressed on both mononuclear phagocytes (MPs) and T cells—key drivers of pathological processes. While it is well established that P2X7 mediates ATP-dependent immune activation, its cell-specific contributions to innate versus adaptive immunity in autoimmune conditions remain unclear, especially in autoimmune uveitis. Here we used the experimental autoimmune uveoretinitis (EAU) mouse model to delineate the cellular mechanisms underlying P2X7’s role in autoimmune responses. Using a combination of multiple cell-specific conditional models and transcriptomic approaches, we showed a pivotal role forP2X7 expressed by MPs in orchestrating T-cell mediated autoimmune responses. P2X7 deficiency in MPs decreased disease severity. Additionally, cell-specific transcriptomic analyses, including single-cell analyses, revealed that P2X7 exerted distinct modulatory effects across monocyte-derived macrophages (MdM) versus microglia. In MdM, lack of P2X7 was associated with reduced expression of genes related to the inflammasome, phagocytosis pathways, and components of the complement system, leading to a marked decrease in pathogenic Th17 cell frequency in the retina. In microglia, P2X7 deficiency instead particularly impacted an IFN-responsive microglial subset that is normally characteristic of EAU. By specifically deleting P2X7 in microglia, we demonstrate its role in driving pathogenic processes in this cell population. These findings suggest that inhibition of P2X7 could be a promising therapeutic strategy in autoimmune neuroinflammatory disorders. Supplementary Information The online version contains supplementary material available at 10.1186/s12974-025-03529-w.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/31d6dca4ac613c86885fb67afae84c460cb78a38" target='_blank'>
              Macrophage expression of P2X7 controls autoimmune uveitis
              </a>
            </td>
          <td>
            Paul-Alexandre Déchelle-Marquet, Yueshen Che, Camille Roux, Frédéric Blond, Kaitryn E. Ronning, S. Augustin, Pauline Lagouge-Roussey, C. Nous, Sara Touhami, Bahram Bodaghi, Jean Kanellopoulos, S. Adriouch, X. Guillonneau, Florian Sennlaub, Cécile Delarasse
          </td>
          <td>2025-09-25</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="Abstract In the tumour microenvironment (TME) of renal cell carcinoma (RCC), tertiary lymphoid structures (TLS) play a crucial role in anti‐tumour immune responses. Resembling secondary lymphoid organs, TLS comprises B cells, T cell zones, high endothelial venules, and antigen‐presenting cells, facilitating local immune activation. While TLS has shown correlations with improved immune checkpoint inhibitors (ICIs) outcomes in other cancers, its role in RCC is still under investigation. Emerging evidence indicates that mature TLS enhances anti‐tumour activity by activating T and B cells, whereas immature TLS may contribute to immune suppression. The RCC TME is highly immunosuppressive, marked by regulatory T cells, myeloid‐derived suppressor cells, and elevated pro‐angiogenic and immunosuppressive cytokines. In this context, TLS, particularly mature TLS, can counteract immunosuppression, boost local immune responses, and improve ICIs efficacy. However, TLS in RCC is heterogeneous, with their formation and function affected by factors like CXCL13 expression. The presence, maturity, and functionality of TLS may serve as valuable predictors of ICIs response and patient prognosis. Further research is required to understand TLS regulation and leverage their potential to enhance personalised immunotherapy for RCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e06e4f2c0f51b0e1b714cfca628cbbc454ea7b91" target='_blank'>
              Role of tertiary lymphoid structures in the tumour microenvironment and immunotherapy response of renal cell carcinoma
              </a>
            </td>
          <td>
            Lin Yang, Wentai Shangguan, Weijia Li, Wenxue Huang, Zhuohang Li, Boyuan Sun, Cunzhen Ma, Xunguo Yang, Bisheng Cheng, Peng Wu
          </td>
          <td>2025-10-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="ABSTRACT Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) has demonstrated consistent clinical efficacy in treating advanced melanoma and other “hot” tumors. However, it has shown limited success in “cold” tumors like glioblastoma. We present the successful treatment of a rapidly progressing glioblastoma patient with TILs expanded using a defined cytokine combination of IL-2, IL-15, and IL-21. The patient received lymphodepletion with cyclophosphamide one day pre-TIL infusion, followed by a single dose of IL-2 post-transfer. Complete tumor regression was observed after two TIL infusions administered two weeks apart. The TIL products were enriched for CD8+ T-cells and demonstrated specific lysis of the autologous tumor cell line. Transcriptomic analysis of tumor biopsies post-TIL infusion revealed increased expression of genes associated with immunological synapse formation and T-cell effector function, correlating with the patient’s clinical outcome. T-cell receptor (TCR) next-generation sequencing of the infused TILs and post-treatment tumor biopsies confirmed the infiltration and expansion of TIL-derived clonotypes within the tumor microenvironment. CD8+ T-cell clonotypes exhibited robust tumor migration and expansion, while CD4+ T-cells showed limited tumor infiltration. In conclusion, TILs expanded with IL-2/IL-15/IL-21 represent a promising therapeutic approach for glioblastoma, overcoming traditional challenges posed by the tumor microenvironment and achieving significant clinical outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2803e1a4de6f344e11b914032849f558f3ea1e42" target='_blank'>
              Tumor-infiltrating lymphocytes-derived CD8+ clonotypes infiltrate the tumor tissue and mediate tumor regression in glioblastoma
              </a>
            </td>
          <td>
            Lucas C M Arruda, J. Karbach, D. Kiselicki, H. Altmannsberger, E. Sinelnikov, D. Gustavus, H. Hoffmeister, A. Atmaca, E. Jäger
          </td>
          <td>2025-10-07</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="In the last few decades, chimeric antigen receptor (CAR) T-cell therapy has led to a paradigm shift in the treatment of hematological malignancies, including various subtypes of B-cell non-Hodgkin’s lymphoma, B-cell acute lymphoblastic leukemia, and multiple myeloma. However, most patients experience refractoriness to CAR T-cells or relapse after treatment. Many efforts are underway to understand the mechanisms behind CAR T-cell failure, which are mainly related to CAR T-cell dysfunction, tumor-intrinsic resistance, an immunosuppressive tumor microenvironment, manufacturing issues, or patient-related factors. Several strategies are being developed to overcome these resistance mechanisms, including the engineering of more functional allogeneic CAR T-cell products, the targeting of alternative tumor antigens, and combination therapies with other drugs such as checkpoint inhibitors or small molecules to enhance CAR T-cell efficacy. In this review, we will provide an updated overview of the mechanisms of CAR T-cell failure and the therapeutic advances currently under development to address them.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/718b2c38347b01dda84f75d691a550e2af23f316" target='_blank'>
              Mechanisms of Resistance to CAR T-Cells and How to Overcome Them
              </a>
            </td>
          <td>
            L. Legato, M. Bisio, Filippo Fasano, Corrado Benevolo Savelli, Carolina Secreto, C. Dellacasa, Barbara Botto, A. Busca, M. Cerrano, R. Freilone, M. Novo
          </td>
          <td>2025-09-11</td>
          <td>Methods and Protocols</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Cancer remains a leading cause of mortality worldwide, with rising incidence and death rates continuing to rise. While conventional treatments such as surgery, radiotherapy, and chemotherapy form the backbone of cancer care, they are often limited by adverse effects, recurrence risk, and incomplete tumor eradication. Tumor immunotherapy—particularly immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cell therapy—has emerged as a transformative approach by activating and reprogramming anti-tumor immune responses. Despite these advances, significant challenges persist, including limited response rates to checkpoint inhibitors, the immunosuppressive nature of the tumor microenvironment (TME), and resistance mechanisms employed by tumor cells. Growing evidence suggests that immune cell senescence is a critical contributor to TME-driven immunosuppression. Senescent immune cells exhibit functional decline, elevated expression of inhibitory immune checkpoint molecules, and increased secretion of pro-inflammatory cytokines, collectively impairing anti-tumor immunity and reducing the efficacy of immunotherapy. This review highlights the role of immune cell senescence in shaping the immunosuppressive TME and driving resistance to immunotherapy. It further discusses emerging therapeutic strategies that combine immunotherapy with senescence-targeting interventions, aiming to provide novel insights into the development of more effective cancer treatment strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/56cdaa455cdfae646c5bce11b54ada6d03f2699c" target='_blank'>
              Senescent immune cells in the tumor microenvironment: emerging insights into cancer immunotherapy resistance
              </a>
            </td>
          <td>
            Duolun Gao, Peiyan Kan, Yanjie He, Siyu Sun, Lei Tang, Fan Yang
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/786ef752b978a035a89ee81980fbcbdfae5e26b6" target='_blank'>
              Platelet-Mediated Suppression of T Cell Function Drives Immune Evasion in Triple Negative Breast Cancer through the P-Selectin / P-Selectin glycoprotein ligand-1 Pathway
              </a>
            </td>
          <td>
            Margaret R. Smith-Oliver, Deepa Gautam, Emily M. Clarke, Grace Petrarca, Megan Sullivan, Giovanni Goggi, M. Spasic, Natalie Kane, Harvey G. Roweth, A. Garrido-Castro, Patricia E. Davenport, Joanna Baginska, Sandra S McAllister, E. Battinelli
          </td>
          <td>2025-09-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="The development of FGFR1-driven stem cell leukemia and lymphoma syndrome (SCLL) in mouse models is accompanied by an increase in highly heterogenous myeloid derived suppressor cells (MDSCs), which promote immune evasion. To dissect this heterogeneity, we used a combination of CyTOF and scRNA-Seq to define the phenotypes and genotypes of these MDSCs. CyTOF demonstrated increased levels of circulating macrophages in the peripheral blood of leukemic mice, and flow cytometry demonstrated that these macrophages were derived from Ly6CHi M-MDSC as well as the Ly6CInt and Ly6CLow monocytic populations. Consistently, scRNA-Seq analysis demonstrated the accumulation of non-classical monocytes (ncMono) during leukemia progression, which also express macrophage markers. These leukemia-induced macrophages show continuous transcriptional reprogramming during leukemia progression, with the upregulation of cellular stress response genes Hspa1a and Hspa1b and inflammation-related gene Nfkbia. Trajectory analysis revealed a transition from classical monocytes (cMono) to ncMono, and potential genes orchestrating this transition process have been identified. Furthermore, T-cell suppression assays demonstrated the immune suppressive abilities of leukemia-induced circulatory macrophages. Targeting these macrophages with the GW2580 CSF1R inhibitor leads to restored immune surveillance and improved survival. Overall, we demonstrate that circulating macrophages are responsible, at least in part, for the immune suppression in SCLL leukemia models, and targeting macrophages in this system improves the survival of leukemic mice.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/90323cdfca5109b7eebd83a2972f944c9a6e8f2d" target='_blank'>
              Genomic Analysis Defines Increased Circulating, Leukemia-Induced Macrophages That Promote Immune Suppression in Mouse Models of FGFR1-Driven Leukemogenesis
              </a>
            </td>
          <td>
            Ting Zhang, A. Matsunaga, Xiao-ming Lu, Hui Fang, Nandini Chatterjee, Ahmad Alimadadi, S. Mori, Xuexiu Fang, Gavin Wang, Huidong Shi, Litao Zhang, Catherine C. Hedrick, Bo Cheng, Tianxiang Hu, J. K. Cowell
          </td>
          <td>2025-09-30</td>
          <td>Cells</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb0d181b971ab9d5141b1475ee18608b8080d802" target='_blank'>
              Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 Tumors
              </a>
            </td>
          <td>
            Md. Iftehimul, Robert H. Newman, Scott H Harrison, Roshonda B. Jones, P. Muganda, Bryan L. Holloman, M. T. Hossain, C. J. Rorie, Misty D. Thomas, Joseph L. Graves, Howard L. Kaufman, Dipongkor Saha
          </td>
          <td>2025-10-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/25cf0de6f70fb418ecf166b4bb716bc0fd141f86" target='_blank'>
              Myeloid Specific Ablation of SHIP1 Boosts ex vivo Expansion and Regulatory Function of Myeloid-Derived Suppressor Cells in Inflammatory Arthritis
              </a>
            </td>
          <td>
            E. So, Moon Jung Choi, Young Eun Lee, Bedia Akosman, Euy-Myoung Jeong, Anthony M. Reginato, Olin D. Liang
          </td>
          <td>2025-10-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Kaposi’s sarcoma (KS) is a highly inflammatory, angiogenic tumor driven by Kaposi’s sarcoma-associated herpesvirus (KSHV), yet the origins of tumor cells and mechanisms of progression remain unclear. Here, we present the first spatial single-cell atlas of KS, profiling 256 samples across patch, plaque, and nodular lesions and normal controls. We identify CD34⁺ progenitor lymphatic endothelial cells (LECs) as the primary targets of KSHV, whose clonal expansion drives tumor growth. KSHV infection induces widespread cellular reprogramming across the tumor microenvironment, including LECs, vascular endothelial cells, fibroblasts, and macrophages, generating hybrid phenotypes that support angiogenesis, inflammation, and immune modulation. KSHV⁺ macrophages are enriched in tumor-proximal niches, further promoting a proangiogenic, immunosuppressive environment. Spatial analysis reveals evolving tumor-associated niches, with a core-to-periphery gradient correlating with infection, immune modulation, and cellular remodeling. We identify disease progression predictive signatures, offering mechanistic insights into KS pathogenesis and potential new therapeutic strategies by reprogramming the tumor microenvironment. Highlights ➣ CD34+ progenitor lymphatic endothelial cells are the primary KSHV target cells, with their clonal expansion driving Kaposi’s sarcoma growth. ➣ KSHV infection reprograms broad cell types into hybrid identities, and drives tumor-specific niche and vascular remodeling, endothelial plasticity, and immune modulation. ➣ KSHV-reprogrammed macrophages drive inflammation, angiogenesis, and immune modulation. ➣ Spatially resolved molecular and cellular signatures predict Kaposi’s sarcoma progression, offering novel therapeutic strategies targeting the tumor microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/835b859927d90c9b0c5454b990e0f2840ed6f867" target='_blank'>
              Spatial Single-Cell Atlas Reveals KSHV-Driven Broad Cellular Reprogramming, Progenitor Expansion, Immune and Vascular Remodeling in Kaposi’s Sarcoma
              </a>
            </td>
          <td>
            Wen Meng, Arun Das, Harsh Sinha, Rana Naous, P. Bracci, Mike McGrath, Yufei Huang, Shou-Jiang Gao
          </td>
          <td>2025-09-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>72</td>
        </tr>

        <tr id="Abstract Background The tolerization of plasmacytoid dendritic cells (pDCs) within the tumor microenvironment facilitates immune evasion, thereby significantly limiting the efficacy of cancer immunotherapy. Metabolic regulators are crucial in determining immune cell fate. However, the specific metabolic modifications influencing tumor-associated pDCs (TA-pDCs) are largely uncharacterized. Methods We isolated TA-pDCs from patients with colon cancer and mouse models for RNA sequencing detection and immunofluorescence staining. Further, in vitro and in vivo models of colon cancer were used to explore the underlying mechanisms of the fatty acid oxidation (FAO) regulatory pathway of TA-pDCs and its immunosuppressive function. Results Peroxisome proliferator-activated receptor gamma pathway promotes FAO in TA-pDCs by upregulating the expression of carnitine palmitoyltransferase-1A (CPT1A). The inhibition of CPT1A significantly reduced the immunosuppressive checkpoint inducible co-stimulator ligand (ICOSL) and increased the levels of the immune-activating protein OX40L and pro-inflammatory cytokines interferon-α and tumor necrosis factor-α. These alterations enhanced CD8+ T-cell functionality and diminished the generation of regulatory T cells, thereby bolstering antitumor immunity. The efficacy of combined immunotherapy using anti-ICOSL and anti-programmed cell death 1-ligand 1 antibodies was markedly improved in murine models of colon cancer. Conclusions These findings elucidate the molecular mechanism of CPT1A-mediated FAO in TA-pDCs and its implications in immune evasion, suggesting a novel therapeutic strategy for colon cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6dd26361bcb4cdeceefec09bd4907a4fee0847a" target='_blank'>
              CPT1A inhibition alleviates plasmacytoid dendritic cell-mediated immune suppression in colon cancer through fatty acid oxidation modulation
              </a>
            </td>
          <td>
            Jing Wu, Shan Zhu, Guoxia Zang, Helei Wang, Ning Yang, Yuan Qiao, Qiuyu Wei, Liyan Wang, Ziyu Ren, Yong-Jun Liu, Jingtao Chen
          </td>
          <td>2025-10-23</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d873cf1a853679b8699fa77326e1c8cf526550ab" target='_blank'>
              Intestinal challenges shape the polarisation of protective dural memory CD4 T cells
              </a>
            </td>
          <td>
            Aaron Fleming, Rafael Di Marco-Barros, David A. Posner, C. Lee, Andrew P. Stewart, Z. Tuong, Karen Neish, Ana Ivis Peñalver, Mia Cabantous, N. Richoz, A. Portet, K. Harcourt, Eleanor Gillman, David Ruano-Gallego, Gad Frankel, David R. Withers, Simon Clare, M. Clatworthy
          </td>
          <td>2025-09-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>59</td>
        </tr>

        <tr id="Inflammatory cytokines, particularly interferon-γ (IFN-γ), are markedly elevated in the peripheral blood of patients with immune checkpoint inhibitor-induced myocarditis (ICI-M). Endomyocardial biopsies from these patients also show GBP-associated inflammasome overexpression. While both factors are implicated in ICI-M pathophysiology, their interplay and cellular targets remain poorly characterized. Our aim was to elucidate how ICI-M-associated cytokines affect the viability and inflammatory responses of endothelial cells (ECs) and cardiomyocytes (CMs) using human induced pluripotent stem cell (hiPSC)-derived models. ECs and CMs were differentiated from the same hiPSC line derived from a healthy donor. Cells were exposed either to IFN-γ alone or to an inflammatory cytokine cocktail (CCL5, GZMB, IL-1β, IL-2, IL-6, IFN-γ, TNF-α). We assessed large-scale transcriptomic changes via microarray and evaluated inflammatory, apoptotic, and cell death pathways at cellular and molecular levels. hiPSC-ECs were highly sensitive to cytokine exposure, displaying significant mortality and marked transcriptomic changes in immunity- and inflammation-related pathways. In contrast, hiPSC-CM showed limited transcriptional changes and reduced susceptibility to cytokine-induced death. In both cell types, cytokine treatment upregulated key components of the inflammasome pathway, including regulators (GBP5, GBP6, P2X7, NLRC5), a core component (AIM2), and the effector GSDMD. Increased GBP5 expression and CASP-1 cleavage mirrored the findings found elsewhere in endomyocardial biopsies from ICI-M patients. This hiPSC-based model reveals a distinct cellular sensitivity to ICI-M-related inflammation, with endothelial cells showing heightened vulnerability. These results reposition endothelial dysfunction, rather than cardiomyocyte injury alone, as a central mechanism in ICI-induced myocarditis. Modulating endothelial inflammasome activation, particularly via AIM2 inhibition, could offer a novel strategy to mitigate cardiac toxicity while preserving antitumor efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b44a86d0d285abf8234f227db3003743d74f4e32" target='_blank'>
              Distinct Inflammatory Responses of hiPSC-Derived Endothelial Cells and Cardiomyocytes to Cytokines Involved in Immune Checkpoint Inhibitor-Associated Myocarditis
              </a>
            </td>
          <td>
            S. Conte, I. Firoaguer, S. Lledo, T. T. Tran, C. El Yazidi, Stéphanie Simoncini, Z. Rebaoui, Claire Guiol, Christophe Chevillard, Régis Guieu, D. Puthier, F. Thuny, J. Cautela, Nathalie Lalevée
          </td>
          <td>2025-09-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Cold tumors, defined by insufficient immune cell infiltration and a highly immunosuppressive tumor microenvironment (TME), exhibit limited responsiveness to conventional immunotherapies. This review systematically summarizes the mechanisms of immune evasion and the therapeutic strategies for cold tumors as revealed by multi-omics technologies. By integrating genomic, transcriptomic, proteomic, metabolomic, and spatial multi-omics data, the review elucidates key immune evasion mechanisms, including activation of the WNT/β-catenin pathway, transforming growth factor-β (TGF-β)–mediated immunosuppression, metabolic reprogramming (e.g., lactate accumulation), and aberrant expression of immune checkpoint molecules. Furthermore, this review proposes multi-dimensional therapeutic strategies, such as targeting immunosuppressive pathways (e.g., programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors combined with TGF-β blockade), reshaping the TME through chemokine-based therapies, oncolytic viruses, and vascular normalization, and metabolic interventions (e.g., inhibition of lactate dehydrogenase A (LDHA) or glutaminase (GLS)). In addition, personalized neoantigen vaccines and engineered cell therapies (e.g., T cell receptor-engineered T (TCR-T) and natural killer (NK) cells) show promising potential. Emerging evidence also highlights the role of epigenetic regulation (e.g., histone deacetylase (HDAC) inhibitors) and N6-Methyladenosine (m6A) RNA modifications in reversing immune evasion. Despite the promising insights offered by multi-omics integration in guiding precision immunotherapy, challenges remain in clinical translation, including data heterogeneity, target-specific toxicity, and limitations in preclinical models. Future efforts should focus on coupling dynamic multi-omics technologies with intelligent therapeutic design to convert cold tumors into immunologically active (“hot”) microenvironments, ultimately facilitating breakthroughs in personalized immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f521c611e55896b93cee504ac14c36afaf25953" target='_blank'>
              Igniting Cold Tumors: Multi-Omics-Driven Strategies to Overcome Immune Evasion and Restore Immune Surveillance
              </a>
            </td>
          <td>
            Xinyao Huang, Renjun Gu, Ziyu Li, Fangyu Wang
          </td>
          <td>2025-09-26</td>
          <td>Oncology Research</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Chronic lymphocytic leukemia (CLL) is associated with immune dysfunction, but how disease-intrinsic mechanisms in treatment-naive patients influence the coordination of adaptive responses to novel antigens remains unclear. Here, we assessed SARS-CoV-2-specific antibody and T cell immunity in 38 treatment-naive CLL patients and 13 healthy controls (HCs) following vaccination. Despite significantly reduced total immunoglobulin levels compared to HCs, 94.7% of CLL patients developed SARS-CoV-2-specific IgG, and 89.5% mounted IgA responses, with serum titers comparable to those of HCs. Virus-specific T cell responses, measured by IFN-γ release following antigen stimulation, were detected in 78.9% of patients. CLL patients had significantly more circulating CD4+ T follicular helper (Tfh) and T follicular regulatory (Tfr) cells than HCs. These expansions correlated with B cell abundance, which, in untreated CLL, predominantly reflects malignant B cells. Notably, Tfh cell frequencies and absolute counts were highest in patients lacking a SARS-CoV-2-specific T cell response, indicating a decoupling between Tfh expansion and functional antiviral immunity. Overall, these findings demonstrate that while SARS-CoV-2-specific immune responses are largely preserved in treatment-naive CLL patients, disease-driven alterations in T cell composition may compromise the coordination and quality of antigen-specific T cell-mediated immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/380a2444f13a61f76a9c9706f853d8210212d10f" target='_blank'>
              Attenuated SARS-CoV-2-Specific T Cell Responses Are Associated with T Follicular Helper Cell Expansion in Treatment-Naive Chronic Lymphocytic Leukemia Patients
              </a>
            </td>
          <td>
            B. Šlisere, R. Kārkliņš, A. Rivkina, Sandra Lejniece, K. Oļeiņika
          </td>
          <td>2025-09-01</td>
          <td>Pathogens</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="INTRODUCTION
Hepatocellular carcinoma (HCC) is a major cause of cancer-related death globally, characterized by an immunosuppressive tumor microenvironment (TME) that impairs immune surveillance. Immunotherapy has emerged as a transformative option; however, durable responses remain limited. The purpose of this review is to synthesize recent advances in HCC immunology, immunotherapy, and the TME.


AREAS COVERED
Literature was identified via PubMed and ClinicalTrials.gov (January 2001-May 2025), focusing on clinical and translational studies. We outline the immunological landscape of HCC, emphasizing the roles of T cells, natural killer cells, macrophages, dendritic cells, myeloid-derived suppressor cells, and regulatory T cells in shaping tumor immunity. TME components include cancer-associated fibroblasts, tumor-associated macrophages, suppressive cytokines, angiogenesis, hypoxia, metabolic reprogramming, and the gut-liver axis. We examine their interactions with immunotherapy, mechanisms of resistance, and combination strategies. Emerging biomarkers - such as tertiary lymphoid structures, PD-L1, tumor mutational burden, gene signatures, and gut microbiota - are reviewed for patient stratification.


EXPERT OPINION
Immunotherapy has reshaped HCC management, but resistance, biomarker limitations, and heterogeneity remain major challenges. Advances will require TME reprogramming, multi-parametric biomarkers, and personalized strategies. Integration with targeted and locoregional approaches may achieve durable responses and move toward precision immuno-oncology, transforming HCC into a manageable or curable disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3f81fb97115d4549912d0ac1a8a271a719cc8ad4" target='_blank'>
              Immunology, immunotherapy, and the tumor microenvironment in hepatocellular carcinoma: a comprehensive review.
              </a>
            </td>
          <td>
            Miho Akabane, Yuki Imaoka, Ghee Rye Lee, T. Pawlik
          </td>
          <td>2025-09-29</td>
          <td>Expert review of clinical immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Abstract Background Mounting evidence shows that myeloid‐derived suppressor cells (MDSCs) reprogramming can significantly enhance the outcomes of immunotherapy. However, the therapeutic potential of targeting MDSCs alone is limited by persistent immunosuppressive cytokines and cellular crosstalk. In our previous study, we found that novel cryo‐thermal therapy (CTT) can drive MDSCs maturation and induce CD4+ T helper type (Th)1‐dominant differentiation, improving long‐term survival in spontaneous high metastatic mouse models. Considering the established roles of Interleukin (IL)‐6 and IL‐17A in non‐small cell lung cancer (NSCLC) progression and immune evasion, we developed a combination strategy integrating cytokine neutralization with CTT (combination therapy) in LLC1 tumor‐bearing mice. Although the combination therapy successfully promoted MDSCs maturation and Th1 differentiation, the underlying mechanistic basis remained unclear. Methods The combination therapy was implemented in LLC1 tumor‐bearing mice. We then observed its impacts on MDSCs maturation and Th1 differentiation and explored the related mechanisms by examining various aspects including the expression of CD40, the reactive oxygen species (ROS)‐nuclear factor‐kappa B (NF‐κB) pathway, and the induction of tumor necrosis factor‐α (TNF‐α). Results It was observed that the combination therapy increased the expression of CD40 on MDSCs through the ROS‐NF‐κB pathway‐dependent TNF‐α induction. This TNF‐α‐mediated CD40 upregulation facilitated Th1 polarization via CD40L engagement on CD4+ T cells. Our results provided the first mechanistic evidence that autocrine TNF‐α production by reprogrammed MDSCs governs CD40 expression following combination therapy. Conclusion Our research elucidated the methods and mechanisms of MDSCs reprogramming and offered a promising therapeutic strategy for patients with NSCLC and other types of cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b5c584eeb86580107a4b77d49be11b90194d483" target='_blank'>
              Reprogrammed MDSCs promote Th1‐dominant antitumour response via CD40 induced by autocrine TNF‐α after combining cryo‐thermal therapy with IL6 and IL17A neutralization
              </a>
            </td>
          <td>
            Yuankai Hao, Shicheng Wang, Junjun Wang, Zelun Zhang, Yichen Yao, Ke-fu Wang, Ping Liu, Lisa X. Xu
          </td>
          <td>2025-10-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Steroid-refractory gut acute graft-versus-host disease (SR-Gut-aGVHD) is the major cause of nonrelapse death after allogeneic hematopoietic cell transplantation. High numbers of donor-type IL-22+ T cells, IL-22–dependent dysbiosis, and loss of antiinflammatory CX3CR1hi mononuclear phagocytes (MNPs) play critical roles in SR-Gut-aGVHD pathogenesis. CEACAM1 on intestinal epithelial cells (IECs) is proposed to regulate bacterial translocation and subsequent immune responses in the intestine. Here, with imaging mass cytometry (IMC), combined scRNA-Seq with ATAC-Seq, and high-dimensional flow cytometry analysis, we show that CEACAM1 expression was enhanced on IECs in murine and human SR-Gut-aGVHD. Ceacam1 deficiency on host IECs effectively prevented SR-Gut-aGVHD in murine models. Ceacam1 deficiency on IECs resulted in (i) higher numbers of IL-22+IL-10+Foxp3+CD4+ peripheral Tregs (pTregs) and lower numbers of conventional IL-22+CD4+ T (Tcon), Th/Tc1, and Th17 cells in the intestine; (ii) higher prevalence of beneficial commensal bacteria that augment colonic pTreg expansion, with lower prevalence of pathogenic bacteria; and (iii) higher numbers of antiinflammatory CD103–CX3CR1hi MNPs that produce indoleamine 2,3-dioxygenase (IDO) and IL-10, with lower numbers of proinflammatory CD103+CX3CR1lo MNPs that produce IL-6. Thus, specifically targeting IEC CEACAM1 represents a promising approach for prevention of SR-Gut-aGVHD.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8a4f7e858458632b7df7483d7853affa9bc70fd6" target='_blank'>
              Intestinal epithelial Ceacam1 deficiency prevents steroid-refractory acute gut graft-versus-host disease
              </a>
            </td>
          <td>
            Qingxiao Song, Moqian Zheng, Qinjian Li, Xiwei Wu, Boxi Lin, T. Kang, H. Qin, Maciej Kujawski, Raju K Pillai, James L. Lin, Ryo Nakamura, John Shively, Paul J Martin, Defu Zeng
          </td>
          <td>2025-09-09</td>
          <td>JCI Insight</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f4351e4631d8211b190a8d6ec360061e187ffa46" target='_blank'>
              Convection-enhanced delivery of dexamethasone in glioma suppresses myeloid inflammation while avoiding systemic toxicities
              </a>
            </td>
          <td>
            Nathaniel W Rolfe, Nicholas B Dadario, Liang Lei, Damian E Teasley, Misha Amini, Peter J Chabot, Nkechime Ifediora, Nathan J Winans, N. Yoh, Anthony Tang, Nadine Khoury, J. Furnari, Corina P Kotidis, Clara H Stucke, Nivia M Urena, Yanping Sun, Pavan S. Upadhyayula, Michael G. Argenziano, Colin P. Sperring, Abby Brand, Ashwin Viswanathan, N. Humala, Peter A. Sims, B. Gill, Peter D Canoll, Jeffrey N. Bruce
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3651c50a8e2062accc65992142e066db9d98b287" target='_blank'>
              TET2 loss impairs MPLA-induced innate immune memory during infection and disrupts hematopoiesis via RIPK1 in mice
              </a>
            </td>
          <td>
            Alyssa N. L. Jarabek, Xenia D. Davis, Mary A. Oliver, Yongchao Wang, Heidi Chen, Julia K. Bohannon, Sandra S. Zinkel
          </td>
          <td>2025-09-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Ovarian cancer represents a typically immune “cold” tumor, where obvious immunosuppression, spatial T-cell exclusion, and cellular dysfunction collectively limit immunotherapy effectiveness. Especially in high-grade serous ovarian carcinoma (HGSOC), the immune low-response state is driven by complex interactions among tumor-associated macrophages (TAMs), suppressive stromal networks, and the T-cell compartment (regulatory T cells, Tregs, and exhausted effector T cells). Emerging multi-omics technologies—particularly single-cell RNA sequencing and spatial transcriptomics—have showed the heterogeneity and spatial immune organization underlying this suppressed state. Here, we integrate these datasets to describe TAM phenotypes and spatial niches, T-cell exhaustion, Tregs accumulation, NK-cell dysfunction, and stromal barriers that enforce exclusion. We then derive phenotype-guided combination strategies to remodel the tumor microenvironment and improve responsiveness to immune checkpoint blockade. This synthesis provides a concise, multi-dimensional framework for precision immunotherapy and for overcoming resistance in immune-low ovarian cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/880f6c405f773eb38fd078c68256074438417fa2" target='_blank'>
              Decoding immune low-response states in ovarian cancer: insights from single-cell and spatial transcriptomics for precision immunotherapy
              </a>
            </td>
          <td>
            Yalan Yan, Jiaan Lu, Huanyu Luo, Zizhang Wang, Ke Xu, Lexin Wang, Qin Wang
          </td>
          <td>2025-09-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Macrophages, the most abundant immune cells in many solid tumors, are no longer viewed solely as accomplices of cancer but as powerful therapeutic allies. This review charts the rapid rise of macrophage-based immunotherapies, from CD47/SIRPα checkpoint blockade and CAR-macrophages to macrophage-drug conjugates (MDCs). We emphasize emerging frontiers - RNA-based reprogramming, epigenetic modulation, small activating RNA and circRNA approaches, and macrophage-derived extracellular vesicles - that are redefining how tumor-associated macrophages can be targeted or harnessed. Distinct from earlier TAM reviews, we integrate outcomes from ongoing and completed clinical trials, highlight therapeutic platforms beyond classical depletion and polarization, and frame macrophages not only as targets but also as delivery vehicles. By spotlighting both innovative strategies and the challenges of moving them into the clinic, we aim to provide a forward-looking guide for researchers and clinicians shaping the next generation of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4428b6586c89846cb3b8b68bdea944ac3933e4e6" target='_blank'>
              Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances
              </a>
            </td>
          <td>
            Jan Brancewicz, P. Kucharzewska
          </td>
          <td>2025-10-02</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8281ef2e327a04cd03020998a1ff0f93c045d012" target='_blank'>
              Differential CD8+ T/NK cell-mediated reduction of HIV-1 replication after combination of ART with TIGIT or KLRG1 blockade in humanized mice
              </a>
            </td>
          <td>
            I. Sánchez-Cerrillo, I. Tsukalov, M. Agudo-Lera, O. Popova, P. Fuentes, J. Alcain, R. Gonzalez, L. García-Fraile, I. de los Santos, M. Lázaro-Díez, D. Perea, J. Grau-Expósito, J. Sevilla-Montero, Vladimir Vrbanac, Alejandro B. Balazs, C. Muñoz-Calleja, M. L. Toribio, F. Sánchez-Madrid, JG Prado, M. Genescà, MJ Buzón, E. Martín-Gayo
          </td>
          <td>2025-09-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Background/Objectives: Colorectal cancer (CRC) remains a major global health challenge and current therapies are not always effective. In addition, certain immune cell populations, such as myeloid-derived suppressor cells (MDSCs), pose a significant barrier to immune-based treatments. Some phytochemicals, particularly compounds derived from Allium spp. like Propyl-Propane Thiosulfonate (PTSO), have shown strong immunomodulatory potential in digestive disorders. This study aims to investigate the capacity of PTSO to modulate immune responses and affect tumor progression in CRC models, in vitro and in vivo, with a focus on the immune cell populations that comprise the tumor microenvironment. Methods: Human peripheral blood mononuclear cells (hPBMCs) were incubated with PTSO (25 μM for 48 h) and characterized by flow cytometry. These cells (1 × 106) were then injected into NOD scid gamma (NSG) immunodeficient mice, which were simultaneously induced to develop a subcutaneous tumor by injection of HCT116 enriched cancer stem cells (CSCs) colonospheres (60,000 cells/mouse). Results: PTSO reduced MDSC populations, specifically, it significantly reduced monocytic (M-MDSCs, Control: 7.27 ± 0.53% vs. PTSO: 4.70 ± 2.39%; p = 0.0458) and polymorphonuclear (PMN-MDSCs, Control: 5.28 ± 0.99% vs. PTSO: 3.41 ± 1.58%; p = 0.0385) MDSCs. In parallel, PTSO increased T cell subpopulations, particularly interferon gamma (IFNG)-producing cytotoxic CD8+ T cells (Control: 9.52 ± 2.06% vs. PTSO: 15.04 ± 5.01%; p = 0.0685). In the humanized tumor xenograft mouse, the administration of PTSO-pretreated hPBMCs led to a significant reduction in tumor size (Control: 1.43 ± 0.82 cm3 vs. PTSO: 0.44 ± 0.35 cm3; p = 0.0068), accompanied by increased infiltration of CD4+ T lymphocytes and Natural Killer (NK) cells and downregulation of immunosuppressive genes. These effects resulted in a reduction in cancer cell proliferation and invasiveness. Conclusions: The dual effect of PTSO on immune cell populations, reducing immunosuppressive myeloid cells and enhancing effector T lymphocyte and NK cell responses, resulted in an anti-tumor effect, highlighting this bioactive compound as a promising adjuvant in CRC immunotherapy and opening avenues for future research combining immunotherapy with PTSO in alternative models to optimize dosing and enhance translational potential.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f1b9d6e925feb9fc117d019b92795dc3113b3db0" target='_blank'>
              Modulation of Human Immune Cells by Propyl-Propane Thiosulfonate (PTSO) Inhibits Colorectal Tumor Progression in a Humanized Mouse Model
              </a>
            </td>
          <td>
            María Jesús Rodríguez-Sojo, Luckman Gbati, José Alberto Molina-Tijeras, A. Ho‐Plagaro, T. Vezza, Laura López-Escánez, C. Griñán-Lisón, J. A. Marchal, A. Baños, María José Rodríguez-Sánchez, Jorge García-García, A. Ruiz-Malagón, Julio Gálvez, M. E. Rodríguez-Cabezas, A. Rodríguez‐Nogales
          </td>
          <td>2025-09-01</td>
          <td>Nutrients</td>
          <td>0</td>
          <td>39</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0838b88efd55ea4313fdb66d64dabeba09d0173a" target='_blank'>
              Impaired IL-10 Receptor Signaling Leads to Inflammation Induced Exhaustion in Hematopoietic Stem Cells
              </a>
            </td>
          <td>
            W. L. Wadley, Helen Huang, H. Lai, Jianhong C Heidmann, Jane Chen, Eli M Soyfer, Kalei Guillermo, Eshika Arora, Lauren Chen, Brianna M Hoover, Angela G Fleischman
          </td>
          <td>2025-10-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Introduction Tumor-associated macrophages (TAMs) promote immunosuppression, hindering immune checkpoint blockade and immunotherapy efficacy. To overcome this, we developed a novel multifunctional nanovaccine based on hepatitis B core virus-like particles (HBc VLP) to synergistically remodel the immunosuppressive tumor microenvironment through integrated TAM reprogramming and B7-H3 checkpoint blockade. Methods The core VLP co-displayed tumor antigen peptide MAGE-A10 and TAM-targeting peptide M2pep via fusion expression. Immunostimulatory CpG oligodeoxynucleotide 1826 (CpG) was encapsulated within VLP. Anti-B7-H3 antibody (αB7-H3) and polyethylene glycol (PEG) were chemically conjugated to the surface for checkpoint blockade and prolonged circulation, forming CpG@VLP-αB7-H3-PEG. Results Structural characterization using transmission electron microscopy and dynamic light scattering confirmed the hollow spherical self-assembly of VLP. Nanovaccines efficiently targeted TAMs in vitro and in vivo. Following CpG encapsulation (5.60 µg/mg), the nanovaccine reprogrammed M2-like TAMs into an M1-like phenotype. This was achieved by elevating the M1/M2 ratios of CD86/CD206 and MHC II/CD206 to 15.50-fold and 3.11-fold, respectively, as determined by flow cytometry. Further conjugation of αB7-H3 (250 µg/mg) significantly enhanced T-cell activation in TAM-T cell co-culture assays. In B16-F10 melanoma-bearing mice, reprogrammed iNOS+ M1-like macrophages triggered robust antitumor immunity, achieving a tumor inhibition rate of 63.47%. These macrophages also function as antigen-presenting cells and increase the proportion of tumor-infiltrating Granzyme B+CD8+ T cells. αB7-H3 conjugation further boosted infiltrating immune cells, M1-like macrophages, activated CD69+CD4+/CD8+ T cells, and cytotoxic T lymphocytes. PEGylation amplified systemic tumor-specific immunity and increased tumor inhibition by 80.12%. Conclusion This HBc VLP-based nanovaccine constitutes a pioneering multifunctional platform designed to overcome TAM-mediated immunosuppression through synergistic integration of three modalities: antigen presentation, TAM phenotype reprogramming, and B7-H3 checkpoint blockade. To the best of our knowledge, this is the first nanovaccine architecture to enable coordinated immunomodulation. Its modular design supports the clinical translation of solid tumors and personalized immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b26fad415e7667975cc7d27803dcdbb589e0756" target='_blank'>
              Multifunctional HBc Virus-Like Particles Reprogram Immunosuppressive Macrophages and Potentiate CD8+ T Cell Responses for Enhanced Cancer Immunotherapy
              </a>
            </td>
          <td>
            Shuntao Liang, Xiaoxuan Yin, Yongjie Chi, Keyue Wang, Li Ma, Zhuo Yang, X. Xue, Shoucheng Wang, K. Zhao, Lianyan Wang, Juan Ma
          </td>
          <td>2025-10-01</td>
          <td>International Journal of Nanomedicine</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Philadelphia-negative myeloproliferative neoplasms (Ph-MPNs) are clonal hematologic malignancies characterized not only by driver mutations such as JAK2V617F, CALR, and MPL but also by a profoundly dysregulated immune microenvironment. Chronic inflammation and immune remodeling sustain malignant hematopoiesis and contribute to disease progression from essential thrombocythemia (ET) and polycythemia vera (PV) to overt myelofibrosis (MF). Pro-inflammatory cytokines and chemokines—including IL-2, IFN-α, IL-23, and TNF-α—drive abnormal T cell polarization, favoring a pathogenic Th17 phenotype. Lymphocyte subset analysis reveals a predominance of exhausted PD-1+ T cells, reflecting impaired immune surveillance. Concurrently, alterations in neutrophil apoptosis lead to persistent inflammation and stromal activation. GRO-α (CXCL1) is elevated in ET but reduced in MF, suggesting a subtype-specific role in disease biology. Fibrosis-promoting factors such as TGF-β and IL-13 mediate bone marrow remodeling and megakaryocyte expansion, while VEGF and other angiogenic factors enhance vascular niche alterations, particularly in PV. These immunopathologic features underscore novel therapeutic vulnerabilities. In addition to JAK inhibition, targeted strategies such as CXCR1/2 antagonists, anti-TGF-β agents, and immune checkpoint inhibitors (PD-1/PD-L1 blockade) may offer disease-modifying potential. Understanding the interplay between cytokine signaling and immune cell dysfunction is crucial for developing precision immunotherapies in MPNs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e18c28287e8a33b68b77cc41389b1e6354349c14" target='_blank'>
              Cytokine Landscapes, Immune Dysregulation, and Treatment Perspectives in Philadelphia-Negative Myeloproliferative Neoplasms: A Narrative Review
              </a>
            </td>
          <td>
            Samuel-Bogdan Todor, R. Mihaila
          </td>
          <td>2025-09-01</td>
          <td>Journal of Clinical Medicine</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e9548413eead4ef27aaf74c21a5d1666743368c3" target='_blank'>
              Metabolic Immunosuppression Mediated by Proliferative CD168+ TAMs in Colon Cancer
              </a>
            </td>
          <td>
            Zhihao Wei, Yan Dong, Ruiyang Zi, Taorui Liu, Yahan Fan, Rui Zhang, Yongning Shang, Haoran Jiang, Xiang Zhao, Jianjun Li
          </td>
          <td>2025-09-07</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Objectives Regulatory T (Treg) cells may become dysregulated in checkpoint blockade-related inflammatory arthritis (CBIA), and we aimed to profile phenotypes and cytokine-secreting patterns of Tregs in CBIA. Methods Using a 77-protein panel, we here profiled and compared single-cell membrane proteomics of Treg cells in synovial fluid (SF) in 15 patients with active CBIA onset, 12 patients with active rheumatoid arthritis (RA), and 9 CBI-treated cancer patients with non-autoimmune inflammatory knee swelling. Microbead-sorted Treg subsets from CBIA patients underwent 32-cytokine panel secretome analysis. Peripheral blood (PB) Tregs from seven CBIA and six RA patients were similarly analyzed. Findings were correlated with the modified Clinical Disease Activity Index (mCDAI) in CBIA patients. Results Unsupervised clustering revealed two atypical immune-activating Treg cell clusters common to both CBIA and RA patients, in which an immunoactivating (featuring ICOS+CD134+CD137+) cluster was distinct to CBIA patients. This immunoactivating cluster was found to have a positive correlation to the mCDAI in CBIA patients. In single-cell secreting proteomics of SF-derived Treg cells in CBIA patients, we found that clusters distinct to the immunoactivating cell group featured inflammatory cytokine secretion of mainly MCP1 and MCP4, which was validated by peripheral CBIA secreting proteomics (vs. RA, which preferentially secreted CCL11/CXCL10). Other non-immunoactivating cells mainly secreted immune-modulatory cytokines of IL-10, IL-4, and TGFB1. Consistently, the MCP1/MCP4+ polysecreting cluster proportion was also positively correlated with mCDAI. Conclusion At the single-cell proteomic level, an atypical, MCP1/MCP4+ polysecreting immunoactivating Treg cell type is found to have a strong relation to clinical disease activity of CBIA.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/07f1e4acab7e56b19f4a6ab626628e1f6644e97f" target='_blank'>
              Phenotypes of synovial fluid Treg cells in checkpoint blockade-related inflammatory arthritis
              </a>
            </td>
          <td>
            Heyu He, Ning Zhou, Kaidi Wu, Junhong Lin, Shaowei Zhou, Yuntao Gu, Xinjia Wang, Weidong Wang, Lichuan Mo, Chuanzhu Lv
          </td>
          <td>2025-09-10</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Immunotherapy is currently effective in less than half of patients with solid tumors, and most responders develop secondary progression. High infiltration of the tumor microenvironment (TME) with CD8+ cytotoxic T cells (CTLs) and low infiltration with regulatory T cells (Treg) predicts the patients’ responses to immunotherapy and long-term outcomes. To identify the mechanisms regulating long-term stability of CTL infiltration, we analyzed the impact of CTL-produced cytokines on the TME by co-culturing patient-isolated ascites cells with activated T cells. Unexpectedly, we observed that activated CTLs selectively induce cytotoxic T cell-attracting chemokines but not chemokines that attract T regulatory cells in ovarian cancer TME and tumor-associated myeloid cells, resulting in recruitment of additional CTLs without Tregs. This selectivity resulted from the unique dependence of CCL22 induction on both canonical and alternative NF-κB and the suppression of alternative NF-κB signaling by T cell-released IFNγ. Our data demonstrate that T cell-produced IFNγ suppresses alternative NF-κB signaling in TME-associated myeloid cells, allowing for the induction of CTL-attracting chemokines with the concomitant suppression of Treg-attracting CCL22. These novel functions of IFNγ and activated T cells in regulating the balance between canonical and alternative NF-κB signaling in myeloid cells provide new opportunities to enhance and stabilize the selective CTL influx in the TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5a5a14adab24415a821ab9194596f9d27a53e37" target='_blank'>
              IFNγ-mediated suppression of alternative NF-κB in tumor-resident myeloid cells promotes selective recruitment of cytotoxic but not regulatory T cells
              </a>
            </td>
          <td>
            Adam Brinkman, Ravikumar Muthuswamy, Bowen Dong, Robert P Edwards, Pawel Kalinski
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e655b3f34a47917eb0c1eab5cc8dbd65bd366140" target='_blank'>
              P2RY2 is a purinergic immune checkpoint linking extracellular ATP to immune evasion and adaptive resistance to immunotherapy
              </a>
            </td>
          <td>
            Zhaoqing Hu, Hitoshi Matsuo, Shangce Du, Cecilia Berzain Battioni, L. Jassowicz, Rafael Carretero, Melanie Sator-Schmitt, Xiyue Zhao, Beiping Miao, Cansu Eris, Helena Engel, Mohamed A.A. Mahmoud, Elke Laport, Yanling Xiao, Ilse Hofmann, Christel Herold-Mende, Chong Sun
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="It has become evident from decades of clinical trials that multimodal therapeutic approaches with focus on cell intrinsic and microenvironmental cues are needed to improve understanding and treat the rare, inoperable, and ultimately fatal diffuse intrinsic pontine glioma (DIPG), now categorized as a diffuse midline glioma. In this study we report the development and characterization of an in vitro system utilizing 3D Tumor Tissue Analogs (TTA), designed to replicate the intricate DIPG microenvironment. The innate ability of fluorescently labeled human brain endothelial cells, microglia, and patient-derived DIPG cell lines to self-assemble has been exploited to generate multicellular 3D TTAs that mimic tissue-like microstructures, enabling an in- depth exploration of the spatio-temporal dynamics between neoplastic and stromal cells. The 3D-TTA model recapitulates clinical patterns of DIPG growth, evidenced by resistance to chemotherapy, HDAC and proteasome inhibitors, as well as sensitization to the antibody-activated innate immune microenvironment including complement proteins and surrounding microglia. Multimodal fluorescence imaging platforms integrated with high-throughput omics revealed that alterations in tumor cell motility and growth in the 3D-TTA model compared to tumor cell only spheroids correlated with specific transcriptomic and proteomic changes. STAT3, ITGA5, LGALS1, SOD2, MVP, and CLIC1, associated with microenvironment signaling, DNA replication, and immune regulation, were identified as potential novel targets in the 3D model. The results indicate that the 3D TTA platform developed here represents a powerful tool for preclinical studies, paving the way for identification/validation of tissue specific biomarkers and novel drug targets, thus advancing disease management strategies for DIPG in children.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47b07b858c6fd1cb8139cba6229ad20ebbdfab9d" target='_blank'>
              Multicellular tumor-stromal interactions recapitulate aspects of therapeutic response and human oncogenic signaling in a 3D disease model for H3K27M-altered DIPG
              </a>
            </td>
          <td>
            Meenakshi Upreti, Astgik Petrosyan, M. Thornton, A. Hovsepyan, G. E. Fernandez, David S. Koos, S. Byrum, Samuel G Mackintosh, Jacob K Al-Husseini, Tania Porras, Joseph Ha, A. Tackett, Miqin Zhang, M. Johal, Anat Erdreich-Epstein, Susan Durham, Mark D Krieger, Ashley S Margol, Brendan H. Grubbs, T. Chambers, S. Asgharzadeh, Rex A. Moats, Peter A Chiarelli
          </td>
          <td>2025-09-06</td>
          <td>Oncogene</td>
          <td>0</td>
          <td>48</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/71a064ec4f382624ca451589f6f8e5a61d23490b" target='_blank'>
              Tissue localization of natural killer cells dictates surveillance of lung metastasis.
              </a>
            </td>
          <td>
            Marijne Vermeer, Colin Sparano, Nicolò Coianiz, M. Mayoux, Gioana Litscher, André Fonseca, Stanislav Dergun, Caroline Mussak, Lukas Rindlisbacher, Philipp Häne, Laura Ducimetière, Tobias Wertheimer, Burkard Becher, Lothar C. Dieterich, Sònia Tugues
          </td>
          <td>2025-10-27</td>
          <td>Nature communications</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Success of cancer immunotherapy (CIT) is intricately influenced by the tumor microenvironment (TME), a complex ecosystem that encompasses immune cells, stromal elements, and extracellular components. Despite the clinical breakthroughs of immune-checkpoint inhibitors (ICIs), adoptive cell therapies, cancer vaccines, and other immunotherapeutic interventions, many patients fail to respond and eventually die. Emerging evidence points to cancer stem cells (CSCs) as critical drivers of immune evasion, therapy-resistance, and tumor relapse. CSCs modulate the TME by secreting immune-suppressive factors, recruiting regulatory immune cells, and inducing phenotype-switching of anti-tumor TME subsets, thereby creating a protective niche that hinders immune surveillance. Conversely, the TME protects CSCs through hypoxia, altered metabolism, and immuno-suppressive cell populations. This bi-directional crosstalk supports tumor progression and provides resistance to immunotherapeutic strategies mainly by: (i) escaping immune-recognition and inhibiting active T cells via high immune-checkpoint molecule expression, (ii) creating immunosuppressive pro-tumor environment, and (iii) evading immune-mediated apoptosis of CSCs along with therapy-induced enrichment of their pool. Targeting CSCs in concert with reprogramming the TME via CSC-directed agents, metabolic modulators, or combinatorial immunotherapies, therefore, offers a promising avenue to overcome immunotherapy-resistance and achieve durable clinical responses. This review discusses the deeper mechanistic understanding of CSC-TME interactions, in light of designing next-generation immunotherapies with broader efficacy across diverse tumor types.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aca3d3e4dee0506258a76ae1d6a57f98c14366a7" target='_blank'>
              Cancer Stem Cells Decide the Fate of Cancer Immunotherapy by Remodeling Tumor Microenvironment
              </a>
            </td>
          <td>
            S. Chakraborty, Udit Basak, S. Mukherjee, Sumoyee Mukherjee, Tanya Das
          </td>
          <td>2025-09-01</td>
          <td>Cancer Control: Journal of the Moffitt Cancer Center</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/01d23f6e4d0fadd94bb32dc65cae50f988969ac5" target='_blank'>
              Re-shaping the immune response to influenza vaccination in a host with immune memory from influenza
              </a>
            </td>
          <td>
            Chantelle L. White, Lara Mengu, Siva K. Gandhapudi, K. Richards, A. J. Sant
          </td>
          <td>2025-10-01</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9df59581d16bbc7c53120355c1f9a6d0a14f9300" target='_blank'>
              The Role of Inflammation in CMML Pathobiology and Progression.
              </a>
            </td>
          <td>
            Niraj Neupane, E. Padron
          </td>
          <td>2025-10-09</td>
          <td>Current hematologic malignancy reports</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide, frequently arising in the setting of chronic liver inflammation and cirrhosis. Immune checkpoint inhibitors have transformed the treatment landscape for HCC, although response rates remain variable with only a subset of patients deriving durable benefit. The present review provides a comprehensive overview of immune checkpoint biology in HCC, examining their mechanisms of action and their roles within the tumor microenvironment. The present review discusses not only well-established checkpoints (programmed cell death-1 and cytotoxic T-lymphocyte antigen-4) but also emerging inhibitory targets (lymphocyte-activation gene 3, T-cell immunoglobulin and mucin-domain 3, T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains, B and T lymphocyte attenuator, V-domain immunoglobulin suppressor of T-cell activation, B7 homolog 3, B7 homolog 4 and CD47) increasingly recognized in HCC immunology. The clinical implications of checkpoint expression patterns are explored, including their prognostic significance and potential as predictive biomarkers. Current therapeutic strategies are reviewed, from monotherapy approaches to combination regimens involving dual checkpoint blockade and anti-angiogenic agents. Despite recent advances, significant challenges persist, including primary and acquired resistance, the immunosuppressive liver microenvironment and safety concerns in patients with underlying liver dysfunction. Future directions focusing on novel checkpoint targets, innovative combination approaches, personalized cellular therapies and biomarker-driven treatment selection offer potential avenues to improve outcomes for patients with HCC in the future.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8b763ec8ba5df4dabd80400d1c9e55867e7483d0" target='_blank'>
              Immune checkpoint biology in hepatocellular carcinoma (Review)
              </a>
            </td>
          <td>
            Ching-Hua Hsieh, Pei-Chin Chuang
          </td>
          <td>2025-10-07</td>
          <td>Oncology Letters</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Objectives Preclinical models that accurately recapitulate the human immune response, particularly within the tumor microenvironment (TME), are needed for the translational and predictive testing of new therapies. Here, we examine whether the genO-BRGSF-HIS model—characterized by robust reconstitution of both human lymphoid and myeloid cells following engraftment with CD34+ cord blood cells—could be a translatable mouse model for human tumor biology and a relevant platform for evaluating novel immunotherapies. Methods genO-BRGSF mice were reconstituted with human CD34+ cord blood cells (genO-BRGSF-HIS) and treated with exogenous human Flt3 ligand (hFlt3L). Myeloid and dendritic cell functionality was analyzed following treatment with different compounds (TLR agonists, TREM1 agonist, STING agonist, or T-cell engagers) and following the implantation of different tumor cell lines (MDA-MB-231, A549, HPAF-II). Results We show that myeloid, dendritic and lymphoid cells (including NK and γδ T cells) are functional and recruited into the TME in genO-BRGSF-HIS mice implanted with different tumor cell lines, and that different immune cell populations are activated and get polarized within the TME. The composition of the TME is dependent on tumor type and tumor burden, demonstrating plasticity in the crosstalk between the human immune system and the tumor cells. Furthermore, we observed polarization of the cells recruited to the TME, as well as a wide diversity of recruited cell populations, suggesting that this model reproduces human physiopathology in the context of cancer. Based on the recruitment of the different cell populations according to tumor type, we also demonstrate that this model can be used for testing new therapies targeting lymphoid cells, such as T-cell engagers. Conclusions genO-BRGSF-HIS mice do not exhibit adverse effects associated with the development of human lymphoid and myeloid cells following CD34+ cord blood cell reconstitution, and their extended lifespan allows for longer experimental study windows. Overall, we show that this model develops functional myeloid and lymphoid cells which are recruited to the TME, making it a valuable tool for testing new immunotherapies that modulate the interaction between the tumor and the immune system.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1662e798082e5fa1dd090b48ee63a699548c1383" target='_blank'>
              Tumor-dependent myeloid and lymphoid cell recruitment in genO-BRGSF-HIS mice: a novel tool for evaluating immunotherapies
              </a>
            </td>
          <td>
            Gaelle H. Martin, Siham Hedir, Florent Creusat, A. Gonon, Amélie Marguier, P. Martin-Jeantet, L. Nouveau, L. Cons, Florence Renart-depontieu, V. Moine, Marc Derive, Yacine Chérifi, Margarida T Grilo Ruivo, F. Sônego, Kader Thiam
          </td>
          <td>2025-09-17</td>
          <td>Frontiers in Immunology</td>
          <td>1</td>
          <td>19</td>
        </tr>

        <tr id="Abstract Background Despite comparable survival benefit has been obtained, the drug resistance remarkably reduced lenvatinib clinical efficacy. Here, we aimed to identify the potential mechanism by which cysteine and glycine-rich protein 2 (CSRP2) regulates the development of hepatocellular carcinoma (HCC) and participates in the resistance to lenvatinib. Methods We harnessed RNA sequencing, multiplex immunofluorescence staining, and hydrodynamic tail vein (HTV) injection HCC model to systematically explore the function of CSRP2 in HCC progression. To precisely delineate how immunosuppressive macrophages, influenced by CSRP2-regulated C-C motif chemokine ligand 28 (CCL28) signaling, respond to lenvatinib-induced cytotoxicity, we established an in vitro co-culture system and conducted functional cytotoxicity assays. Results Using RNA sequencing, multiplex immunofluorescence staining and HTV injection HCC mouse model, we identified CSRP2 as one of the most significantly upregulated genes in HCC tissues. CSRP2 overexpression drives anti-lenvatinib resistance by inducing high levels of tumor-associated macrophages (TAMs) infiltration and reshaping an immunosuppressive microenvironment. Then flow cytometry, mass spectrometry and chromatin immunoprecipitation were conducted to clarify the underlying mechanism of CSRP2. We showed CSRP2 promotes phosphorylation of activating transcription factor 2 (ATF2) at Thr69/71, leading to the transcriptional activation of CCL28 expression. HCC-derived CCL28 recruits TAMs to drive immunosuppression and anti-lenvatinib tolerance. BI6901, a potent and selective CCR10 antagonist, blocked TAMs recruitment and enhanced T-cell activation. Combining CCR10 inhibition improved the therapeutic benefit of anti-lenvatinib in HCC. Conclusions These results illustrate that CSRP2 regulates the tumor microenvironment to promote HCC growth and drive lenvatinib tolerance via the CSRP2/ATF2/CCL28 axis. Targeting this pathway could synergize with lenvatinib to treat HCC more effectively.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/646010ea35e5f944e326bc9fb7b7f5f1bbb8f30b" target='_blank'>
              Targeting immunosuppressive macrophages by CSRP2-regulated CCL28 signaling sensitizes hepatocellular carcinoma to lenvatinib
              </a>
            </td>
          <td>
            Changzhou Chen, Sheng Su, Pengcheng Wang, Xinming Ye, Songyang Yu, Yu Gong, Zehuan Li, Jia Li, Zhiqiang Hu, Xiaowu Huang
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Autoimmune diseases are driven by a breach of self-tolerance, leading to chronic inflammation and organ damage. While the Th1 and Th17 paradigms have long dominated our understanding of T-cell-mediated pathology, a distinct subset of CD4+ T helper cells defined by the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) has emerged as a central and non-redundant pathogenic driver. These GM-CSF-producing Th cells orchestrate autoimmune pathology across a spectrum of diseases, including multiple sclerosis, rheumatoid arthritis, and type 1 diabetes, among others. Mechanistically, they act as critical amplifiers of inflammation by activating and recruiting myeloid cells, which in turn mediate tissue destruction. Furthermore, they establish vicious feedback loops, enhancing their own differentiation and promoting the function of other effector T cells. Despite their established importance, significant heterogeneity and plasticity exist in their phenotype and regulatory networks, with context-dependent variations across different diseases and species. This review synthesizes our current understanding of these pivotal cells, critically evaluating their classification, molecular identity, and the signaling pathways governing their differentiation. We further dissect their specific roles in major autoimmune diseases and provide a forward-looking perspective on their immense translational potential, from novel therapeutic strategies targeting the GM-CSF axis to their use as biomarkers for patient stratification and monitoring.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a4e6daed52915c02f33af0850503172340f333d9" target='_blank'>
              GM-CSF+ Th: a central player in autoimmunity
              </a>
            </td>
          <td>
            Sha-Sha Fan, Xuan Xu, Yu-Bin Luo, Xiang-Yu Meng, Yi Liu
          </td>
          <td>2025-09-12</td>
          <td>Theranostics</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/745f967a05c41eac9e9afeb28f2af2215f527b3c" target='_blank'>
              CD155 regulates tumor growth and immune evasion in diffuse midline glioma
              </a>
            </td>
          <td>
            Theophilos Tzaridis, Ester Calvo Fernandez, Tanja Eisemann, Augusto Faria Andrade, C. A. de Biagi-Junior, Jennifer L. Hope, Oren J. Becher, Nada Jabado, Jon D. Larson, Suzanne J. Baker, Andrea Califano, Anindya Bagchi, M. Filbin, Linda M. Bradley, Peter D. Adams, Jovana Pavisic, Robert J Wechsler-Reya
          </td>
          <td>2025-09-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Chimeric antigen receptor T cell (CAR-T) is the main salvage therapy for relapsed or refractory large B-cell lymphoma (r/r LBCL). However, over 50% of patients relapse after CAR-T therapy. In this work, we transduced the CAR gene into hematopoietic stem cells (HSCs) using a lentiviral vector. Chimeric antigen receptor-modified HSC (CAR-HSCs) were transplanted into mice after lethal irradiation. CAR gene transduction did not compromise the ability of HSCs to expand, self-renew, or reconstitute. CAR was expressed on T cells, natural killer cells, B cells, monocytes, and neutrophils in the peripheral blood. CAR-HSCs transplantation significantly reduced CD19+ tumor burden and prolonged the survival of mice with preclinical tumor without severe toxicity. CAR-HSCs also differentiated into different CAR-expressing immune cells that reshaped the tumor microenvironment by increasing the proportion of antitumor cells (like CD8+ T cells) and the antitumor response, and by decreasing immunosuppressive cells, such as tumor-associated macrophage subtype 2. This study demonstrated a preclinical proof-of-principle for CAR-HSCs therapy in r/r LBCL, suggesting an opportunity for its clinical translation. Supplementary Information The online version contains supplementary material available at 10.1186/s40164-025-00715-7.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/699a2afcf60d13e0d7c490646a6df52053b04045" target='_blank'>
              Chimeric antigen receptor modified hematopoietic stem cells (CAR-HSCs) arm all immune forces for anti-tumor in mice
              </a>
            </td>
          <td>
            Tao Wang, Ping Liu, Dongliang Zhang, Zhiqiang Song, Mingyang Yu, D. Feng, Xuejun Yu, Na Liu, Gusheng Tang, Jianmin Yang
          </td>
          <td>2025-10-22</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="B cell maturation antigen (BCMA) has emerged as a prominent immunotherapeutic target in multiple myeloma (MM) due to its restricted expression on MM cells, plasma cells and mature B cells, with minimal presence in other normal tissues. In this study, we demonstrate through RNA sequencing and flow cytometry analyses of acute myeloid leukemia (AML) cell lines and primary patient samples that BCMA is also a relevant AML-associated antigen. Its robust surface expression on AML cells positions it as a promising candidate for targeted immunotherapy. Functionally, our findings indicate that BCMA in AML operates similarly to its role in MM – engaging the NF-kB pathway upon ligand binding, thereby activating gene expression programs that support leukemia cell survival and proliferation. We assessed several BCMA-targeted immunotherapeutic strategies, including bispecific T-cell engagers (TCE) and chimeric antigen receptor (CAR) transduced T-cells, NK-cells, and macrophages. We found that TCE treatment and BCMA CAR engineering markedly improved effector cell mediated cytotoxicity against AML cells, underscoring BCMA’s potential as a viable therapeutic target in AML. Furthermore, BCMA- directed TCE therapy significantly augmented the anti-leukemic activity of adoptively transferred CD8+ T-cells in a human AML xenograft model. Taken together, these findings support BCMA as a novel immunotherapeutic target in AML. Leveraging existing BCMA-directed treatments developed for MM could enable rapid clinical translation and broaden immunotherapy options for patients with AML. Supplementary Information The online version contains supplementary material available at 10.1186/s13045-025-01741-y.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/436fa158d1ac2800e0090f3db5638326935534d4" target='_blank'>
              B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia
              </a>
            </td>
          <td>
            Ashley Varkey, Manpreet Bariana, Mark Batistick, John Church, Elena Cassella, Shaina A. Anuncio, Shabnam Samimi, Alexander J Vallone, Zephyr Hameem, Sarvarinder K. Gill, James McCloskey, Yiming Chen, Ming Tan, M. Albitar, Benjamin Tycko, Kar F Chow, Giuditta Mantile-Selvaggi, David S Siegel, Johannes L Zakrzewski
          </td>
          <td>2025-10-24</td>
          <td>Journal of Hematology & Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Background By examining the B-cell receptor (BCR) repertoire of metastatic melanoma (MM) patients with favorable treatment outcomes, it is now possible to identify unique patterns of immune responses, with the potential of discovering novel antitumor antibodies. Methods Here, we isolated CD27-positive circulating memory B cells from non responders, partial responders, and complete responders MM patients to first-line therapy with anti-PD-1 immune checkpoint inhibitor (ICI) nivolumab, to perform a BCR repertoire sequencing analysis. We looked for complementarity-determining region 3 (CDR3) sequences that were enriched (de novo formed) following ICI treatment. Fully-human immunoglobulins were then produced in Expi293F™ cells using CDR3-sequencing information and tested for specificity and sensitivity on different MM cell lines and patient-derived xenograft cells by flow cytometry and by immunohistochemistry on human tissue microarrays. Results As a result of immunotherapy stimulation in responder patients, we observed that some CDR3 clonotypes have emerged de novo. Among the nine candidate antibodies we assessed, two antibodies exhibited encouraging tumor-targeting properties, although they also showed a degree of cross-reactivity with normal skin and melanocytes. Conclusions Although our study is based on a limited number of individuals, our observations indicate that it may be possible to further investigate the human response to immunotherapy for the identification of rare mature B clonotypes targeting plasma membrane antigens on tumor cells. These preliminary findings could contribute to the future development of fully human-compatible immunotherapies, pending additional validation and in vivo studies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fb882d4a17f01ac5d97be071afdb716cc4bce647" target='_blank'>
              Circulating memory B-cell receptor repertoire analysis identifies novel candidate antibodies against metastatic melanoma in immunotherapy-responsive patients
              </a>
            </td>
          <td>
            F. Nicolini, Anna Gaimari, Luciana Mazzotti, Anna De Lucia, Miriana Ghirelli, V. Ancarani, Patricia Borges de Souza, Matteo Zurlo, Luca Gazzola, Chiara Magnoni, Simona Capobianco, D. Angeli, S. Bravaccini, Claudio Cerchione, M. Guidoboni, Luisa Lanfrancone, F. Marocchi, R. Maltoni, M. Tumedei, Francesco Limarzi, Luigi Pasini, L. Ridolfi, Massimiliano Mazza
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e8782e43d5a359ec11f1397979fbb249cbe9fbe7" target='_blank'>
              Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response
              </a>
            </td>
          <td>
            Alexandre Marraffa, C. Berrevoets, Margherita Mosiello, R. Wijers, Daphne Roelofs, Mandy van Brakel, Kim Kroese, Marlies J. W. Peeters, Wim Dik, A. Kunert, Rachel Judith Mary Abbott, Dora Hammerl, C. Schliehe, R. Debets
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="T cell-based therapies, involving ex vivo expansion of patients’ T lymphocytes, hold significant promise for chemotherapy resistant cases of breast cancer (BC), although their effectiveness remains challenging. Building on our previous findings that the expression of the antigen presenting molecule, HLA-DR, is crucial on tumor-infiltrating cytotoxic T lymphocytes (CTLs) for a favorable response to neoadjuvant chemotherapy, we further investigated the role of HLA-DR-expressing CTLs in anti-tumor responses and evaluated strategies to amplify these cells. Through in vitro and in vivo experiments, we demonstrated that HLA-DR expression on CTLs is important for effective tumor cell elimination. Notably, blocking HLA-DR or depleting CD4+ T cells impaired CTLs activation, suggesting a critical role for antigen presentation by CTLs to CD4+ T cells through HLA-DR in promoting robust anti-tumor responses. Based on these findings we optimized an ex vivo stimulation protocol that increases the proportion of HLA-DR+CTLs with improved cytotoxicity, prioritizing cell quality over yield. Moreover, we showed that adding anti-PD-1 to the stimulation, further upregulated HLA-DR expression, and intensified CTLs’ cytotoxic ability. This aligns with our in silico analysis suggesting a potential regulatory link between PD-1 and HLA-DR via non-coding RNAs. Overall, our findings open new avenues for advancing T cell-based therapies and improve the outcomes of chemotherapy-resistant-BC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8306ef56b938be304f4192ecb25cae36b9f4d781" target='_blank'>
              HLA-DR expression in cytotoxic T lymphocytes: a key to boost the therapeutic potential of T cell-based strategies for breast cancer
              </a>
            </td>
          <td>
            R. Salvador, B. F. Correia, D. Grosa, Telma Martins, Suelen Cristina, Soares Baal, D. P. Saraiva, So ﬁ a Cristo ´ vão-Ferreira, Isabel Lopes Pereira, Rebelo de Almeida, Rita Fior, A. Jacinto, C. Mathias, S. Braga, M. Cabral, Jacob T. Jackson, Wenda Zhong, Peiwen Ma, BF Correia, DP Saraiva, Cristo ´ vão-Ferreira, IL Pereira, M. Cabral
          </td>
          <td>2025-09-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Exosomes, nanoscale extracellular vesicles secreted by various cell types, play pivotal roles in intercellular communication. In cancer, tumor-derived exosomes—referred to as cancer-derived exosomes (CDEs)—have emerged as critical regulators of immune evasion, tumor progression, and therapy resistance within the tumor microenvironment (TME). CDEs modulate immune cell function through the transfer of immunosuppressive proteins, cytokines, and non-coding RNAs, ultimately reprogramming immune surveillance mechanisms. This review provides an in-depth analysis of how CDEs influence major immune cell subsets—including T cells, B cells, NK cells, dendritic cells, macrophages, and myeloid-derived suppressor cells—thereby establishing an immunosuppressive TME. We also explore the potential of immune cell-derived exosomes (IDEs) as emerging immunotherapeutic tools capable of counteracting the suppressive effects of CDEs. Furthermore, we highlight exosome engineering strategies aimed at improving therapeutic cargo delivery, tumor targeting, and antitumor immune activation. Finally, we discuss how exosome profiling offers promise in liquid biopsy diagnostics and how integration with 3D tumor models and advanced bioengineering can accelerate the clinical translation of exosome-based cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eae1e39741f5db67d36338284089286232d39875" target='_blank'>
              Cancer-derived exosomes: mediators of immune crosstalk and emerging targets for immunotherapy
              </a>
            </td>
          <td>
            Ridwan Mahamed, Bernice Monchusi, Clement Penny, S. Mirza
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Metastatic liver cancer (MLC) remains a leading cause of cancer-related mortality due to the liver’s unique immunotolerant microenvironment and high vascularization. Key mechanisms involve KC-mediated fibronectin deposition, neutrophil extracellular traps (NETs), and MDSC-driven T-cell exhaustion. Clinically, therapeutic strategies targeting the tumor microenvironment (TME) such as CSF1R inhibition, CCR2/CCR5 blockade, and CD40 agonism show promise in preclinical and early-phase trials, especially when combined with immunotherapy. However, challenges remain in overcoming systemic immunosuppression. This review summarizes the dual roles of hepatic immune cells including Kupffer cells (KCs), neutrophils, and myeloid-derived suppressor cells (MDSCs) in either suppressing or promoting metastatic colonization. We elucidate how the liver’s immunological balance, governed by innate and adaptive responses, shifts toward immunosuppression during metastasis, fostering a pro-tumor niche. This synthesis of immunological insights underscores the potential of TME-modulating therapies to improve outcomes in MLC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/106592c4224525a57d0ce8f76cd85d021982d4ff" target='_blank'>
              Immune microenvironment regulation and clinical immunotherapy strategies of metastatic liver cancer
              </a>
            </td>
          <td>
            Dan Liu, Mingzhu Li, Ying Liang, Fangbiao Xu, Runtian Li, Yang Sun
          </td>
          <td>2025-09-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="The tumor microenvironment in breast cancer is typically immunosuppressive. Combined neoadjuvant chemotherapy and immunotherapy is the standard of care for high-risk, triple-negative breast cancer patients, but it is not routinely applied to other breast cancer subtypes. Somatic mutation of STK11 (serine/threonine kinase 11), a tumor suppressor, occurs in the MSK-IMPACT platform in 1.9% of 3116 breast cases. A potential link between inactivation of STK11 and immune response regulation has been suggested in breast cancer, but the impact of STK11 suppression on tumor–immune interactions remains under investigation. In this study, we established Stk11-knockout (Stk11-KO) mouse breast cancer cell lines, performed RNA sequencing and cytokine array analysis to assess alterations in gene expression and cytokine profiles. Our results revealed significant enrichment of several immune-related pathways and a marked increase in C-X-C motif chemokine ligand 1 (Cxcl1) expression in response to Stk11 knockout. Moreover, analysis of breast cancer patient samples showed an inverse association between the plasma CXCL1 levels and STK11 expression. To evaluate the in vivo effects of STK11 loss, we established an orthotopic breast cancer model in immunocompetent female mice. Tumors derived from Stk11-KO mouse breast cancer cells demonstrated greater tumorigenicity. In addition, mice-bearing Stk11-KO tumors exhibited elevated levels of circulating polymorphonuclear myeloid-derived suppressive cells. In summary, STK11 suppression enhances immune-related pathways and promotes Cxcl1 expression, correlating with the expansion of immunosuppressive MDSC populations. Our findings suggest that targeting STK11-associated immunosuppressive mechanisms may provide a novel therapeutic option for STK11-deficient breast cancer patients. Supplementary Information The online version contains supplementary material available at 10.1007/s00262-025-04189-8.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c31d86f908d14d37e2803389cd1c9e71bee4f15b" target='_blank'>
              Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer
              </a>
            </td>
          <td>
            Tzu-Hui Wei, Chi-Che Hsieh, Zhu-Jun Loh, Wei-Pang Chung, Kuo-Ting Lee, Yi-Ling Chen, Hui-Ping Hsu, Che-Hung Shen
          </td>
          <td>2025-10-06</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Sjögren’s disease (SjD) targets the salivary and lacrimal glands and is characterized by autoantibody production and glandular lymphocytic infiltrate with ectopic germinal centers (EGCs). The chemokine CCL25 recruits CCR9+ CD4+ T cells to the salivary glands to promote B cell activation. However, the therapeutic potential of targeting the CCL25–CCR9 axis to limit glandular inflammation and lymphoid neogenesis remains largely unexplored. Evaluate whether blocking the CCL25–CCR9+ T cell axis with a monoclonal antibody could reduce immune infiltration, ectopic germinal center (EGC) formation, and local autoantibody production in the NOD.H2(h4) mouse model of SjD. Female NOD.H2(h4) mice were administered anti-CCL25 antibody, isotype control, or PBS intraperitoneally for 12 weeks. Sera and saliva were collected to evaluate anti-Ro52 antibodies via ELISA across treatment groups. Salivary glands were harvested and processed for H&E staining to assess lymphocytic infiltration and focus scores. Treatment with α-CCL25 was well tolerated, with no significant differences in body weight or stimulated salivary flow between treatment groups. Histopathological evaluation revealed no reduction in lymphocytic infiltration, focus scores, or percentage of inflamed tissue in α-CCL25-treated mice compared to controls. Anti-Ro52 antibodies were undetectable in plasma or saliva across all groups and timepoints. Systemic CCL25 blockade did not significantly alter salivary gland inflammation, function, or autoantibody production in NOD.H2(h4) mice. These findings suggest that monotherapy targeting the CCL25–CCR9 axis may be insufficient to resolve glandular autoimmunity in this model and that additional or combinatorial strategies may be necessary for effective intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fb19afd9003f45610d013c7277583bd5a2c16211" target='_blank'>
              Evaluating Anti-CCL25 as a Therapeutic Strategy to Disrupt Foci Formation in a Spontaneous Murine Model of Sjögren’s Disease
              </a>
            </td>
          <td>
            Martha Tsaliki, B. Kurien, Joshua Cavett, John A. Ice, Kristi A. Koelsch, R. H. Scofield
          </td>
          <td>2025-09-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Recently, we have identified CD4+PD-1+CXCR5+ T-follicular helper (TFH) cells with a distinct cytotoxic phenotype and named them “killer TFH (TF K )” cells. In this study, we aim to elucidate their presence and functional relevance in two different lymphoma subtypes, follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Flow cytometric analysis of tonsillar versus FL-cell suspensions revealed a heightened number of GZMK+NKG7/TIA-1+ TF K cells in the latter, accompanied by a significant increase in T-regulatory and T-follicular regulatory (TFR) cells. In contrast, DLBCL exhibited a decrease in TFH and TFR cell numbers, while concurrently demonstrating heightened frequencies of GZMK+TIA-1+ and especially GZMB+TIA-1+ TF K cells within the TFH population. Analysis of single-cell RNA sequencing data confirmed an origin-specific phenotype of TF K cells. Immunofluorescence staining of biopsy specimens detected CD4+BCL-6+TIA-1+ TF K cells within follicles and germinal centers (GC) in reactive lymph nodes and within their atypical counterparts in malignant lymph nodes. Their propensity to migrate into atypical GCs was more pronounced in higher grade FLs. Furthermore, the release of cytotoxic cargo by degranulation could be induced by stimulation of CD4+ cells in cultures of FL and DLBCL suspensions. In line, the direct cytotoxic capacity of TF K cells against lymphoma cells was demonstrated by killing assays with isolated cells, underscoring their potential as a prospective therapeutic target in lymphoma control.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f102197501ec1b3397057559e69720ba226376a3" target='_blank'>
              Cytotoxic CD4+ T-follicular cells may mediate killing against lymphoma cells
              </a>
            </td>
          <td>
            Yin Xiao, Sigrun S Haeusl, Gaurav Jethva, Johannes Weber, A. Rosenwald, F. Berberich-Siebelt
          </td>
          <td>2025-09-15</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="B7 homolog 3 (B7-H3, CD276) has emerged as a promising target for chimeric antigen receptor (CAR) T cell therapy, with limited expression in normal tissues and high level cell-surface expression across various tumor types. Clinical studies are ongoing, with a focus on pediatric cancers. As an immune checkpoint molecule of the B7-CD28 family, B7-H3 has a proposed immune-modulatory role, though the precise nature of B7-H3-mediated cell interactions and functional contributions to immune responses are contradictory and likely context-dependent. Within tumors, B7-H3 is expressed also on non-tumor cell types in the tumor microenvironment (TME), including myeloid immune cells, endothelial cells of abnormal vasculature and cancer-associated fibroblasts. Consequently, CAR T cells directed against B7-H3 will not only target tumor cells but also components of the TME, which will affect the nature and outcome of B7-H3-targeted therapeutic immune responses. Here we review the expression of B7-H3 protein in pediatric solid tumors and in various cell types known to infiltrate the TME of solid tumors. On this background, we discuss the potential of B7-H3-targeted CAR T cells to reshape the TME and the key challenges and future directions to improve B7-H3-targeted CAR T cell therapy for pediatric patients with solid cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/649b83099536525155f2e82b6d45425c1ee80892" target='_blank'>
              B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors
              </a>
            </td>
          <td>
            Lena Jansen, J. Wienke, Ronja Molkenbur, Claudia Rossig, Ramona Meissner
          </td>
          <td>2025-10-11</td>
          <td>Cancer Metastasis Reviews</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8e4d37620ca392d7a89bb01813d9698710108a7a" target='_blank'>
              Autophagy disruption primes CAR-T cell metabolism for sustained rejection of ovarian tumors
              </a>
            </td>
          <td>
            G. Carleton, Sébastien Levesque, Lauren G. Zacharias, João S. Patrício, Tracey Sutcliffe, Peter H Watson, Ralph J. DeBerardinis, Yannick Doyon, Julian J. Lum
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Background Circulating lymphocytes are essential for the immune response to helminth infections, as they secrete cytokines and thus coordinate subsequent immunological processes. In canine angiostrongylosis, a potentially fatal disease caused by the metastrongylid nematode Angiostrongylus vasorum, the underlying immune mechanisms driving disease progression remain poorly understood despite the severe clinical consequences. Canine peripheral blood mononuclear cells (PBMCs) were isolated from healthy dogs and stimulated with three different antigens of A vasorum, including adult excretory-secretory products (ESP), adult full-worm somatic antigen, and first-stage larval (L1) somatic antigen. Temporal dynamics and magnitude of relative cytokine expression (IFNγ, TNF, IL-4, IL-6, IL-10, IL-13) was evaluated after 4 h, 24 h, and 5 days of antigen exposure via quantitative reverse transcription PCR. To determine whether the cytokine expression changes translated into shifts in circulating mononuclear cell subsets or proliferative activity, phenotypic characterisation by flow cytometry was conducted after a 72 h stimulation with L1 antigen or ESP, and compared to unstimulated controls. Results Early responses varied across antigen types, with ESP promoting a regulatory cytokine profile with modest upregulation of IL-4, IL-6, and IL-10, and downregulation of IFNγ, TNF, and IL-13. Adult antigen induced increased expression of all examined cytokines, while L1 antigen triggered the strongest inflammatory response compared to the other antigens. At 24 h, all responses were amplified, particularly those to L1 and adult antigen, and showed a shift towards a Th2 cytokine profile with increased IL-4 and IL-13 expression. By five days, IL-4 and IL-13 remained predominant. No change in the relative abundance of major immune cell populations (CD4⁺ T cells, CD8⁺ T cells, B cells, neutrophils, monocytes, and CD14⁻ CD22⁻ antigen-presenting cells) was observed in flow cytometry following stimulation. However, a notable increase in Ki67 expression, a marker of cell proliferation, was detected in CD8⁺ T cells after L1 antigen stimulation. Conclusions Distinct cytokine profiles elicited by different A. vasorum antigens suggest that the parasite’s modulation of host immunity and induction of stage-specific responses are key to persistence and clinical presentation of canine angiostrongylosis. Further investigation into the antigenic components and immune pathways may lead to tailored therapies, improved clinical management, and to a deeper understanding of stage-specific aspects of helminth infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/966d24f4232243990a6917d702fdc78980641c19" target='_blank'>
              In vitro cytokine response of circulating mononuclear cells from healthy dogs to stage-specific antigens of Angiostrongylus vasorum
              </a>
            </td>
          <td>
            Janine Hertaeg, U. Salazar, J. vom Berg, S. Leibundgut-Landmann, Andreas W. Oehm, Manuela Schnyder
          </td>
          <td>2025-10-02</td>
          <td>BMC Veterinary Research</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare, aggressive subtype of diffuse large B-cell lymphoma characterized by a profoundly immunosuppressive tumor microenvironment. PD-L1 overexpression by tumor cells is a recognized immune escape mechanism and may underlie resistance to cellular therapies, including CAR T-cell therapy. We report a case of a 29-year-old woman with refractory stage IV-B THRLBCL treated with anti-CD19 CAR T-cell therapy (varnimcabtagene autoleucel), who achieved an initial response (day +28) but experienced disease progression by day +100 despite robust CAR T-cell expansion. Peripheral blood analysis revealed persistent absolute B-cell aplasia, while bone marrow biopsy confirmed CD19-positive disease. Comparative immunohistochemistry demonstrated markedly increased PD-L1 expression in post-CAR T-cell samples, suggesting adaptive immune resistance via PD-1/PD-L1-mediated CAR T-cell inhibition. Nivolumab was initiated at month +4 to overcome this checkpoint-mediated resistance. Notably, a complete metabolic response was documented on PET/CT after four doses of nivolumab (month +6). The patient remains in sustained remission, with persistent B-cell aplasia, four years post-intervention. This case provides clinical and pathological evidence supporting the use of immune checkpoint blockade to rescue CAR T-cell efficacy, highlighting the potential of this synergistic approach in THRLBCL and possibly other B-cell malignancies exhibiting similar immune evasion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/30bbc27d73802edea098491ebe987fd06d629f31" target='_blank'>
              Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report
              </a>
            </td>
          <td>
            Daniel Munárriz, O. López-Godino, N. Martínez-Cibrian, N. Albiol, H. Brillembourg, Sergio Navarro-Velázquez, M. Español-Rego, Sebastián Casanueva, Lucía García-Tomás, Guillermo Muñoz-Sánchez, L. Alserawan, D. Benitez-Ribas, L. Magnano, J. Correa, A. Rivero, P. Mozas, Eva Giné, L. Rodríguez-Lobato, A. Martínez-Roca, Mercedes Montoro-Lorite, P. Ayora, Jordi Esteve, Laura Frutos, Olga Balagué-Ponz, Á. Urbano-Ispizua, E. A. González-Navarro, Manel Juan, Julio Delgado, V. Ortiz-Maldonado
          </td>
          <td>2025-09-23</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Natural killer (NK) cells are critical components of the first-line immune defense, responsible for eliminating tumorigenic cells. NK cell-based adoptive immunotherapy has gained increasing attention; however, cryopreservation, a standard technique for NK cell storage, significantly impairs NK cell cytotoxicity, particularly in physiological 3D environments. Here, we demonstrate that short-term co-culture with effector T cells markedly enhances NK cell motility and killing functionality. Notably, a brief 1-day co-culture is sufficient to restore cryopreservation-impaired NK cell functionality in 3D environments. This enhancement requires direct contact between T cells and NK cells, which facilitates localized high concentrations of IL-2 at the cell contact sites. To develop a controled, donor-independent solution, we demonstrate that synthetic T cells with surface-bound IL-2 exhibit superior efficiency in revitalizing cryopreserved NK cells. These findings uncover a previously unrecognized role for physical contact-mediated local IL-2 signaling and provide an efficient, cost-effective, and tunable strategy to rescue NK cell functionality post-cryopreservation, paving the way for more scalable, potent, and clinically viable NK cell-based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6041365acd5e2fb4bf5c716d07c128661901f209" target='_blank'>
              Restoring NK Cell Cytotoxicity Post-Cryopreservation via Synthetic Cells.
              </a>
            </td>
          <td>
            Xiangda Zhou, Sijia Zhang, Wenjuan Yang, S. Gonder, Zeinab Sadjadi, Nils Piernitzki, A. Moter, Shulagna Sharma, A. Largeot, Nadja Küchler, Lea Kaschek, Gertrud Schäfer, Eva C Schwarz, Hermann Eichler, Evelyn Ullrich, Heiko Rieger, Oskar Staufer, J. Paggetti, E. Moussay, Markus Hoth, Bin Qu
          </td>
          <td>2025-09-18</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Tumor immune evasion and incomplete responses to immunotherapy are some of the most significant obstacles in current cancer treatment. Since tumor-draining LNs (tdLNs) are cradles for anti-tumor immunity, and tumor-specific memory cells in tdLNs are the bona fide responders to immune-checkpoint blockade, tdLNs are increasingly valued in oncoimmunology research and cancer treatments. Recent progress has revealed that lymph nodes (LNs) are innervated and regulated by sensory and sympathetic nerve fibers. Because tumor cells, nerves, and immune cells coexist inside tdLNs—sites where anti-tumor immunity is initiated and compromised—it is critical to investigate whether tumor-neuro-immune crosstalk also occurs in these nodes. Although direct evidence in tdLNs is lacking, we synthesize emerging evidence supporting this possibility. We argue that validating this hypothesis will be essential for elucidating immune evasion mechanisms and advancing surgical and immunological strategies against tumors. In this review, we first introduce LN anatomy, highlighting its innervation by sensory and sympathetic fibers. We then examine the neural regulation of immune activities, especially those within LNs and those associated with a tumor context. We further discuss the multifaceted roles of tdLNs in tumor immunology, including orchestration of anti-tumor immunity and local immunosuppression, pre-metastatic LN remodeling, and induction of systemic tumor-specific immune tolerance. Furthermore, we look into tumor-neural interactions from two angles: tumor-induced nerve growth and activation, and neural regulation of tumor progression. Finally, we propose potential tumor-neuro-immune interactions in tdLNs, discuss current perspectives on LN handling in cancer therapy, and discuss clinical implications of the progress summarized in this review.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aab5fd4af47b27933d6fc3e53d0b08f085e3a967" target='_blank'>
              Nerves, nodes, and neoplasia
              </a>
            </td>
          <td>
            Minjun Wang, Censhan Ran, Quan Liu
          </td>
          <td>2025-09-15</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Distinct from conventional Foxp3+ regulatory T cells (Tregs), T-bet+ Tregs represent a stable subset of immunosuppressive T cells characterized by co-expression of the transcription factors (TFs) Foxp3 and T-bet. Given that Tregs were also reported to co-express Foxp3 together with effector T cell TFs such as GATA3, or RORγt, we propose the term hybrid Tregs (hTregs) to distinguish between these Tregs that co-express Foxp3 together with effector T cell TFs from conventional Foxp3+ Tregs. Therefore, this review will focus on hTreg cells, a specific subset of CD4+ T cells, and discuss the different types of hTregs with particular emphasis on T-bet+ hTregs. T-bet+ hTregs exhibit unique features including IFN-γ production, high expression of immune checkpoints (PD-1, CTLA-4, GITR, OX40, TIGIT), and chemokine receptors (CXCR3, CCR5). Through secretion of IL-10, TGF-β and IFN-γ, T-bet+ hTregs modulate both innate and adaptive immune responses within the tumor microenvironment (TME). Their high expression of CD73 contributes to adenosine-mediated immunosuppression, while CXCR3 and CCR5 facilitate their recruitment to inflammatory sites. T-bet+ hTregs were reported to accumulate in multiple human cancers, including lung, ovarian, and colorectal carcinomas. Despite these advancements, the function of hTregs in diseases such as cancer remains poorly understood, and requires further investigations. For instance, some studies suggest T-bet+ hTregs to be anti-inflammatory due to their production of IL-10, TGF-β, and superior suppressive capacity compared to conventional Tregs. Yet, other studies have reported that T-bet+ hTregs exhibit enhanced proinflammatory functions in colitis and other pathologies. We will then highlight current known mechanisms that promote the differentiation and functions of T-bet+ hTregs in cancer. Lastly, we will discuss the advancements and opportunities for therapeutic targeting of T-bet+ hTregs in cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b1b199c5c7e77a91a50e430bccd367ec9c53c27c" target='_blank'>
              Hybrid regulatory T cells: camouflaged architects of tumor immunity
              </a>
            </td>
          <td>
            Parviz Azimnasab-sorkhabi, Maryam Soltani-asl, José Roberto Kfoury Júnior, Ephraim A. Ansa-Addo
          </td>
          <td>2025-09-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="The tumor microenvironment (TME), comprising malignant and non-transformed cells like immune cells, endothelial cells, and cancer-associated fibroblasts, significantly affects tumor growth and progression. Tumor cells manipulate the TME by releasing chemokines and inhibitory cytokines, reprogramming surrounding cells to support their survival and evade immune detection. Innate immune cells within the TME play dual roles, either promoting or inhibiting tumor progression, impacting immunotherapy outcomes. Recent studies highlight the influence of innate immune cells in shaping the TME and the pivotal role of tumor-derived microRNAs (miRNAs) in modulating these cells. miRNAs regulate gene expression and enhance tumor immune evasion, angiogenesis, drug resistance, and invasion. Their tumor-specific expression patterns suggest potential as biomarkers and therapeutic targets. This study focuses on how miRNAs affect innate immune cells like macrophages, dendritic cells, myeloid-derived suppressor cells, and natural killer cells, contributing to immunosuppressive or immunogenic environments. Understanding miRNA-mediated interactions between cancer and immune cells opens new possibilities for improving targeted immunotherapy and advancing cancer treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e85aa9b654355b3e4b7e9a3784ef3b6054fa10e" target='_blank'>
              Ambivalent roles of miRNAs in cancer development via modulating tumor-associated innate immune cells
              </a>
            </td>
          <td>
            Bahar Naseri, Amirhossein Mardi, N. Shekari, Neda Shajari, Samin Abdolzadeh, Hossein Khorramdelazad, Amirhossein Hatami-Sadr, Milad Taghizadeh Anvar, Mohammad Reza Javan, Amirhossein Heibatollahi, Javad Masoumi, Farid Ghorbaninezhad, B. Baradaran
          </td>
          <td>2025-10-04</td>
          <td>BioImpacts</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Immunotherapy has transformed the landscape of cancer treatment, offering hope to patients who were once considered beyond the reach of effective care. However, its success is restricted to a limited fraction of patients. This discrepancy in response is largely due to the complex and dynamic nature of the tumor immune-microenvironment. At the heart of this complexity is the concept of cancer immunoediting—a dynamic process through which the immune system both sculpts and is shaped by the tumor. This process unfolds in three key stages: Elimination, Equilibrium, and Escape, each representing a shifting balance between immune defenses and tumor adaptation. Central to this interaction are tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs). TILs are frontline defenders in targeting tumor cells, while TAMs can either hinder or facilitate tumor growth based on their polarization. As cancer progresses, immune selection pressure induces phenotypic alterations that promote immune evasion, fostering an environment detrimental to effective immune response. This review explores the role of these immunological components in each phase of immunoediting and their impact on the efficacy or failure of immunotherapy. Gaining deeper insight into these interactions is crucial for developing advanced immunotherapies that reshape tumor microenvironment and expand the reach of immunotherapy to more patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/533054cdcbdd77797ff00beb224f1aa7830e71f8" target='_blank'>
              Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis
              </a>
            </td>
          <td>
            S. Mukherjee, Ahana Ghosh, S. Chakraborty, Udit Basak, Sumoyee Mukherjee, Tanya Das, Gaurisankar Sa
          </td>
          <td>2025-09-11</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="CD8+ T lymphocytes are central effectors of anticancer immunity. Their abundance and spatial distribution within solid tumors are strongly correlated with patient prognosis and response to immune-checkpoint inhibitors (ICIs). Tumors have been categorized into “hot,” “excluded,” and “cold” types based on the infiltration patterns of CD8+ T cells, which reflect the underlying immune contexture and therapeutic potential. However, many tumors remain resistant to T-cell infiltration, posing a significant barrier to immunotherapy. This review systematically outlines the seven critical steps of the Cancer-Immunity Cycle that govern CD8+ T-cell infiltration: antigen release, antigen processing and presentation, T-cell priming, trafficking through the vasculature, tumor infiltration, target recognition, and cytolytic activity. At each step, tumor-intrinsic and microenvironmental barriers—including low tumor mutational burden, defective antigen-presenting machinery, immunosuppressive cytokines (e.g., TGF-β, IL-10), abnormal vasculature, fibroblast-derived extracellular matrix, and inhibitory cell populations (e.g., Tregs, MDSCs, TAMs)—can stall the immune response. We further discuss the roles of immune-checkpoint signaling, metabolic competition, and suppressive cell networks in shaping T-cell exhaustion and exclusion. Cutting-edge technologies—such as single-cell RNA-sequencing, spatial transcriptomics, imaging mass cytometry, and TCR repertoire profiling—have revealed spatial and functional heterogeneity within intratumoral CD8+ T cells and informed the design of rational combination therapies. Understanding and targeting these barriers is critical for converting immune-cold tumors into immune-infiltrated, therapy-responsive states. We conclude with a perspective on the future of immunoengineering and immune-atlas integration to optimize CD8+ T-cell–based interventions in solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/efa77bd4c813b73b425c3c8514e6eec6c6ede00f" target='_blank'>
              Infiltration characteristics and regulatory mechanisms of CD8+ T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment
              </a>
            </td>
          <td>
            Ouyang Peng, Jianhong Zhang, Xiao He, Congcong Yang, Dingcheng Zeng, Daofeng Xu
          </td>
          <td>2025-10-01</td>
          <td>Frontiers in Immunology</td>
          <td>1</td>
          <td>1</td>
        </tr>

        <tr id="Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, with chronic liver inflammation being a major risk factor. Tertiary lymphoid structures (TLS) have been associated with improved survival and better response to immune checkpoint inhibitors in several cancers. However, their role in HCC remains unclear, and findings are often contradictory. Methods: The study investigated the presence and composition of TLSs across multiple liver disease models, including livers containing HCC. TLSs were characterized to identify the essential cellular components for functional lymphoid activity. The functional role of age-associated B cells (ABCs) was further explored by blocking T-bet expression in B cells, thereby preventing their differentiation into ABCs. Results: TLS frequency was increased in livers containing HCC. Characterization confirmed the presence of key immune cell subsets supporting lymphoid function. Blocking T-bet in B cells led to a reduction in ABCs, which resulted in smaller TLS, a specific decrease in hepatic B cells, and reduced tumor lesion size in HCC-bearing mice. Conclusions: These findings demonstrate that ABCs promote TLS formation and growth, facilitating B-cell recruitment to the liver and supporting HCC progression. Targeting T-bet–dependent ABC differentiation may represent a novel strategy to limit TLS formation and slow HCC progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e21fbe2d38cd74b5f2d808bff239d29949051ea0" target='_blank'>
              Age-associated B cells enhance tertiary lymphoid structures in the liver and promote HCC formation
              </a>
            </td>
          <td>
            Anne E Morsing, Kenneth Green, Signe Clausen, Camilla R Benjaminsen, Mathilde S. Blaavand, Julia K Demtröder, Johannes Skraep, Lisbeth Jensen, Peter Breining, Mads Kjølby, Mikkel Vendelbo, S. Degn, Martin K Thomsen
          </td>
          <td>2025-09-22</td>
          <td>Hepatology Communications</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="CD19-targeted therapies, including monoclonal antibodies, antibody–drug conjugates, and chimeric antigen receptor (CAR) T-cell products, have significantly improved outcomes in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Despite their clinical efficacy, resistance and antigen modulation pose substantial challenges, especially in patients requiring sequential therapy. This review provides a comprehensive overview of CD19 biology and its relevance as a therapeutic target. We examine mechanisms of resistance such as antigen loss, epitope masking, and T-cell exhaustion, as well as the implications of tumor microenvironmental immunosuppression. Future efforts should prioritize the integration of real-time diagnostics, such as flow cytometry, immunohistochemistry, and transcriptomic profiling, and AI-assisted predictive models to optimize therapeutic sequencing and expand access to personalized immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d4c1d7b69c6eb2962871f35ffca5844b78a37738" target='_blank'>
              Sequencing Anti-CD19 Therapies in Diffuse Large B-Cell Lymphoma: From Mechanistic Insights to Clinical Strategies
              </a>
            </td>
          <td>
            F. Laddaga, Mario Della Mura, Joana Sorino, Amanda Caruso, Stefano Martinotti, Giuseppe Ingravallo, Francesco Gaudio
          </td>
          <td>2025-09-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>1</td>
          <td>6</td>
        </tr>

        <tr id="Abstract Activated PI3K delta syndrome 1 (APDS1) is caused by a heterozygous germline gain‐of‐function (GOF) variant in PIK3CD, which encodes the p110δ catalytic subunit of phosphoinositide 3‐kinase (PI3K). APDS1 patients display a broad range of clinical manifestations and perturbations in cellular phenotype. One of the most striking features is the dysregulation of the T‐cell compartment, characterized by an increase in memory T cells, including Tfh cells, and a concomitant decrease in naïve T cells. We have previously shown that many of these changes in T‐cell populations were T‐cell extrinsic and were also induced in WT T cells that developed in the presence of PI3K GOF cells. Here we dissected the drivers of dysregulated T‐cell activation using a mouse model of APDS1. This revealed that PI3K GOF macrophages and DCs made little contribution to the aberrant T‐cell activation. Instead, PI3K GOF T cells were able to drive the loss of WT naïve CD4+ T cells, while dysregulated PI3K GOF B cells mediated an increase in Tfh cells. Surprisingly, despite previous reports of increased PI3K signalling driving dysregulated inflammatory Tregs, we saw no evidence for Pik3cd GOF Tregs acquiring an inflammatory phenotype and driving T‐cell activation. These studies provide new insights into the role of PI3K in immune cells and how increased PI3K can drive T‐ and B‐cell dysregulation and contribute to the phenotype of APDS1 patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b02f686f7f272f7136a7b1186843ff70bd4a00c9" target='_blank'>
              PI3K GOF leads to dysregulation of T and B cells that both contribute to extrinsically driving activation and differentiation of other CD4 + T cells
              </a>
            </td>
          <td>
            Julia Bier, A. Lau, Katherine Jl Jackson, Stephanie Ruiz-Diaz, Timothy J. Peters, Robert Brink, S. Tangye, E. Deenick
          </td>
          <td>2025-09-14</td>
          <td>Immunology and Cell Biology</td>
          <td>0</td>
          <td>103</td>
        </tr>

        <tr id="Pathogen-associated cancers account roughly 15–20% of all malignancies worldwide and arise from chronic infections by oncogenic viruses, bacteria and parasites. Pathogens can alter the tumor microenvironment (TME) into an immune-suppressive niche using multiple mechanisms, including immune checkpoint manipulation, chronic inflammation, metabolic reprogramming, and direct epigenetic modifications. Immune dysfunctions related to infections linked to cancers can include M2-polarized macrophages, expansion of MDSCs, exhausted T/NK cells, and tolerogenic dendritic cells, all progressing immune evasion and resistance to cancer therapy. Advances in therapeutics exist in prophylactic vaccines, immune checkpoint inhibitors, and next-generation methods such as the engineered Salmonella to deliver to hypoxic tumors and the targeting the microbiome. The advancement of pathogen-, cancer-, and patient-specific therapeutics is not without its challenges, including heterogeneity of the pathogens, absence of clinically useful biomarkers, concerns about the safety of the restoring anti-pathogen immunity and challenges of scale for manifold interventions. This review will provide a synthesis of the mechanistic aspects of pathogen-mediated TME remodeling, contemporary clinical therapeutics, and ongoing investigations into using pathogen/host dynamics to enhance measurable precision immunotherapy strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5c3df00e71b61c4351ef47d4ffaceec6dacd20b" target='_blank'>
              The immune microenvironment of pathogen-associated cancers and current clinical therapeutics
              </a>
            </td>
          <td>
            Xiao-Yu Wei, Hui-Jing Feng, Ying-Yin Zhu, Shi-Jing Guo, Hong Wang, Ming Li, Qi Mei
          </td>
          <td>2025-10-02</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Over the last decade, immunotherapy has revolutionized lung cancer treatments, particularly in non-small cell lung cancer, where immune checkpoint inhibitors have achieved significant clinical success. However, high percentages of patients do not respond initially or eventually develop a resistance to these therapies. This review explores the evolution and challenges of immunotherapy in lung cancer, highlighting its clinical milestones and intrinsic and extrinsic resistance mechanisms. We investigate tumor-intrinsic resistance factors, including alterations in antigen presentation, the loss of Beta-2 microglobulin function, impaired interferon signaling, immune editing, epigenetic modifications, and tumor-extrinsic resistance, such as an immunosuppressive lung tumor microenvironment, dysregulated cytokine profiles, and the upregulation of immune checkpoints. Then, we focus on the emerging role of resistance biomarkers and the development of personalized treatment strategies to overcome these challenges. The complex interplay between tumor biology and immune modulation in lung cancer paves the way for novel approaches for improving the effectiveness of immunotherapeutic treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/be521ad9dbd5fb1b3f963d8423b3bfabe7d4614d" target='_blank'>
              Unraveling Resistance in Lung Cancer Immunotherapy: Clinical Milestones, Mechanistic Insights, and Future Strategies
              </a>
            </td>
          <td>
            Maria Vitale, Raffaella Pagliaro, G. Viscardi, Lucio Pastore, Giuseppe Castaldo, F. Perrotta, Susan F M Campbell, Andrea Bianco, Filippo Scialò
          </td>
          <td>2025-09-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Significance Mice are essential for studying immune responses, but functional differences between human and murine systems limit their utility, particularly for neutrophils. Humanized mice with a human immune system have advanced understanding of human immunity, yet suboptimal myelopoiesis and lack of functional neutrophils remain challenges. We developed MaGIC mice, a model expressing human CD47, M-CSF, GM-CSF, IL-6, and thrombopoietin while reducing murine CD47 on the C57Bl/6 N background. MaGIC mice support robust human hematopoiesis, including functional neutrophils, monocytes, and tissue macrophages. These neutrophils, phenotypically and developmentally comparable to human neutrophils, exhibit chemotaxis, phagocytosis, reactive oxygen species production, and neutrophil extracellular trap formation in response to inflammatory stimuli, providing an innovative platform to study human neutrophils in infectious, autoimmune, and inflammatory diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/126240af442ecbc18a530ec09fcfd6b09d5cb9e6" target='_blank'>
              Humanization of CD47 enables development of functional human neutrophils via postirradiation remodeling of the bone marrow
              </a>
            </td>
          <td>
            Esen Sefik, William Philbrick, Fengrui Zhang, Kriti Agrawal, Brian Van Lee, Johannes Sam, Kutay Karatepe, Yunjiang Zheng, Kaixin Liang, Sophia Peng, Haris Mirza, Athreya Rangavajhula, Perrine Simon, Neha Arun, Priyanka Babu, E. Eynon, Michael Chiorazzi, L. Shan, Stephanie Halene, Hongbo R. Luo, A. Rongvaux, Y. Kluger, Richard A. Flavell
          </td>
          <td>2025-09-16</td>
          <td>Proceedings of the National Academy of Sciences of the United States of America</td>
          <td>0</td>
          <td>68</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/185efc2fedc960d3a37275db1d6e3e38acba4899" target='_blank'>
              Antigen stimulation drives clonal expansion of latent CD4+ T cells using a full-length HIV latency reporter
              </a>
            </td>
          <td>
            N. Ikeogu, Oluwaseun Ajibola, Riley Greenslade, W. Koh, A. Pagliuzza, R. Fromentin, Michelle Perner, Roshan Parvarchian, Xinyun Liu, Paul Lopez, Catherine Card, Paul McLaren, N. Chomont, Mario Ostrowski, Thomas Murooka
          </td>
          <td>2025-09-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>62</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ee3f27abcdad8802c7b336bd7048ce99a21bec72" target='_blank'>
              Differentiation of naïve into memory-phenotype CD8+ T cells does not promote the breakdown of peripheral tolerance in irradiated mice
              </a>
            </td>
          <td>
            Marine Villard, Gabriel Espinosa-Carrasco, Javier Hernandez
          </td>
          <td>2025-09-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Background Immune checkpoint inhibition (ICI) has become a standard treatment to re-invigorate tumor-attacking T cell responses in multiple cancer indications, yet a patient’s response is unpredictable even with a confirmed expression of the relevant targets such as PD-1 or PD-L1. Previously identified biomarkers of response have relatively low accuracy, making it difficult to reliably employ them as predictors of clinical response. Methods We comprehensively phenotyped peripheral blood CD8+ T cells from patients with non-small cell lung cancer by analyzing surface marker expression, transcriptome, and TCR repertoire with single-cell sequencing technology. The cohorts were comprised of patients who (a) responded to anti-PD(L)1 treatment for a prolonged period of time (b) were new-on-treatment responders, and (c) were new-on-treatment nonresponders. Using various bioinformatics analyses, we defined the signatures of ICI response and evaluated their performance on external scRNA-seq datasets. Results We identified response-specific signals in cell type and cell state proportions as well as in TCR repertoire diversity and TCR inter-donor similarity. The enrichment analysis revealed several pathways and regulatory modules enriched in different response groups. Using machine learning, we identified cell-type-specific signatures that predicted the ICI response with an accuracy between 66% and 93% at the single cell level and up to 94% at the patient level. Effector memory CD8+ T cells in long-term responders were most predictive of response, and the inferred effector memory signature could be successfully applied to two related scRNA-seq datasets. CD44, GIMAP4, CD69, and CCL4L2 were among the most relevant contributing markers defining the predictive ML signatures on lung cancer samples. Conclusion Our findings suggest that CD8+ T cell subset-specific models reach an accuracy that possesses the potential to inform treatment decisions in a clinical setting.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/603fbb89ae7bbe1845836d60a2cff69028215f4b" target='_blank'>
              Blood memory CD8 T cell phenotypes in lung cancer patients predict immune checkpoint treatment responses
              </a>
            </td>
          <td>
            Florian Schmidt, K. Wu, Yovita Purwanti, N. Tan, Daniel Carbajo, Ke Xin Bok, Andreas Wilm, M. Fehlings, Daniel MacLeod, Alessandra Nardin, Daniel S W Tan, Katja Fink
          </td>
          <td>2025-09-08</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), is notorious for its aggressive nature and dismal prognosis, ranking as a leading cause of cancer-related mortality worldwide. Despite advancements in surgical techniques, chemotherapies, and novel therapeutic approaches, the overall survival rates remain bleak, primarily due to the complex and dynamic tumor microenvironment (TME) which fosters cancer progression and therapeutic resistance. Central to the TME are cancer-associated fibroblasts (CAFs), which exhibit significant heterogeneity and play multifaceted roles in tumor progression, ranging from remodeling the extracellular matrix to modulating immune responses. Recent breakthroughs in single-cell sequencing and spatial omics have unraveled the diverse functional states and spatial organization of various cell types within the TME, including distinct subtypes of CAFs which differ vastly in their influence on pancreatic cancer pathophysiology. This review delves into the intricate interactions between CAFs and pancreatic cancer cells, highlighting how metabolic reprogramming and immune regulation by CAFs contribute to the high malignancy of PDAC. By integrating single-cell and spatial resolution data, we offer new insights into the metabolic crosstalk and immune landscape remodeling driven by CAFs, establishing a foundation for targeting these stromal interactions in therapeutic strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2add2bd80d02d372a76aab262dddc13647852fe6" target='_blank'>
              Metabolic and immune crosstalk between cancer-associated fibroblasts and pancreatic cancer cells
              </a>
            </td>
          <td>
            Qiyao Zhang, Z. Cao, Shangcheng Yan, Bingrong Chen, Hao Wu, Hongtao Cao, Chen Lin, Ziwen Liu
          </td>
          <td>2025-10-17</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Emerging evidence reveals that exercise modulates immune signaling to enhance the efficacy of immunotherapy in diseases like allergic rhinitis (AR) and nasopharyngeal carcinoma (NPC). By influencing immune cell trafficking, reprogramming inflammatory pathways within the tumor microenvironment (TME), and altering drug pharmacokinetics, exercise improves immune responses and therapeutic outcomes. Exercise enhances immune cell activation and infiltration into tumors, modulates checkpoint and cytokine signaling cascades, and mitigates treatment-related side effects, thereby improving patient compliance. Recent advancements in single-cell technologies, such as single-cell RNA sequencing and spatial omics, provide unprecedented insights into immune cell heterogeneity and signal transduction dynamics in the TME, uncovering new targets for exercise-modulated therapies. This review explores the synergistic effects of combining exercise with immune-based therapies, particularly in cancer treatment, highlighting the role of exercise in reshaping TME inflammation, overcoming immune evasion, and enhancing immune-mediated drug bioavailability. Personalized exercise regimens, tailored to individual patient profiles, are critical for optimizing therapeutic responses. Integrating exercise with immunotherapy, guided by single-cell and systems-level analyses, may provide a transformative approach for improving the clinical outcomes of AR and NPC patients, paving the way for more effective, individualized cancer treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/383016a745417bbcac5cfaacd289ccec795aa759" target='_blank'>
              Exercise induced immune regulation and drug efficacy in rhinitis nasopharyngeal carcinoma implications for tumor microenvironment single cell immune signal transduction
              </a>
            </td>
          <td>
            Guanwen He, Weijing Bao, Jiansheng Yang, Xiuqin Guo, Wenxian Lu, Xiuhui Ji, Shang Gao, Rifu Wei, Yisheng Chen
          </td>
          <td>2025-10-13</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Interleukin-10 (IL-10), a potent anti-inflammatory cytokine, plays a vital role in regulating immune responses across various infectious and inflammatory conditions. While IL-10 is essential for preventing excessive tissue damage and maintaining immune homeostasis (e.g., respiratory syncytial virus), its elevated levels could result in immunosuppression during viral infections, enabling viruses to evade host defenses (e.g., foot-and-mouth disease virus). This review aims to elucidate the mechanisms through which IL-10 mediates immunosuppression in viral infections and to explore the implications of these mechanisms for therapeutic intervention. The key scientific concepts outlined in this review include the mechanisms of IL-10 production and its varied impacts on the immune response during viral infections. Specifically, we discuss the multifaceted inhibitory effects of IL-10 on innate and adaptive immunity, including its implications for antigen presentation, T cells activation, pro-inflammatory cytokine production, immune cell differentiation, trafficking, apoptosis, and co-inhibitory expression related to T cells exhaustion. Finally, we discuss the therapeutic potential of targeting IL-10, such as monoclonal antibodies and small molecule inhibitors, and their potential to restore effective immune responses. By summarizing current knowledge on IL-10’s role in viral infections, this review offers a thorough insight into its immunosuppressive mechanisms and their therapeutic potential, paving the way for innovative treatment strategies in viral diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/81f19d4be7b3fb1e4992b0845489ba32435aebfd" target='_blank'>
              Mechanisms of Interleukin-10-Mediated Immunosuppression in Viral Infections
              </a>
            </td>
          <td>
            Zijing Guo, Qifu He, Yan Zhang, Yuling Li, Zhidong Zhang
          </td>
          <td>2025-10-01</td>
          <td>Pathogens</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Introduction Toll-like receptors 7 and 8(TLR7/8) recognize purine-rich single-stranded RNA from pathogens, triggering immune responses. Although TLR7/8 agonists are emerging as potential novel adjuvants, their impact on the adaptive B cell response, particularly antibody repertoire, remains unclear. Methods Six Indian rhesus macaques(IRMs) and six African green monkeys(AGMs) were stimulated with a TLR7/8 agonist. Peripheral blood samples were collected pre-stimulation and multiple timepoints within one week post-stimulation for flow cytometry and antibody repertoire sequencing. Results B cell activation was observed at 24 hours. Significant increases in antibody repertoire diversity were detected at 48 and 72 hours in both species; however, diversity remained elevated at one week in IRMs but returned to baseline in AGMs. Analysis of antibody lineage distributions revealed a marked increase in increased lineages at 48 and 72 hours, characterized by higher frequency, a greater number of antibody clonotypes, and increased mutation rates. The identified expanded lineages, induced by the TLR7/8 agonist, exhibited λ chain bias and divergent antibodies across individuals, and primarily originated from highly mutated antibodies, likely corresponding to memory/effector-like B cells. Conclusions Our findings demonstrate that the TLR7/8 agonist rapidly induces a divergent expansion of B cells, establishing an immune foundation supporting vaccine responses and offering new insights into the dynamic B cell modulation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5daef9f40e9473cb595d9f22ac1da398eeaebc35" target='_blank'>
              Toll-like receptor 7/8 agonist stimulation rapidly skews the antibody repertoire of B cells in non-human primates
              </a>
            </td>
          <td>
            Shi-Yin Wang, Michael Citron, Lihua Luo, I-Ming Wang, Xiao Liu, Wei Zhang
          </td>
          <td>2025-09-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Natural Killer (NK) cell-based immunotherapy is rapidly emerging as a promising modality for cancer treatment. As pivotal players in the innate immune system, cells independently recognize and eliminate malignant cells without prior sensitization, offering distinct advantages over other cell-based therapies. This review highlights the current landscapes of NK cell adoptive therapy, from fundamental biology to cutting-edge clinical applications. It highlights how advancing NK cell sources, including peripheral blood, umbilical cord blood, established cell lines, and the increasingly significant induced pluripotent stem cells (iPSCs), are driving wider, more standardized therapeutic use. The multifaceted strategies employed to enhance NK cell efficacy are being explored, including advanced expansion protocols and sophisticated genetic engineering techniques such as the introduction of Chimeric Antigen Receptors (CARs) and modifications to bolster antibody-dependent cellular cytotoxicity. Additionally, it also addresses the significant hurdles that remain, primarily the immunosuppressive tumor microenvironment (TME), and discusses innovative strategies being developed to overcome these challenges. By synthesizing preclinical data and results from the latest clinical trials, this review highlights the remarkable progress and bright future of NK cell therapy as a safer, effective, and more accessible cornerstone of cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/907e688bbe5ee6289ded49ffbefb7a3664df42bb" target='_blank'>
              Harnessing the Innate Effector: A Narrative Review of Advancing Strategies in CAR Engineering, Metabolic Reprogramming, and TME Resistance of Natural Killer Cells for Cancer Immunotherapy
              </a>
            </td>
          <td>
            Rita Agustina, Endah Agustina Lestari, Husni Ahmad Sidiq, M. A. Nazar
          </td>
          <td>2025-10-13</td>
          <td>International Journal of Cell and Biomedical Science</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Obesity is a rapidly growing public health crisis associated simultaneously with increased metabolic disease and humoral immune suppression to vaccination or infection. Inflammatory CD11c+T-bet+ B cells increase in spleen and adipose tissue during obesity and exacerbate metabolic dysfunction via antibodies. We now find that during obesity Tbet+ B cells also expand in the liver but not omentum or mesenteric fat. Obese mice also develop increased splenic CXCR5+ TFH and hepatic CXCR5-TPH cells which serve as likely partners for antigen-experienced MHC-II+ CD11c+ Tbet+ B cells. We also observed that antibodies in obese mice, previously found to contribute to metabolic disease, largely circulate as inflammatory autoantigen-bound immune complexes. Obese mice lacking T-bet in B cells also develop increased autoantibody titers and expanded splenic germinal center (GC) B and T helper cells. T-bet+ B cell-deficient mice make a similarly enhanced GC, TFH, TPH response to haptenated-protein vaccination with a corresponding increase in antibody affinity, although there is no additive effect of obesity. These results are consistent with GC inhibition by expanded CD11c+ B cells demonstrated by others to occur during autoimmunity, suggesting a broadly universal mechanism which may explain reduced humoral immunity and poor clinical outcomes following infection in patients with obesity and other forms of chronic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ddcdf93e03ae9e235c8c47713808c4e577e47286" target='_blank'>
              CD11c+ Tbet+ B cells constrain obesity- and vaccination-induced germinal center B cells and T helper cells
              </a>
            </td>
          <td>
            Carlo Vanz, Benjamin T Enslow, Emma Collins, Madilyn Dominguez-Lowry, Nathaniel Liendo, Elizabeth A. Dudley, E. Leadbetter
          </td>
          <td>2025-09-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b55c35cb06dbcb951b8f88a8b1249e1f91df0097" target='_blank'>
              Chronic Myelomonocytic Leukemia Microenvironment in Disease Progression and Therapy: Focus on Stepwise Reconfiguring of Myeloid-Immune Cell Interactions Driving Immune Tolerance
              </a>
            </td>
          <td>
            A. Alsugair, Abhishek Mangaonkar
          </td>
          <td>2025-09-26</td>
          <td>Current Hematologic Malignancy Reports</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Cancer continues to be a significant global health issue, influenced by genetic mutations and external factors like carcinogenic exposure, lifestyle choices, and chronic inflammation. The myelocytomatosis (MYC) oncogene family, including c-MYC, MYCN, and MYCL, is essential in the development, progression, and metastasis of various cancers such as breast, colorectal, osteosarcoma, and neuroblastoma. Beyond its well-known roles in cell growth and metabolism, MYC significantly shapes the tumor immune microenvironment (TIME) by altering immune cell dynamics, antigen presentation, and checkpoint expression. It contributes to immune evasion by upregulating checkpoints such as programmed death-ligand 1 (PD-L1) and cluster of differentiation (CD)47, suppressing antigen-presenting major histocompatibility complex (MHC) molecules, and promoting the recruitment of suppressive immune cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). While direct targeting of MYC has proven challenging, recent advances in therapeutic strategies, including MYC-MYC-associated factor X (MAX) dimerization inhibitors, bromodomain and extra terminal domain (BET) and cyclin dependent kinase (CDK) inhibitors, synthetic lethality approaches, and epigenetic modulators, have shown promising results in preclinical and early clinical settings. This review discusses MYC's comprehensive impact on TIME and examines the promising therapeutic strategies of MYC inhibition in enhancing the effectiveness of immunotherapies, supported by recent preclinical and clinical findings.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec1348f06f8cc8d1b1f7ddaa9bea0e5801ca6bda" target='_blank'>
              The Role of MYC in Tumor Immune Microenvironment Regulation: Insights and Future Directions.
              </a>
            </td>
          <td>
            B. Nirala, Jason Yustein
          </td>
          <td>2025-09-23</td>
          <td>Frontiers in bioscience</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Background: Respiratory syncytial virus (RSV) remains a leading cause of respiratory illness globally, with limited vaccine options, particularly for infants and high-risk populations. This study investigates Cyclosporin A (CsA), traditionally an immunosuppressant, as a novel adjuvant to enhance RSV-specific immunity. Methods: BALB/c mice were subcutaneously immunized with RSV G protein co-administered with varying Cyclosporin A doses, challenged intranasally with RSV, and analyzed for RSV-specific humoral immunity and mechanistic Treg-dependent B-cell responses. Results: We demonstrate that co-administration of CsA with the RSV G protein (G+CsA) dose-dependently boosts RSV-specific IgG and neutralizing antibodies, with selective augmentation of IgG1 and IgG2 subclasses. Mechanistically, G+CsA induces regulatory T cells (Tregs) expressing CD40L and IL-10, which directly promote B-cell activation, proliferation, and plasma cell differentiation. Depletion of Tregs or neutralization of IL-10/CD40L abrogated antibody production, confirming these pathways as critical mediators. Notably, G+CsA-induced Tregs adopt a helper phenotype distinct from conventional Tregs, balancing immune enhancement and homeostasis. Conclusions: CsA demonstrates dual adjuvant properties by enhancing RSV-specific neutralizing IgG titers through Treg-driven B-cell activation, offering a potential strategy to optimize vaccine-induced humoral immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/392d3aa03c4c55fdfdc81b38eae64df52d59059d" target='_blank'>
              Dual-Function Adjuvant Cyclosporin A: Enhancing RSV-Specific Humoral Immunity via Treg-Driven B-Cell Activation
              </a>
            </td>
          <td>
            Chaofan Li, Yiwei Zhong, Shuren Zhang, Caixia Su, Gan Zhao, Bin Wang
          </td>
          <td>2025-09-23</td>
          <td>Vaccines</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/122eb17de2469e40c3c0527892590ac5486b1c27" target='_blank'>
              Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors and evades HLA I-driven inhibition
              </a>
            </td>
          <td>
            Stacey N. Lee, Riley J Arseneau, Thomas Arnason, Jeanette E. Boudreau
          </td>
          <td>2025-09-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Diffuse large B-cell lymphoma and follicular lymphoma exhibit complex metabolic and immune microenvironments that influence disease progression and treatment response. Metabolic reprogramming, including glycolysis, amino acid, and lipid metabolism, supports tumor growth while suppressing anti-tumor immunity. Immune components such as tumor-infiltrating lymphocytes and checkpoint molecules (PD-L1, LAG-3, TIM-3) further modulate prognosis. Elevated tumor metabolic volume and glycolytic activity correlate with aggressive disease and poor outcomes. Conversely, high TIL density often predicts better responses. Integrating metabolic and immune biomarkers enhances risk stratification and therapeutic strategies, highlighting the potential for combined metabolic inhibitors and immunotherapies to improve precision medicine in lymphoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/35d2711154e88d30ee1749837827464d818a40eb" target='_blank'>
              Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL
              </a>
            </td>
          <td>
            Chengqian Chen, Wei Guo, Haotian Wang, Luming Cao, Out Bai
          </td>
          <td>2025-10-01</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Giant cell arteritis (GCA) is a form of large vessel vasculitis that primarily affects older adults and forms granulomatous inflammation in the aorta and its major branches. Recent advances in immunology and multi-omics technologies have elucidated several key mechanisms involved in the pathogenesis of GCA, including immune checkpoint dysregulation, clonal hematopoiesis, and age-associated immune dysfunction. From the perspective of immune cell subsets, a diverse range of immune cells—including tissue-resident memory T cells, stem-like T cells, macrophage subsets, B cells, and myofibroblasts—play distinct roles in sustaining vascular inflammation and tissue remodeling. This review summarizes the latest immunopathological and omics-based insights into GCA, proposes potential therapeutic targets, and discusses future directions for precision medicine aimed at achieving sustained remission.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f4f09fb5b89982c86ed926083baed9f9ea53f065" target='_blank'>
              Uncovering the New Biology of Giant Cell Arteritis to Guide Therapeutic Strategies
              </a>
            </td>
          <td>
            Mayu Shiomi, R. Watanabe, Ryuhei Ishihara, Sayaka Tanaka, Goichi Kageyama, Motomu Hashimoto
          </td>
          <td>2025-09-01</td>
          <td>Journal of Clinical Medicine</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="


 Glioblastoma, the most common and lethal primary brain tumor, creates profound immunosuppression that has resisted clinical interventions. The mechanisms behind immunotherapy failures in glioblastoma remain unclear. We conducted a systematic comparison of different immunotherapeutic approaches in mouse models to better understand treatment responses.



 Using multiomic single-cell analysis and spatial profiling, we evaluated GL261 glioma-bearing mice treated with anti-PD-L1 antibodies, NKG2D-CAR-expressing T cells, natural killer (NK) cells, or macrophages.



 All treatment models induced immune cell migration through chemotaxis. Additionally, PD-L1 and CAR T cell treatments led to an exhaustion-associated T cell signature alongside increased cytotoxic T cell presence. Further, we observed higher numbers of immunomodulatory lymphocytes and macrophages associated with these two immunotherapies. CAR macrophages and CAR NK cells exhibited enhanced cytotoxic gene signatures without increasing T cell numbers. Also, the immunomodulatory macrophage response appeared attenuated in CAR NK cells and macrophages. Notably, CAR NK cells demonstrated an enhanced antiviral response with interferon-beta expression that was not observed in other models.



 While PD-L1 and CAR cell treatments successfully polarized the lymphoid compartment toward cytotoxic phenotypes, these approaches alone appear insufficient as they were accompanied by pronounced immunomodulatory cell responses. CAR NK cells and macrophages were characterized by attenuated immunomodulatory responses. Our findings suggest that cytotoxic lymphocytes alone fail to override tumor-associated immune suppression. This is in line with recent evidence on T helper cell roles in CAR therapy. Future immunotherapy approaches should balance cytotoxic and helper lymphocyte populations while enhancing inflammatory macrophages to overcome the immunosuppressive environment of glioblastoma
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dde65cb7289ab4952a15cc4d954df652b303b749" target='_blank'>
              P08.22.B SYSTEMATIC COMPARISON OF IMMUNOTHERAPIES IN GLIOBLASTOMA REVEALS DISTINCT IMMUNE RESPONSE PATTERNS
              </a>
            </td>
          <td>
            Y. Liu, T. Look, J. Fang, A. Dalmau Gasull, M. Prinz, T. Weiss, R. Sankowski
          </td>
          <td>2025-10-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, thus, there is an urgent need to develop more effective therapeutic options for this dismal condition. Tumor-infiltrating lymphocytes (TILs) are associated with improved response to immune checkpoint blockade in HCC, but their low abundance in most cases limits their therapeutic efficacy. Here, we demonstrate, in mice, that low-dose intratumoral immunovirotherapy with the trivalent measles, mumps, and rubella vaccine (MMR) induces superior tumor-growth delay and extended host survival compared to individually administered vaccines for measles, mumps, or rubella viruses. Further, our results show that MMR therapy synergizes with PD-1 and CTLA-4 blockade to reprogram the tumor microenvironment, resulting in increased CD8+ TIL infiltration and reduced PD-1 expression on TILs, among other effects. These changes in the immunological landscape translated into greater survival and more durable tumor-specific and memory immune responses for hosts. Comprehensive toxicology analysis revealed no evidence of MMR-induced liver or kidney toxicity after intrahepatic administration. This work reinforces an unrecognized role of MMR plus ICB in reprogramming the immune landscape in HCC through multimodal immune activation, providing a strong rationale for further development of MMR-based therapies for HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a0ee9f74230079389edd57b51b6b1e849660e18a" target='_blank'>
              Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
              </a>
            </td>
          <td>
            M. Tesfay, Aleksandra Cios, K. U. Ferdous, Randal S. Shelton, Bahaa Mustafa, Camila C Simoes, Murat Gokden, I. Miousse, Kimberly J. Krager, Marjan Boerma, Alicja Urbaniak, Anuradha Kunthur, Sri Obulareddy, Joshua M. Eichhorn, Steven R Post, J. C. Chamcheu, Omeed Moaven, C. Chabu, D. Duda, Matteo Conti, Bruno Nardo, Rang Govindarajan, M. Fernandez-Zapico, Lewis R. Roberts, M. Borad, Martin J Cannon, Alexei G. Basnakian, B. Nagalo
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>62</td>
        </tr>

        <tr id="Introduction Kidney transplant rejections are classified as active antibody mediated rejection (AMR) and cell mediated rejection (TCMR), with AMR primarily driven by antibodies produced by B cells, whereas TCMR is mediated by T lymphocytes that orchestrate cellular immune responses against the graft. Emerging evidence highlights the essential roles of innate immune cells in rejections, especially monocytes/macrophages and natural killer (NK) cells. However, the roles of specific innate immune cell subpopulations in kidney allograft rejection remain incompletely understood. Methods We performed the spatial transcriptomics using the formalin-fixed paraffin-embedded (FFPE) core needle biopsies from human kidney allografts. Results We demonstrated that non-rejection, AMR, acute TCMR and chronic active AMR have distinct transcriptomic features. Subclusters of monocytes/macrophages with high Fc gamma receptor IIIA (FCGR3A) expression were identified in C4d-positive active AMR and acute TCMR, and the spatial distribution of these cells corresponded to the characteristic histopathological features. Key markers related to monocyte/macrophage activation and innate alloantigen recognition were upregulated, along with metabolic pathways associated with trained immunity in AMR and TCMR. Discussion Taking together, these findings revealed that intragraft monocytes/macrophages with high FCGR3A expression play a critical role in kidney transplant rejections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1fe937879ab369d45f22b51042e1b560cb3fdbb3" target='_blank'>
              Spatial transcriptomics reveals distinct role of monocytes/macrophages with high FCGR3A expression in kidney transplant rejections
              </a>
            </td>
          <td>
            Yan Chen Wongworawat, Chirag Nepal, Mark Duhon, Wanqiu Chen, Minh-Tri Nguyen, Adam Godzik, Xinru Qiu, Wei Vivian Li, Gary Yu, R. Villicana, Craig Zuppan, Michael De Vera, Michael T. Eadon, Mark Haas, Charles Wang
          </td>
          <td>2025-09-15</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="ABSTRACT Tolerogenic dendritic cells (tolDCs) that dampen T cell responses can be induced from blood monocytes in vitro using factors such as Vitamin D3 (VitD), dexamethasone, IL‐10, or rapamycin. However, challenges remain in obtaining robust and efficient generation of cell therapy‐based tolDCs without compromising their viability. We recently reported that CCR2‐dependent recruitment of monocytic cells, with the capacity to dampen T‐helper responses, occurs in mice treated with a single‐stranded oligonucleotide (ssON). Here, we investigated the effects of this immunomodulatory noncoding ssON on differentiating human monocytes towards DC in the presence of IL‐4 and GM‐CSF (moDC). The moDC differentiated in the presence of ssON upregulated CD1a but also increased their expression of PD‐L1. The differentiation of monocytes to moDC in the presence of ssON introduced transcriptomic changes, many of which overlapped with VitD‐moDC and resulted in moDCs with altered lipopolysaccharide (LPS)‐responsiveness. Moreover, ssON‐moDC exhibited a low capacity to stimulate alloreactive T cells in vitro and instead promoted the induction of CD4+FoxP3+CD25+ T cells. Experiments using chemical reagents support a role for PPAR‐γ in the generation of ssON‐moDC. Collectively, our data show that monocytes differentiated with IL‐4, GM‐CSF, and ssON generate cells with phenotypic and functional characteristics of tolDCs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7fee9e6189995b66ddd3a571d7811184f6d38e1" target='_blank'>
              Induction of Tolerogenic Dendritic Cells by a Noncoding Oligonucleotide
              </a>
            </td>
          <td>
            Kahkashan Kamal, James Trumbo, Elina Richardsdotter-Andersson, Marie Wahren-Herlenius, A. Spetz
          </td>
          <td>2025-10-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Over the past 30 years, work of immunologists worldwide has phenotypically and functionally defined “Natural Killer T cells” (NKT) and their subsets, including “invariant Natural Killer T cells” (iNKT). NKT cells make up a substantial fraction of T cells that express NK cell markers and have TCRs restricted to either conventional MHC molecules or the monomorphic CD1d molecule. Among these, iNKT cells are CD1d-restricted and more common within NKT cells than T cells without NK markers. While the definition of NKT cells, whether based on phenotype, function, or both, remains a topic of debate, iNKT cells represent a distinct T cell population characterized by a recurrent, conserved TCR rearrangement (TRAV10–TRAJ18 in humans) paired with a limited Vβ repertoire (mostly encoded by TRBV25-1 in humans). iNKT cells are restricted by CD1d, which, unlike CD1a-c molecules, is expressed not only on professional antigen-presenting cells and thymocytes but also on certain non-hematopoietic somatic tissues, both normal and neoplastic. Like all CD1 family members, CD1d presents various lipid antigens by accommodating their long hydrophobic tails in deep binding pockets, in contrast to the shallow peptide grooves of conventional MHC molecules. However, the ligand repertoire of CD1d is distinct from that of CD1a-c. This review focuses on CD1d-restricted iNKT cells. Activation of iNKT cells via their semi-invariant TCR, often in synergy with NK receptors and other co-stimulatory molecules, triggers a rapid, polyfunctional response. Unlike conventional MHC-restricted T cells, individual iNKT cells can simultaneously produce both Th1- and Th2-type cytokines and exert cytotoxic activity in an immune synapse-directed fashion. Through this combination of direct cytotoxicity and cytokine-mediated immunomodulation, iNKTs can eliminate target cells while activating myeloid and other lymphoid populations to amplify immune responses. Their versatility has fueled growing interest in harnessing iNKT cells across inflammatory, infectious, and oncological diseases, where early-phase studies have demonstrated their safety and preliminary efficacy. Moreover, because they are restricted by the non-polymorphic CD1d molecule and possess immune-regulatory properties, iNKT cells lack graft-versus-host potential, making them ideal candidates for allogeneic, off-the-shelf therapies. This review summarizes how iNKT cells are being reimagined as innovative tools for immune intervention across a range of clinical settings.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dcea494db3f709d49b9396731dd006351c3dc434" target='_blank'>
              Innate iNKT cells: from biological insight to clinical impact
              </a>
            </td>
          <td>
            Antonia Rotolo, Nicola J. Mason, Mark A Exley
          </td>
          <td>2025-09-10</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, presents major therapeutic challenges due to molecular heterogeneity and high relapse rates. While autologous hematopoietic stem cell transplantation (ASCT) has been a cornerstone for relapsed/refractory (R/R) B-cell lymphoma, its efficacy is often compromised by minimal residual disease (MRD) persistence and an immunosuppressive tumor microenvironment. Chimeric antigen receptor (CAR)-T cell therapy has transformed treatment paradigms but faces limited long-term durability due to antigen escape and T-cell exhaustion. The integration of ASCT with CAR-T therapy may offer a complementary approach to address these limitations, leveraging ASCT-induced immune reconstitution to enhance CAR-T-cell persistence and reprogram the tumor milieu. Emerging clinical evidence supports this approach, indicating improved disease control and progression-free survival. Although preliminary clinical outcomes are encouraging, unresolved challenges persist, particularly in terms of cumulative toxicity, optimal therapeutic sequencing, CAR-T-cell longevity, and financial feasibility associated with these advanced therapies. This review provides a comprehensive overview of mechanistic synergies between ASCT and CAR-T therapy, critically evaluates emerging clinical evidence on treatment sequencing, and explores innovative strategies to increase safety, efficacy, and accessibility.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8dabb02a640eb6c1d29c8aa3a2cf213056349991" target='_blank'>
              Autologous stem cell transplantation meets CAR-T therapy: A synergistic strategy for B-cell lymphoma.
              </a>
            </td>
          <td>
            Xumeng Zhao, Jiaying Wu, Xiaojian Zhu, Yi Xiao
          </td>
          <td>2025-10-01</td>
          <td>Cell transplantation</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Multiple myeloma (MM), despite therapeutic advances, remains an incurable disease. Therefore, the most patients eventually progress to relapsed/refractory multiple myeloma (RRMM). Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has shown remarkable efficacy in RRMM. However, limitations such as antigen escape, tumor heterogeneity, and T-cell exhaustion led to relapse. This review provides a comprehensive perspective on the transformative potential of bispecific CAR-T cell therapy as a promising strategy to overcome resistance and improve outcomes for patients with RRMM. The mechanisms of resistance to BCMA-targeted CAR-T therapy are comprehensively analyzed and categorized into BCMA-positive and BCMA-negative relapse/refractory mechanisms. The MIF/CD74 pathway as a potential contributor to BCMA CAR-T resistance was supported by single-cell RNA sequencing data and previous studies. The mechanistic advantages of dual-target are explored dual target CAR-T can prevent antigen escape and enhance T-cell activation. Clinical review of clinical trial data demonstrates the superior efficacy of bispecific CAR-T compared to BCMA CAR-T, including higher drug effect and more manageable side effects.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2818175f144550a502e0b40ea3e18bff89a83c0c" target='_blank'>
              Bispecific CAR-T vs. BCMA-Specific CAR-T: Advancing Treatment for Relapsed/Refractory Multiple Myeloma
              </a>
            </td>
          <td>
            Nigmat Rahim
          </td>
          <td>2025-09-05</td>
          <td>Highlights in Science, Engineering and Technology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Introduction Chronic lymphocytic leukemia (CLL) has proven difficult to treat with chimeric antigen receptor (CAR) T cell therapy. CLL cells can negatively alter T cell fitness and induce a pseudohypoxic state. We hypothesized that production of CAR T cells under restricted oxygen conditions resembling physiological oxygen levels that can be encountered in tissues (i.e. 2% O2) could promote outgrowth of hypoxia-tolerant CAR T cells. Methods We performed in vitro phenotypic and functional assessments of CD19-directed CAR T cells produced in either 21% (NorCAR) or 2% (HypCAR) O2 derived from healthy donors (HDs) or patients with CLL. Results Production of HD-derived CAR T cells in 2% O2 promoted the enrichment of a naïve-like subset. HypCAR and NorCAR cells were functionally distinct; CD4+ HypCAR cells produced more IL-2 and tumor necrosis factor than CD4+ NorCAR cells. Production in 2% O2 was not detrimental to viability or proliferation upon cognate antigen-stimulation and led to increased activation. After chronic stimulation in hypoxia, HypCAR-product remained enriched in naïve-like cells, and demonstrated cytotoxic and cytokine production capacity. In CAR T cells derived from patients with CLL, NorCAR and HypCAR subsets were functionally and phenotypically comparable, but displayed different mitochondrial metabolism. Discussion We demonstrated that production in 2% O2 is not detrimental, confers subtle but lasting functional and phenotypic changes in CAR T cells warranting further research on the impact of hypoxic production on CAR T cell functionality in hypoxic tumor microenvironments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3f224ca2fb20ea305b58dbbe807b058fa17875b2" target='_blank'>
              Production of functional CD19 CAR T cells under hypoxic manufacturing conditions
              </a>
            </td>
          <td>
            Isabella Micallef Nilsson, Thomas Poiret, Jinhye Ryu, Mohammadali Mohammadpour, Johan Henriksson, Anders Österborg, Jonas Mattsson, Anna Schurich, Isabelle Magalhaes
          </td>
          <td>2025-10-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Multiple myeloma (MM) is characterized by the malignant proliferation of plasma cells within the bone marrow. The transcriptional mechanisms governing plasma cell differentiation and MM pathogenesis are regulated by an intricate network of transcription factors, the role of RUNX1 in this process remains poorly defined. This study aimed to characterize plasma cell subsets in MM and evaluate the expression and functional role of RUNX1 during B cell differentiation. Bone marrow and peripheral blood samples were collected from 61 MM patients and 18 healthy donors. Flow cytometry was used to identify B cell and plasma cell subsets and measure RUNX1 expression across B cell maturation stages. Functional validation was conducted via siRNA-mediated RUNX1 knockdown in CD19+ B cells followed by in vitro plasma cell differentiation assays. Our data showed that MM patients exhibited significantly increased proportions of plasma cells in bone marrow compared to healthy controls. Intriguingly, RUNX1 expression was low in naive B cell subsets but increased progressively through plasmablast, pre-plasma, and plasma stages. Although RUNX1 expression did not significantly differ across MM stages or between newly diagnosed and relapsed/refractory cases, plasmablasts from MM patients showed higher RUNX1 levels than those from controls. Knockdown of RUNX1 in vitro using siRNA delayed B cell differentiation transiently. In summary, RUNX1 expression is dynamically upregulated during terminal B cell differentiation and is elevated in MM-derived plasmablasts. These findings provide new insights into a potential role for RUNX1 in the B cell differentiation axis and MM disease progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4c9b889e5cfd27d94a0649e42fb6114a2cc56fec" target='_blank'>
              RUNX1 expression dynamics in plasma cell differentiation and pathogenesis of multiple myeloma
              </a>
            </td>
          <td>
            T. F. Tang, Yee Teng Chan, Hui Jing Lim, Y. Y. Cheok, N. A. Anuar, Chin Sum Cheong, C. Looi, Sen Mui Tan, W. Wong, G. Gan
          </td>
          <td>2025-09-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Non-small cell lung cancer (NSCLC) remains the most prevalent and lethal form of lung cancer worldwide. Among the diverse components of the tumor microenvironment, tumor-associated macrophages (TAMs) are increasingly recognized as key regulators of NSCLC progression, metastasis, and treatment resistance. TAMs, particularly those polarized toward the M2-like phenotype, facilitate tumor growth through immunosuppression, angiogenesis, epithelial–mesenchymal transition, and extracellular matrix remodeling. They promote immune evasion via PD-L1, IL-10, and TGF-β signaling, and confer chemoresistance through activation of the IL-6/STAT3 and P2X7/STAT6 pathways. Moreover, high infiltration of M2-TAMs and their expression of immune checkpoint ligands have been associated with poor prognosis and, paradoxically, with improved response to PD-1/PD-L1 blockade in certain patients. Emerging therapeutic strategies aim to reprogram TAM phenotypes, inhibit their recruitment, or selectively suppress their immunosuppressive functions. However, challenges such as macrophage plasticity, lack of specific biomarkers, and potential systemic toxicity remain significant barriers. This review provides a comprehensive overview of the biological functions, mechanistic roles, and clinical implications of TAMs in NSCLC, highlighting both their value as prognostic indicators and their potential as therapeutic targets in the era of precision oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a4441ad90191ecc9c56fe31f7ae42ae5d7cc0668" target='_blank'>
              Targeting tumor-associated macrophages in non-small cell lung cancer: mechanisms, prognosis, and therapeutic opportunities
              </a>
            </td>
          <td>
            Dameng Hao, Shengjie Chen
          </td>
          <td>2025-09-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Introduction Crohn’s disease (CD) is a relapsing inflammatory disease that is currently not curable. Despite the availability of anti-inflammatory treatments, 30–60% of patients develop resistance, necessitating the need for novel therapeutic approaches. Data from colitis models in mice indicate that granulocytemacrophage colony-stimulating factor (GM-CSF)-activated monocytes (GMaMs) may serve as a promising cellular therapy. However, it remains unclear whether inflammatory mediators, medication, or intrinsic defects impair the functionality of monocytes in active CD (aCD), potentially affecting their therapeutic efficacy. Methods Monocytes from 8 aCD patients and healthy donors (HDs) were activated in vitro with GM-CSF, and their migratory capacity, adherence, metabolic activity, surface marker expression, and cytokine release were assessed. Cells were stimulated with lipopolysaccharides (LPS) to evaluate their inflammatory response. Results The GMaM phenotype was characterized by increased metabolic activity, enhanced production of inflammatory cytokines, stronger adhesion, and remodeling of surface receptors involved in T-cell activation, compared to naïve monocytes. These features were largely comparable between aCD patients and HDs. LPS stimulation of GMaMs from both groups resulted in a significant production of pro-inflammatory and chemotactic cytokines, particularly interleukin (IL)-8 and monocyte chemotactic protein 1. Both are crucial recruiters of neutrophils and monocytes. Notably, monocytes from aCD patients showed an increased IL-10 response to GM-CSF, while the LPS-induced tumor necrosis factor-alpha and interferon-gamma release were reduced compared to HDs. Discussion Peripheral monocytes from aCD patients retain functional responsiveness to GM-CSF activation, displaying preserved migratory, adhesive, metabolic, and cytokine responses. Differences in cytokine production by aCD monocytes may reflect disease-specific regulation, but do not appear to limit their suitability as cellular therapeutics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a144942872b55d9aca9ca371e925b5fb9f47b96d" target='_blank'>
              Peripheral monocytes from Crohn’s disease patients retain functional responsiveness to GM-CSF during active disease
              </a>
            </td>
          <td>
            Paul P Winkel, Wendy Bergmann-Ewert, Johannes Reiner, A. Huth, Dana Kleimeier, Rosaely Casalegno Garduño, I. M. Wrobel, G. Domanska, Jan Däbritz, E. Wirthgen
          </td>
          <td>2025-09-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Myeloproliferative neoplasms (MPNs) are hematological diseases predominantly driven by the JAK2V617F mutation. Progression from chronic-phase MPN to secondary acute myeloid leukemia (sAML) is a severe complication that dramatically worsens disease prognosis. While progression to sAML is classically linked to MPN clones acquiring additional mutations, the absence of JAK2V617F in some cases of post-MPN sAML cases suggests alternative mechanisms of transformation. Utilizing patient samples and in vivo modeling, we establish that leukemic clones can emerge independently of JAK2-mutant cells and undergo positive selection in the pro-inflammatory MPN environment, leading to parallel disease evolution. Genetic and pharmacological inhibition of IL-12 and TNFα mitigates this competitive advantage. Our data establish a new paradigm and show that disease progression in MPN can arise from parallel acute myeloid leukemia (pAML) clones.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20ff6d29f584df92c999c40dceb108095a3eb565" target='_blank'>
              JAK2V617F Myeloproliferative Neoplasms Support Parallel Evolution of Independent Leukemic Clones
              </a>
            </td>
          <td>
            Tyler M. Parsons, A. Krishnan, Infencia Xavier Raj, Andrew L. Young, David R. O’Leary, Jason Arand, Maggie J Cox, Stephen T. Oh, Grant A. Challen
          </td>
          <td>2025-09-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Simple Summary Donor-derived Vγ9Vδ2 T cells demonstrate potent anti-leukemic activity both in vitro and in vivo, offering a promising immunotherapeutic approach for acute myeloid leukemia (AML). These γδ T cells efficiently induce apoptosis in AML cells in vitro, highlighting their direct cytotoxic potential. In an aggressive AML xenograft mouse model, treatment with donor-derived Vγ9Vδ2 T cells significantly prolonged survival, indicating their therapeutic relevance in a clinically challenging setting. Importantly, these cells remain effective against venetoclax-resistant AML; in vivo studies further show that Vγ9Vδ2 T cells extend survival in mouse survival with or without venetoclax. These findings suggest the therapeutic potential of harnessing donor-derived Vγ9Vδ2 T cells as a novel strategy to overcome drug resistance and improve outcomes in AML, including in patients with limited responses to existing therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6e72a592035e114a06e58e1013ea6e52ae060ba" target='_blank'>
              Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach
              </a>
            </td>
          <td>
            Amanda Eckstrom, Anudishi Tyagi, Maryam Siddiqui, Jenny Borgman, Jieming Zeng, Adishwar Rao, A. Maiti, V. Battula
          </td>
          <td>2025-09-29</td>
          <td>Cancers</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="The Interferon-Stimulated Gene 15 (ISG15) has a key role during viral infections, since it can modify and regulate the expression of proteins from the host and from viruses. Isg15−/− mice are more susceptible to infectious diseases. ISG15 is induced by type I Interferons (IFN-I) and apart from defense against pathogens, it can also play an important function in cancer or immune-mediated inflammatory diseases. Previous studies reported that ISG15 expression is increased in post-synaptic dendritic cells (DCs) upon interaction with CD4 + T cells. However, data regarding the role of ISG15 in DCs are scarce. The present study assesses the function of ISG15 in DCs activation, migration and ability to mediate T cell activation using bone marrow-derived DCs (BMDCs) and stimulation with lipopolysaccharide (LPS). Activation of DCs was not impaired but tended to be lower in Isg15-deficient mice, as observed by reduced CD40 induction in Isg15−/− BMDCs. Isg15−/− BMDCs induced less proliferation and Granzyme B expression in co-cultured CD8 + T cells. Interestingly, Isg15−/− BMDCs secreted reduced levels of the pro-inflammatory cytokines IL-1β and IL-12 upon LPS stimulation. Mechanistically, our data suggest that ISG15 regulates Caspase-1 activity in DCs leading to lower IL-1 β secretion. In conclusion, this study reveals an essential role for ISG15 modulating DCs inflammatory activity and raises new questions regarding the specific mechanisms of how this protein regulates innate immune responses. Supplementary Information The online version contains supplementary material available at 10.1007/s00018-025-05849-9.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/05fa00535a2acdc99ae44733e69601b7e28b4dad" target='_blank'>
              ISG15 modulates inflammatory profiles and ability to activate CD8 + T cells in bone marrow-derived dendritic cells
              </a>
            </td>
          <td>
            P. Martínez-Fleta, Clara Pertusa, Irene Fernández-Delgado, R. Izquierdo-Serrano, M. Ramírez-Huesca, Nieves Fernández-Gallego, D. Calzada-Fraile, Elena Moya-Ruiz, Raquel Castillo-González, Susana Guerra, E. Martín-Gayo, F. Sánchez-Madrid
          </td>
          <td>2025-10-24</td>
          <td>Cellular and Molecular Life Sciences: CMLS</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Chronic myeloid leukemia (CML) is a malignant clonal proliferative disease originating from hematopoietic stem cells. While treatment with tyrosine kinase inhibitors (TKIs) effectively eliminates the majority of leukemia cells in patients, residual leukemia cells can still be detected in those achieving deep molecular remission, ultimately leading to drug resistance or relapse. But the exact mechanism is unclear. In recent years, the immune microenvironment has been a hot research topic in hematologic malignancies. CML patients exhibit abnormalities in antitumor immunity. Myeloid-derived suppressor cells (MDSCs), which possess immune-suppressing functions, inhibit the proliferation and activation of CD4+/CD8+ T cells, Tregs, B cells, and NK cells, and play a central role in the antitumor immune response in a wide range of cancers. Abnormalities in numbers and functions of MDSCs are exhibited in CML patients, which affect the immune status of CML patients through multiple mechanisms. This review summarizes the biological properties of MDSCs, their alterations in CML patients, their roles and specific mechanisms in the development of CML, and how these mechanisms can be leveraged to develop new therapeutic strategies, aiming to provide novel insights and approaches for the treatment of CML.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bc96fb2e2a382163dd0d6a3fe8a72e0940472ac8" target='_blank'>
              Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia
              </a>
            </td>
          <td>
            Xing Meng, Yue Zhang, Hong Xu, Yanyan Zhang, Hao He, Jianmin Ma, Xiaoyan Zhang
          </td>
          <td>2025-09-19</td>
          <td>Journal of Cancer Research and Clinical Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Multiple sclerosis (MS) is an autoimmune and neuroinflammation disease characterized by axonal damage, inflammatory demyelination, and neurodegeneration. However, the precise mechanisms underlying MS pathogenesis remain largely unclear. Here, we identify ZNRF1, an E3 ubiquitin ligase, as a critical regulator of experimental autoimmune encephalomyelitis (EAE), a murine model that recapitulates the autoimmune demyelination features of MS. Mice lacking ZNRF1 exhibit increased susceptibility to EAE progression. Notably, ZNRF1 depletion in peripheral myeloid cells, but not in microglia, leads to enhanced immune cell infiltration into the central nervous system, resulting in demyelination and exacerbated disease severity. The heightened EAE severity in Znrf1-deficient mice is associated with increased polarization of Th1 and Th17 cells, elevated antigen-specific T helper cell proliferation, and amplified immune responses. Furthermore, following EAE induction, macrophages from Znrf1-deficient mice display elevated surface expression of MHC class II (MHC-II) molecules. Collectively, our findings suggest that ZNRF1 in peripheral myeloid cells plays a suppressive role in neuroinflammation by regulating MHC-II surface expression, thereby controlling antigen-specific T-cell proliferation and activation. Supplementary Information The online version contains supplementary material available at 10.1186/s12974-025-03550-z.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f962a55325851d781ba99d1de0343d57aac16244" target='_blank'>
              Myeloid ZNRF1 suppresses autoimmune demyelination and neuroinflammation by regulating MHC-II-mediated T cell activation
              </a>
            </td>
          <td>
            Yung-Chi Chang, Ching-Chih Wu, Fu-Ting Hsiao, You-Sheng Lin, Ting-Yu Lai, Kang-Hsuan Huang, Shiue-Cheng Tang, Chih-Yuan Lee, Shen-Ju Chou, Li-Chung Hsu
          </td>
          <td>2025-10-22</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/46bafe0918a9e9450bced743d3386f466d0c3528" target='_blank'>
              Engineering CAR-T cells for solid tumors: bispecific antigen targeting, tumor microenvironment modulation, and toxicity control.
              </a>
            </td>
          <td>
            Tanvi Premchandani, Mohammad Qutub, Amol A Tatode, M. Umekar, Jayshree Taksande, Ujban Md Hussain Hussain, Sameer R Khidkikar
          </td>
          <td>2025-09-20</td>
          <td>Immunologic research</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Background The immunosuppressive microenvironment and limited immune cell infiltration into the tumor bed contribute to the proliferation, metastasis, and invasion of breast cancer (BC) cells. Reprogramming the tumor immune microenvironment has emerged as a promising therapeutic target for BC, but remains challenging in clinical practice. Artemisia annua, a medicinal plant, has shown immune-enhancing and anti-tumor activities, although its potential therapeutic applications in BC remain underexplored. Methods Extracellular vesicles (EVs) were isolated from fresh Artemisia annua using gradient centrifugation and characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), Zetasizer Nano ZS90, ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS/MS), and high-performance liquid chromatography (HPLC). Single-cell RNA sequencing (scRNA-seq) analysis was performed to investigate the mechanism of AEVs on tumor growth in vivo and mRNA sequencing (mRNA-seq) was employed to further explore the mechanism of AEVs-induced polarization shift from M2-like to M1-like macrophages. In vitro and in vivo assays were conducted to assess the polarization of macrophages and recruitment of T lymphocytes into the tumor bed. Results AEVs were successfully isolated and characterized. In vivo, AEVs inhibited tumor growth by shifting macrophage polarization from the M2-like to the M1-like phenotype, and synergistically enhancing the recruitment of CD8+ and CD4+ T cells into the tumor microenvironment. AEVs activated the NF-κB signaling pathway while inhibiting the PPARγ pathway, thereby promoting the M1-like polarization of macrophages. Polarized M1-like macrophages secreted chemokines (CCL5 and CCL3), which facilitated T lymphocyte infiltration into the tumor bed. Notably, AEVs reshaped the BC immune microenvironment without inducing systemic toxicity. Conclusions AEVs from Artemisia annua efficiently reprogrammed the immune microenvironment of breast cancer by inducing macrophage polarization and enhancing T lymphocyte infiltration. This study lays the foundation for using AEVs as a potential immunotherapy for BC and highlights the medicinal value of Artemisia annua in cancer treatment. Supplementary Information The online version contains supplementary material available at 10.1186/s13020-025-01210-1.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8ae2b76c7e2982ae527e2b31089269c261024d90" target='_blank'>
              Artemisia annua-derived extracellular vesicles reprogram breast tumor immune microenvironment via altering macrophage polarization and synergizing recruitment of T lymphocytes
              </a>
            </td>
          <td>
            Yun Wang, Lin Meng, Sicheng Su, Yu Zhao, Xiaoxian Hu, Xiaoqing Xu, Chao Han, Jianguang Luo, Zhong-Rui Li
          </td>
          <td>2025-10-01</td>
          <td>Chinese Medicine</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="


 CD8 T cells are effector cells of the adaptive immune system responsible for mediating protective immune responses in cancer. However, CD8 T cells can also be critical drivers of pathologic responses including autoimmunity. A key feature of these cells is that they must infiltrate tissues to execute their primary function of cell killing. It is well established that naive T cell responses do not originate in these tissues. Rather, prior to antigen-driven activation, naïve T cells are restricted to lymph nodes, spleen, and blood. T cell activation by cognate antigen drives expression of multiple immune checkpoint inhibitors, including programmed cell death protein-1 (PD-1) and/or cytotoxic T lymphocyte associated protein-4 (CTLA-4), as well as migration to nonlymphoid tissues. Work over the last two decades has harnessed T cell effector activities by blocking PD-1 and/or CTLA-4, which has revolutionized cancer care and demonstrated remarkable efficacy in diverse cancer types. However, many patients do not respond to checkpoint blockade therapy, and worse, other patients develop autoimmune-like immune-related adverse events (irAEs), limiting the utility of this approach. To maximize the therapeutic benefit of checkpoint blockade without accelerated irAE development, targeted approaches are needed to increase recruitment of protective CD8 T cells to tumors while preventing pathogenic T cell entry into sensitive tissues. However, an inability to granularly measure recruitment into non-lymphoid tissues has created a significant gap in knowledge in: 1) how checkpoint inhibitors impact T cell entry rates into tissues, 2) whether these entry rates are different for tumors and lesional irAE tissues, 3) where recruited cells localize, and 4) the precise functional contributions of recruited versus resident T cells in driving tumor regression or autoimmunity. To fill this gap in knowledge, we are utilizing an intravenous antibody labeling approach to mark CD8 T cells in the blood prior to entry into tissues, an approach which enables a 72-hour window to track tissue entry. Using this approach in the preclinical setting, we are interrogating how PD-1 inhibitors impact CD8 T cell recruitment to tumors as well as the pancreas in the context of Type 1 Diabetes. In our tumor studies, we have found that PD-1 inhibitors induce an increase in the number of recently recruited CD8 T cells, and that these recruited T cells have a less exhausted phenotype than the T cells that have been in the tumor for longer. In our diabetes studies, we have found that PD-1 inhibitors impact CD8 T cells both in the periphery and the pancreas, and in some mice cause an increase in migration to the pancreas. These studies support a model where peripheral CD8 T cell recruitment can positively contribute to productive anti-tumor immunity but can also exacerbate autoimmunity. Thus, our studies emphasize the doubled-edged nature of T cell recruitment, and our future studies will examine ways to both improve recruitment to tumors and mitigate recruitment to lesional irAE tissues.



 Oluwatoyosi Adewunmi, Arielle G. Dessens, Aloukick K. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken. Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B001.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7cd824c6703eab6c26623afbbb67ccbb6990fccd" target='_blank'>
              Abstract B001: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade
              </a>
            </td>
          <td>
            O. Adewunmi, Arielle G. Dessens, A. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 CD8 T cells are effector cells of the adaptive immune system responsible for mediating protective immune responses in cancer. However, CD8 T cells can also be critical drivers of pathologic responses including autoimmunity. A key feature of these cells is that they must infiltrate tissues to execute their primary function of cell killing. It is well established that naive T cell responses do not originate in these tissues. Rather, prior to antigen-driven activation, naïve T cells are restricted to lymph nodes, spleen, and blood. T cell activation by cognate antigen drives expression of multiple immune checkpoint inhibitors, including programmed cell death protein-1 (PD-1) and/or cytotoxic T lymphocyte associated protein-4 (CTLA-4), as well as migration to nonlymphoid tissues. Work over the last two decades has harnessed T cell effector activities by blocking PD-1 and/or CTLA-4, which has revolutionized cancer care and demonstrated remarkable efficacy in diverse cancer types. However, many patients do not respond to checkpoint blockade therapy, and worse, other patients develop autoimmune-like immune-related adverse events (irAEs), limiting the utility of this approach. To maximize the therapeutic benefit of checkpoint blockade without accelerated irAE development, targeted approaches are needed to increase recruitment of protective CD8 T cells to tumors while preventing pathogenic T cell entry into sensitive tissues. However, an inability to granularly measure recruitment into non-lymphoid tissues has created a significant gap in knowledge in: 1) how checkpoint inhibitors impact T cell entry rates into tissues, 2) whether these entry rates are different for tumors and lesional irAE tissues, 3) where recruited cells localize, and 4) the precise functional contributions of recruited versus resident T cells in driving tumor regression or autoimmunity. To fill this gap in knowledge, we are utilizing an intravenous antibody labeling approach to mark CD8 T cells in the blood prior to entry into tissues, an approach which enables a 72-hour window to track tissue entry. Using this approach in the preclinical setting, we are interrogating how PD-1 inhibitors impact CD8 T cell recruitment to tumors as well as the pancreas in the context of Type 1 Diabetes. In our tumor studies, we have found that PD-1 inhibitors induce an increase in the number of recently recruited CD8 T cells, and that these recruited T cells have a less exhausted phenotype than the T cells that have been in the tumor for longer. In our diabetes studies, we have found that PD-1 inhibitors impact CD8 T cells both in the periphery and the pancreas, and in some mice cause an increase in migration to the pancreas. These studies support a model where peripheral CD8 T cell recruitment can positively contribute to productive anti-tumor immunity but can also exacerbate autoimmunity. Thus, our studies emphasize the doubled-edged nature of T cell recruitment, and our future studies will examine ways to both improve recruitment to tumors and mitigate recruitment to lesional irAE tissues.



 Oluwatoyosi Adewunmi, Arielle G. Dessens, Aloukick K. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken. Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr PR-10.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bd96650135ea1d6c5e4e2bfdec0bd0131105df25" target='_blank'>
              Abstract PR-10: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade
              </a>
            </td>
          <td>
            O. Adewunmi, Arielle G. Dessens, A. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Immune cell migration plays a pivotal role in coordinating inflammatory responses and maintaining immune surveillance. Here, we provide a comprehensive overview of the migratory behaviors of key immune cell subsets, including Th1, Th2, regulatory T cells, macrophages, dendritic cells, and neutrophils and the molecular mechanisms that guide their trafficking from lymphoid organs to inflamed tissues. We highlight the stepwise migration cascade: priming in secondary lymphoid organs, trafficking through blood vessels, adhesion to endothelium, and extravasation into tissues. Each step is critically regulated by chemokines, selectins, integrins, and proteases. We also examine current pharmacological strategies that target immune cell migration in inflammatory diseases, such as integrin blockers and chemokine receptor antagonists, emphasizing both therapeutic potential and clinical limitations. In addition, we discuss emerging technologies including intravital imaging, CRISPR-based screening, and computational modeling that provide novel insights into immune cell dynamics and may guide the development of next generation migration-targeted therapies. Overall, this review integrates fundamental immunological principles with translational medicine by identifying key challenges, unresolved controversies, and future directions in the therapeutic modulation of immune cell migration.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b35de878e1a4e6dc7dfbb8b9e6a7a5a5cdb3f5d" target='_blank'>
              Targeting immune cell migration as therapy for inflammatory disease: a review
              </a>
            </td>
          <td>
            Bingfeng Song, Wenbo Guo, Ying He, Xingli Yao, Jintang Sun, Shijun Wang
          </td>
          <td>2025-09-25</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Monocytes and macrophages are sentinels of the immune system that distinguish themselves from other cells by expressing the beta isoform of the folate receptor (FRβ). Because FRβ does not bind folate until the monocyte/macrophage is exposed to immunosuppressive cytokines, the question naturally arose whether FRβ might also perform an immune-related function. To examine this matter, we compared the properties of wild type (WT) and FRβ knockout mice. We observe that FRβ knockout (KO) mice display autoimmune symptoms that can include alopecia, enlarged spleens, and dermatitis, despite having normal cellular folate levels. We further demonstrate that syngeneic tumors (TRAMP C2, MC38) grow much slower in FRβ KO mice than wildtype mice. Comparison of cells extracted from syngeneic tumors of KO mice further reveal that CD69+ T cells are increased while PD1+ T cells and PD-L1+ myeloid cells are decreased in KO tumors. More detailed comparison of the bone marrow-derived macrophages from KO and WT mice demonstrates that KO mice have upregulated pro-inflammatory genes and downregulated anti-inflammatory genes. Because blockade of FRβ with a monoclonal antibody or deletion of FRβ impairs direct macrophage suppression of T cell activation in vitro, we conclude that FRβ performs a checkpoint function that regulates the immunologic properties of tumor myeloid cells. Since FRβ expression in human cancers is shown to correlate inversely with overall survival, we further posit that FRβ similarly performs an immunosuppressive function in human tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6350926a82e6aa0f4f7b912a7cea7a3b3cca511a" target='_blank'>
              Folate receptor β performs an immune checkpoint function in activated macrophages
              </a>
            </td>
          <td>
            Fenghua Zhang, Md. Yusuf Al-Amin, Sagar M. Utturkar, Rina Jiang, Gregory Cresswell, Rami A. Alfar, Ian Ophaug-Johansen, Gabriel Bachman, M. Srinivasarao, Richard Finnell, Amaya Puig-Kröger, Timothy Ratliff, Philip S. Low
          </td>
          <td>2025-09-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Background Checkpoint inhibitors have revolutionized hepatocellular carcinoma (HCC) treatment, yet their efficacy remains limited in advanced stages, with suboptimal objective response rates. Growth differentiation factor 15 (GDF15), a dual-functional cytokine implicated in tumor progression and immunosuppression, represents a promising therapeutic target. This study aims to develop a novel GDF15-targeted strategy to improve HCC management and synergize with PD-1 blockade. Methods GFRAL-Fc fusion proteins were generated by fusing the extracellular domain of GFRAL with IgG1 Fc. The anti-tumor efficacy and the anti-cachexia ability of GFRAL-Fc was evaluated in a spontaneous HCC model on GDF15 humanized mice. Additionally, the half-life and drug safety were evaluated in mice. To investigate the underlying mechanisms, a CyTOF analysis was utilized to analysis the immunoregulation effects of GFRAL-Fc within HCC. Finally, the anti-tumor effects of GFRAL-Fc in combination with Programmed Death-1 (PD-1) inhibitors were assessed. Results GFRAL-Fc targets GDF15 to simultaneously prevent GDF15-CD48 interaction-driven ERK activation and block GDF15-GFRAL binding. Treatment with GFRAL-Fc achieved dual antitumor effects: reducing tumor progression and attenuating cancer-associated cachexia. Combination with PD-1 blockade further enhanced antitumor efficacy, resulting in a substantial decrease in tumor nodules. Mechanistic studies revealed that GFRAL-Fc reprograms the immunosuppressive tumor microenvironment by suppressing Treg activation while enhancing CD8+ T cell cytotoxicity. Conclusions Our findings validate GDF15 targeting as a viable strategy to overcome checkpoint inhibitor resistance in HCC. The GFRAL-Fc fusion protein demonstrates multimodal therapeutic benefits through metabolic regulation and immune remodeling, providing a clinically translatable approach to optimize PD-1-based regimens. This study addresses critical gaps in current HCC management and warrants further clinical validation. Graphical Abstract Schematic diagram of GFRAL-Fc functional: After binding with GDF15, GFRAL-Fc inhibits the GDF15-GFRAL pathway to suppress cancer-associated cachexia, while also inhibiting the GDF15-CD48 pathway to reprograming the tumor immune microenvironment. Supplementary Information The online version contains supplementary material available at 10.1186/s12964-025-02427-1.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f424c4cc08908ec0d690fea5ad9e9738200e0f9" target='_blank'>
              GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Gege Shi, Wangqian Zhang, Fei Xie, Jiaxin Shi, Minghui Yan, Lei He, Zhaozhao Li, Yang Xiao, Duo Yu, Haiyan Cao, Haichen Du, Yueyuan Qiu, Kuo Zhang, Shuning Wang, Meng Li, Jieyu Zhang, Zhaowei Wang
          </td>
          <td>2025-10-15</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="As a key lymphocyte population in shaping and controlling adaptive immune response, T cells play an important immunomodulatory role in the early stages of autoimmune diseases. Although CD3+CD4−CD8− T (DNT) cells constitute only a small proportion of peripheral T lymphocytes, they may be closely linked to the occurrence and development of autoimmune diseases. However, the role of DNT cells in autoimmune disease pathogenesis still needs to be elucidated. In this review, we first present the origin, functions, and heterogeneity of DNT cells. We then summarize the role of DNT cells in the pathogenesis of various autoimmune diseases. Subsequently, we clarify the recent advances in the applications of DNT cell-based therapy for autoimmune diseases and outline potential drugs (including active ingredients extracted from Chinese medicinal treatments) and approaches that can target the proliferation and expansion of DNT cells. Lastly, the limitations and challenges of applying DNT-cell-based therapy are analyzed. In conclusion, we present an overview to further the understanding of the role of DNT cells in autoimmune disease pathogenesis and of DNT cells as a potential therapeutic tool for immune disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/130f579f8c6e0a3374a93d0e8f2050f3b8d8e91f" target='_blank'>
              CD3+CD4−CD8− T cells: a new potential therapeutic target in treating autoimmune diseases
              </a>
            </td>
          <td>
            Xin Li, Di Guo, Isabelle Xinyue Zou, Lingyan Zhao, Na Yang, Yang Liu
          </td>
          <td>2025-09-26</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Gliomas present as highly heterogeneous and aggressive central nervous system (CNS) tumors with challenging diagnosis and management. Traditional and current therapies are lacking efficacy in overcoming the complex and dynamic behavior of gliomas and the local tumor microenvironment. Emerging research highlights the significant role of innate immune receptors including Toll-like, NOD-like and RIG-like receptors, as well as cGAS-STING receptors, scavenger and C-type lectin receptors in glioma development and progression. These receptors can both impact immune modulation as well as facilitate tumor growth through interactions with tumor-associated macrophages, myeloid-derived suppressor cells and cytokine networks, contributing to immune evasion in the tumor microenvironment. Herein, we discuss the main signaling pathways induced through innate immune receptors in gliomas along with their functional properties in glioma pathology while exploring current applications to treatment. Utilizing innate immune receptors as therapeutic targets holds great promise, especially when used along with traditional chemotherapy and radiation schemes, strengthening immune responses. Future studies focusing on the deeper understanding of innate immune receptors signaling and complexity are highly required to enable novel immunoregulatory treatment schemes for gliomas.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b2b7b3e02786ee96fe5c12a17a3e23bd5c3a936a" target='_blank'>
              Innate Immune Signaling in Gliomas: Regulatory Mechanisms and Targeting Potential in Tumor Progression
              </a>
            </td>
          <td>
            Edmund Jung, Sara Al Jadidi, C. Piperi
          </td>
          <td>2025-10-10</td>
          <td>Life</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="


 Despite promising safety profiles, B7-H3 CAR T cell therapies have yet to demonstrate meaningful clinical efficacy in diffuse intrinsic pontine glioma (DIPG), a devastating pediatric brain cancer characterized by a profoundly immunosuppressive tumor microenvironment (TME). This TME is dominated by tumor-associated macrophages (TAMs) and suppressive resident microglia that restrict CAR T-cell activation and persistence. Importantly, broad myeloid targeting risks eliminating macrophages essential for supporting T cell activation and anti-tumor immunity. We identified CD123 as a selective marker of suppressive TAMs in DIPG and hypothesized that dual targeting of CD123+ TAMs alongside B7-H3+ tumor cells would effectively remodel the TME, restore T cell function, and enhance therapeutic efficacy.



 Using immunocompetent DIPG models, we evaluated a sequential combination of CD123 and B7-H3 CAR T cells to remodel the TME and improve tumor control. In vitro assays included cytotoxicity, repeated antigen stimulation, and co-cultures with M1- or M2-polarized macrophages. Endpoints included TAM depletion, TME remodeling, tumor burden, and survival.



 In vitro, M2 macrophages suppressed B7-H3 CAR T cell proliferation, persistence, and cytokine secretion; these effects were reversed by co-treatment with CD123 CAR T cells. CD123 CAR T cells selectively depleted M2-like TAMs and microglia without cytotoxicity against B7-H3+ DIPG tumor cells. In vivo, CD123 CAR T cell treatment reduced immunosuppressive TAMs and shifted the tumor microenvironment toward a pro-inflammatory phenotype, as demonstrated by intracellular cytokine staining and comprehensive flow cytometry analyses. Notably, administration of CD123 CAR T cells after B7-H3 CAR T cell infusion failed to rescue antitumor activity. However, administering CD123 CAR T cells within a four-day window prior to B7-H3 CAR T cell infusion significantly enhanced tumor control. Dual CAR therapy substantially decreased tumor burden, limited suppressive myeloid and microglial infiltration, and improved T cell activation and persistence, resulting in extended survival compared to monotherapies, with some mice achieving durable tumor remission. Ongoing transcriptomic studies are underway to elucidate the mechanisms driving this robust, lasting antitumor immunity.



 Priming the TME with CD123 CAR T cells significantly improves B7-H3 CAR T cell efficacy in aggressive DIPG models. Dual targeting of CD123+ TAMs and B7-H3+ tumor cells reprograms the DIPG TME and enhances CAR T-cell function by overcoming immunosuppressive barriers while preserving supportive immune populations. This strategy offers a promising mechanistic approach to improving CAR T therapy in DIPG.



 Khatereh Khorsandi, Kaleem Coleman, Jaquelyn T. Zoine, M.Paulina Velasquez, Dalia Haydar. Reprogramming the Myeloid Tumor Microenvironment with CD123 CAR T Cells Enhances B7-H3 CAR T Cell Therapy in DIPG [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer— From Biology to Breakthrough Therapies; 2025 Sep 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_2):Abstract nr A039-PR007.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9467562ec35cf64972931c9ccd0b2e56a2414e52" target='_blank'>
              Abstract A039-PR007: Reprogramming the Myeloid Tumor Microenvironment with CD123 CAR T Cells Enhances B7-H3 CAR T Cell Therapy in DIPG
              </a>
            </td>
          <td>
            Khatereh Khorsandi, Kaleem Coleman, Jaquelyn T. Zoine, M. Velasquez, Dalia Haydar
          </td>
          <td>2025-09-25</td>
          <td>Cancer Research</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="


 Fractionated focal radiation therapy (RT) induces immunogenic cell death and activates the type I interferon pathway via the cGAS/STING pathway, promoting tumor antigen cross-presentation by conventional dendritic cells (cDCs) and driving tumor-specific T-cell activation. However, the impact of RT on tumor regression is often limited by its complex effects on the tumor immune microenvironment (TiME). Several studies have shown that RT increases both the frequency and functional activity of regulatory T cells (Tregs), due in part to their intrinsic radioresistance and to RT-induced modulation of recruitment signals such as TGFβ, CCL17, and CCL221-2. In a recent study, we showed that RT combined with immunotherapy can remodel the TiME3, et persistent infiltration of activated Tregs can dampen the full immunostimulatory effects of RT-driven viral mimicry responses4. Here, we evaluated whether combining RT with blockade of the myeloid checkpoint SIRPα could modulate Treg infiltration and activity. Using mouse models of luminal (TSA) and triple-negative (AT3) breast cancer, we tested RT in combination with a blocking anti-SIRPα antibody (MY1; SIRPα-b). While MY1 monotherapy showed minimal activity, its combination with RT led to enhanced regression of irradiated tumors and inhibition of non-irradiated (abscopal) tumor growth in both tumor models. This effect was lost upon conditional cDC depletion using Zbtb46-DTR mice, highlighting the importance of cDCs in mediating the therapeutic synergy. To dissect the immune mechanisms underlying this synergy, we performed single-cell RNA-sequencing and CITE-seq on CD45+ tumor-infiltrating cells from TSA tumors treated with RT ± SIRPα-b. We observed a significant reduction in Treg infiltration in SIRPα-b–treated tumors, with or without RT. Furthermore, expression of Treg activation markers OX40, CTLA-4, and GITR was reduced, particularly in the RT + SIRPα-b group. Among infiltrating CD45+ cells, expression of Treg recruiting Ccl22 and Ccl17 chemokines was observed only in a highly activated cluster of CCR7high cDCs expressing SIRPα, CXCL16, PD-L1, and IL-15Rα. Notably, expression of both chemokines was strongly decreased following SIRPα-b treatment, suggesting that SIRPα signaling supports Treg recruitment via this cDC population.Studies to understand the mechanisms of Treg recruitment to the tumor via chemokine secretion by CCR7high cDCs and their role in tumor regression after RT + SIRPα-b are underway. Intra-tumoral CCR7high cDCs are known to support the activation and cytotoxic function of CD8+ T cells and NK cells in the tumor through transpresentation of Il-155. Our results suggest that this population also plays a key immunoregulatory role in shaping the TiME. Targeting the CD47/SIRPα axis may thus improve RT efficacy by modulating the dual functions of CCR7high cDCs in both effector stimulation and Treg recruitment.
 1- PMID: 28970196 2- PMID: 30042205 3- PMID: 37620372 4- doi: 10.1038/s41392-023-01462-z 5- PMID: 34343496



 Maud Charpentier, Claire Lhuillier, Alicia Alonso, Doron Betel, Paul Zumbo, Maider Astorkia Amiama, Sergio Trombetta, Sandra Demaria. Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr A023.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/acbd70f4779618ff4cf0238d208283c1e692a84a" target='_blank'>
              Abstract A023: Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression
              </a>
            </td>
          <td>
            M. Charpentier, Claire Lhuillier, Alicia Alonso, D. Betel, P. Zumbo, Maider Astorkia Amiama, Sergio Trombetta, Sandra Demaria
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) play critical roles in tumor immune evasion. These heterogeneous cells are broadly classified into granulocytic (G-MDSC), monocytic (M-MDSC), and their immature precursors, early-stage MDSCs (e-MDSCs). Elucidating their differentiation and expansion mechanisms is crucial for advancing cancer immunotherapy. This review examines the key signaling pathways (e.g., JAK/STAT, NF-κB, Notch), regulatory cytokines, metabolic factors, and epigenetic modifications central to MDSC biology. A comprehensive understanding of these intricate networks provides valuable insights into tumor immune evasion and facilitates the identification of novel therapeutic targets designed to overcome MDSC-mediated immunosuppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4682b63ca9757bb9c1ba2dada7a0f722d5dd5cac" target='_blank'>
              Molecular mechanisms governing the differentiation and expansion of myeloid-derived suppressor cells
              </a>
            </td>
          <td>
            Ke Wang, Xiao Wang, Nan Sun
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Cell and Developmental Biology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Endometriosis (EMs) is a chronic inflammatory disorder characterized by dysregulated innate immunity, particularly impaired cytotoxic function of natural killer (NK) cells. As pivotal effectors of the innate immune response, NK cells fail to eliminate ectopic endometrial lesions due to aberrant receptor–ligand interactions, elevated levels of immunosuppressive cytokines (TGF-β, IL-6, and IL-10), and dysfunction of adhesion molecules. This compromised immune surveillance facilitates the survival and implantation of ectopic lesions, contributing to the hallmark symptoms of pain and infertility. Recent immunotherapeutic strategies, including NK cell checkpoint blockade (anti-NKG2A, anti-PD-1), IL-2-based activation, and adoptive NK cell transfer—seek to restore NK cell cytotoxicity and reestablish immune homeostasis. This review summarizes current advances in understanding NK cell dysfunction in EMs, emphasizing its central role in immune evasion and the therapeutic promise of targeting innate immune pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e51cb74a5017f4e1a0bdc132ed432062f49ec6a8" target='_blank'>
              Dysfunction of natural killer cells promotes immune escape and disease progression in endometriosis
              </a>
            </td>
          <td>
            Weiyu Jiang, Wen Xu, Feng Chen
          </td>
          <td>2025-09-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="


 Adoptive cell transfer-based immunotherapies have shown limited efficacy against most solid tumors. A key barrier to success is the immunosuppressive tumor microenvironment (TME). Beyond local effects, tumors induce systemic immune disturbances that further hinder anti-tumor immunity and promote disease progression. In this study, we investigate how tumor-driven systemic immunosuppression compromises the function of both endogenous and adoptively transferred natural killer (NK) cells, identifying potential strategies to enhance immunotherapeutic outcomes.



 We utilized syngeneic murine cancer models to systematically characterize alterations in immune cell populations within the circulation and spleen. Comprehensive and in-depth assessment of immune cell function, transcriptional activity, and metabolic state was performed using flow cytometry, Seahorse metabolic analysis, RNA sequencing, metabolic tracing, and ex vivo co-culture systems.



 In our PDAC mouse models, tumor burden elicited a robust systemic inflammatory response marked by expansion of myeloid lineage cells, particularly MDSCs, within the TME, peripheral blood, and spleen. Tumor growth led to reduced frequencies and functional deficits in both endogenous and adoptively transferred NK cells in circulation and spleen. Depletion of Gr-1+ MDSCs effectively restored NK cell effector functions. Mechanistic analyses demonstrated that MDSCs in tumor-bearing mice promote NK cell dysfunction through induction of lipid peroxidation. Notably, we observed pronounced upregulation of apolipoprotein E (ApoE)—a central lipid metabolism regulator—in MDSCs, which drove increased lipid oxidation and reactive oxygen species (ROS) production. Disruption of the ApoE-LDL receptor (LDLR) axis in MDSCs, achieved via genetic ablation, reprogrammed their metabolic activities and significantly reduced their immunosuppressive capacity toward both endogenous and transferred NK cells. Furthermore, pharmacological inhibition of lipid utilization rescued NK cell function and, when combined with NK cell adoptive transfer, produced synergistic anti-tumor effects in PDAC models.



 Our results emphasize the pivotal role of MDSC expansion in mediating systemic immunosuppression in tumor-bearing hosts. We identify the ApoE/LDLR axis as a promising therapeutic target to disrupt MDSC-driven immunosuppression, thereby enhancing the efficacy of NK cell–based immunotherapies. These findings underscore the importance of resolving systemic immune dysregulation in cancer patients to maximize the benefits of immunotherapy.



 Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He. Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B026.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7a0540abd909233af3d6405eb6004cd58b6e6586" target='_blank'>
              Abstract B026: Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy
              </a>
            </td>
          <td>
            Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Immune checkpoint inhibitors show minimal activity in patients (pts) with epithelial ovarian cancer (EOC), in part due to an immunosuppressive tumor microenvironment (TME). We are currently investigating the safety and preliminary efficacy of an autologous intraperitoneal cytokine-induced memory-like NK cell therapy in pts with recurrent EOC (NCT06321484). We aimed to define NK cell dysregulation in EOC ascites to inform potential mechanisms of resistance to NK cell therapies in the TME.



 Ascites and matched peripheral blood (PB) were collected from 4 pts with advanced EOC. O-link target 48 was performed on paired ascites and serum from 3 pts; Luminex was performed on ascites from 4 additional EOC pts. 10x Single cell RNA sequencing (scRNAseq) was performed on cells isolated from paired ascites and PB from 3 pts; downstream analyses were conducted using Seurat, ggplot2 and EnrichR using Wilcoxon rank sum test for significance.



 Consistent with prior studies, ascites-derived NK (A-NK) cells exhibited reduced cytotoxic capacity compared with matched PB- derived NK (PB-NK) cells. PB-NK cells showed activation (IFN-g release) and degranulation (CD107a+) in response to cytokine stimulation and target cell exposure, respectively; however matched A-NK cells did not respond to target stimulation. Multiplex immunoassays performed to identify ascites factors contributing to NK cell dysfunction showed enrichment of multiple immunomodulatory secreted factors including CXCL10, IL-6, TGF-b, VEGF-A, CXCL9, CCL2, and CCL8. In line with the functional data, scRNAseq analysis revealed lower expression of cytotoxicity-related genes (PRF1, GZMB, GZMA, GNLY, NKG7) in A-NK compared to PB-NK cells (p<0.0001, n=3 paired samples). Additionally, A-NK showed significant enrichment in type I interferon (IFN) signaling (p≤0.0001), suggesting chronic overstimulation. Flow cytometry revealed elevated CD69 (p<0.05) and NKG2A on A-NK, hallmarks of chronic overstimulation. In a module score analysis using genes for glycolysis and oxidative phosphorylation (e.g. CAPN5, STC2, VEGFA, HK2, CTH, GNE, GLRX, VLDR and CYC1, GRPEL1, TIMM17A), A-NK showed significantly lower expression than PB-NK (p<0.0001). To address this immune dysfunction, we engineered an IL-12-secreting CAR-NK cells targeting mesothelin that maintain high cytotoxic activity in the presence of EOC ascites. Notably, IL-12 CAR NK cells highly express the genes within our metabolic modular score, suggesting increased metabolic fitness.



 Ascites-derived NK cells demonstrate marked immune and metabolic dysfunction, and we hypothesize that IL12-engineering may overcome ascites-induced dysfunction via metabolic reprogramming. Ongoing efforts are focused on RNA and ATAC sequencing analyses of ascites-exposed IL-12-secreting CAR NK to elucidate epigenetic changes that mediate their resistance to the TME.



 Grace C. Birch, Mubin Tarannum, Maily Nguyen, Khanlinh Dinh, Mila Stanojevic, Ursula A. Matulonis, Rizwan Romee, Rebecca L. Porter. Ascites-derived natural killer (NK) cells exhibit chronic overstimulation and metabolic dysfunction in patients with advanced epithelial ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr B062.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bb6b7187b3a8993d43f3efb3c4cfbff661cd8daf" target='_blank'>
              Abstract B062: Ascites-derived natural killer (NK) cells exhibit chronic overstimulation and metabolic dysfunction in patients with advanced epithelial ovarian cancer
              </a>
            </td>
          <td>
            G. Birch, Mubin Tarannum, Maily Nguyen, K. Dinh, Mila Stanojevic, U. Matulonis, R. Romee, Rebecca L Porter
          </td>
          <td>2025-09-19</td>
          <td>Cancer Research</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Adoptive cell transfer-based immunotherapies have shown limited efficacy against most solid tumors. A key barrier to success is the immunosuppressive tumor microenvironment (TME). Beyond local effects, tumors induce systemic immune disturbances that further hinder anti-tumor immunity and promote disease progression. In this study, we investigate how tumor-driven systemic immunosuppression compromises the function of both endogenous and adoptively transferred natural killer (NK) cells, identifying potential strategies to enhance immunotherapeutic outcomes.



 We utilized syngeneic murine cancer models to systematically characterize alterations in immune cell populations within the circulation and spleen. Comprehensive and in-depth assessment of immune cell function, transcriptional activity, and metabolic state was performed using flow cytometry, Seahorse metabolic analysis, RNA sequencing, metabolic tracing, and ex vivo co-culture systems.



 In our PDAC mouse models, tumor burden elicited a robust systemic inflammatory response marked by expansion of myeloid lineage cells, particularly MDSCs, within the TME, peripheral blood, and spleen. Tumor growth led to reduced frequencies and functional deficits in both endogenous and adoptively transferred NK cells in circulation and spleen. Depletion of Gr-1+ MDSCs effectively restored NK cell effector functions. Mechanistic analyses demonstrated that MDSCs in tumor-bearing mice promote NK cell dysfunction through induction of lipid peroxidation. Notably, we observed pronounced upregulation of apolipoprotein E (ApoE)—a central lipid metabolism regulator—in MDSCs, which drove increased lipid oxidation and reactive oxygen species (ROS) production. Disruption of the ApoE-LDL receptor (LDLR) axis in MDSCs, achieved via genetic ablation, reprogrammed their metabolic activities and significantly reduced their immunosuppressive capacity toward both endogenous and transferred NK cells. Furthermore, pharmacological inhibition of lipid utilization rescued NK cell function and, when combined with NK cell adoptive transfer, produced synergistic anti-tumor effects in PDAC models.



 Our results emphasize the pivotal role of MDSC expansion in mediating systemic immunosuppression in tumor-bearing hosts. We identify the ApoE/LDLR axis as a promising therapeutic target to disrupt MDSC-driven immunosuppression, thereby enhancing the efficacy of NK cell–based immunotherapies. These findings underscore the importance of resolving systemic immune dysregulation in cancer patients to maximize the benefits of immunotherapy.



 Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He. Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr PR-01.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/45b7331df483f27859df652eb5ed860e47a52d18" target='_blank'>
              Abstract PR-01: Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy
              </a>
            </td>
          <td>
            Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Introduction Neuroinflammation is a critical factor contributing to secondary brain injury following traumatic brain injury (TBI). This process engages diverse cell types within the central nervous system (CNS), including significant infiltration of myeloid lineage cells–primarily neutrophils and macrophages–during the acute and subacute phases of TBI. These myeloid-derived cells represent a major population that critically influences the development and progression of neuroinflammation. Microglia and peripherally infiltrating macrophages exhibit polarization phenotypes that play a pivotal role in modulating inflammatory changes. Due to their functional and phenotypic similarities, their distinct contributions to the inflammatory response in TBI remain a subject of considerable debate. Lysozyme 2 (Lyz2) is a well-established marker for myeloid lineage cells (including monocytes, macrophages, and neutrophils) in mice, allowing specific targeting and depletion of these cells to dissect their functional roles in TBI. Methods In the present study, we investigated the trend of inflammatory factors during the early stage of TBI using Lyz2-IRES-DTREGFP transgenic mice, which specifically target and deplete Lyz2-positive myeloid cells. Tissue samples for RT-qPCR and flow cytometry were harvested from the perilesional cortex (within a 2-mm radius of the impact site) and the underlying hippocampus. Results and discussion Our findings revealed a considerable reduction in the expression of pro-inflammatory factors (e.g., IL-1β, iNOS, IL-6, IFN-γ) and an increase in the expression of anti-inflammatory factors (e.g., IL-4, IL-10, IL-13, Arg-1). Furthermore, we observed a shift in polarization phenotypes, characterized by a decreased proportion of M1 macrophages and an increased proportion of M2 macrophages. However, during the chronic phase, behavioral and histological analyses revealed worse outcomes. These findings demonstrate that targeted depletion of Lyz2-positive myeloid cells during acute TBI attenuates neuroinflammation. However, this early immunomodulatory shift correlates paradoxically with exacerbated chronic neurological deficits, suggesting that transient suppression of myeloid-driven inflammation may disrupt long-term reparative processes critical for functional recovery after TBI.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f2b62a25efa9a7379563b95a2c6aaa7cdabd0939" target='_blank'>
              Dual role of Lyz2-positive myeloid cells in traumatic brain injury: acute anti-inflammatory effects vs. chronic neurological deterioration
              </a>
            </td>
          <td>
            Hua-Zheng Yan, Yi-Wan Fang, Shi-Yu Zhou, Jian-Xiong Gao, Ming-ming Bian, Yao-Mei Xu, Lin Zhang, Nan Zhang, He-Zuo Lü
          </td>
          <td>2025-10-07</td>
          <td>Frontiers in Cellular Neuroscience</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="ABSTRACT Neutrophils, constituting a predominant subset of innate immune cells in mammalian systems, play pivotal roles in pathogenic clearance and homeostatic maintenance. In the progressive development of cancer, neutrophils exert dual roles in both anticancer and procancer processes through their heterogeneity. In recent years, research into the role of neutrophils in cancer and various nontumor diseases has been continuously deepening. However, current research in this area remains incomplete. This review comprehensively summarizes the tissue homing dynamics, lifespan regulation, and physiological functions of neutrophils, starting from their development and heterogeneity. Furthermore, we delineate the dual regulatory functions of neutrophils in carcinogenesis, encompassing both tumor‐suppressive mechanisms and protumor mechanisms. This section further synthesizes recent advancements in neutrophil‐targeted therapeutic platforms and biomimetic delivery systems, while critically evaluating persistent methodological and translational challenges in clinical applications. In addition, we systematically analyze the role of neutrophils in non‐neoplastic diseases and list several typical diseases, including infectious diseases. Finally, we also discuss current controversies and research perspectives on neutrophils. It is hoped that this review will deepen insights into the role of neutrophils in homeostasis and disease, while exploring their potential in disease treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f7b288be93237ddba7e9a69bb120476c0e12b401" target='_blank'>
              Role of Neutrophils in Homeostasis and Diseases
              </a>
            </td>
          <td>
            Xingyu Chang, Yulin Liu, Junjun Qiu, Keqin Hua
          </td>
          <td>2025-09-18</td>
          <td>MedComm</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Recently, we observed that pars planitis (PP) patients present alterations in peripheral blood (PB) Th17/Treg associated with dysregulation in the Th1 response. Yet, little is known about the systemic distribution of myeloid cells, which drive the recruitment and differentiation of the adaptive effectors toward pathogenic inflammatory Th1 and Th17 as well as regulatory lymphocytes in PP. Although myeloid populations in patients with uveitis have previously been addressed, the data did not provide an exact description of PP patients. Using flow cytometry, we evaluated monocyte and IDO-expressing monocyte-like myeloid-derived suppressor cell (MDSC) subpopulations in PB samples from 15 patients with different courses of PP (cystoid macular edema and non-macular edema subgroups; CME and nCME, respectively) and 17 healthy controls (HCs) in relation to the Th1, Th17, and immunoregulatory subsets. We observed that only PP patients from the CME subgroup presented a significantly higher fraction of CD16+ IDO-expressing MDSCs and intermediate CD14highCD16+ monocytes compared to the HCs; this corresponded with relative up-regulation of Th1 and Th17, and down-regulation of Treg. In addition, alongside the increased percentage of IDO-expressing CD16+ MDSCs, the MDSC compartment displayed an inappropriate level of IDO (more pronounced in the CD16− subset) only in CME patients. At the same time, the fraction of CD16− myeloid cells did not differ significantly among the patient cohorts and healthy participants. Our study is the first to evaluate subpopulations of circulating myeloid cells in PP patients and indicates that an increased fraction of CD16+ myeloid cells might reflect the immunological and clinical severity of PP.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cd1fd2d076c43e8bd265181bbac902c87dc1f38" target='_blank'>
              Circulating CD16-Positive Monocyte-like Myeloid-Derived Suppressor Cells and Intermediate Monocytes Associated with Clinical and Immunological Complications in Pars Planitis Patients
              </a>
            </td>
          <td>
            A. Kosmaczewska, Joanna Przeździecka-Dołyk, L. Ciszak, Zofia Rojek-Gajda, I. Frydecka, A. Turno-Kręcicka, Marta Misiuk-Hojło, Edyta Pawlak
          </td>
          <td>2025-10-21</td>
          <td>Cells</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a9e7ede42ec807daf3ed73c2764d1a68e5042cc8" target='_blank'>
              Sialoglycans on human T cells attenuate death programs executed through the Fas pathway
              </a>
            </td>
          <td>
            Vanessa Affe, Qianmeng Lei, Tim S. Veth, Emmajay Sutherland, Hani Choksi, Fauzia N. Izzati, Qingyu Shi, Haissi Cui, N. Riley, Landon J. Edgar
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>39</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f3584547ac7e81503a8af713b39f86a56f7db64" target='_blank'>
              Plasma Gelsolin Prevents Organ-Specific Inflammation and Enhances Innate Immune Function in a Systemic Candida albicans Infection
              </a>
            </td>
          <td>
            Ł. Suprewicz, Alicja Walewska, A. Namiot, Sylwia Deptuła-Chmielewska, Paul A. Janmey, R. Bucki
          </td>
          <td>2025-09-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>48</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/670883db43566497565d37fb3fd302bbe45873a6" target='_blank'>
              αGalCer/CD1d treatment induces pro-inflammatory iNKT1-associated immune responses without aggravating doxorubicin-induced cardiotoxicity
              </a>
            </td>
          <td>
            Sarojini Singh, R. H. Nanjundappa, H. Kolla, Deepak S. Chauhan, Aahana Palyada, Prasanna Krishnamurthy, C. S. Umeshappa
          </td>
          <td>2025-09-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="


 Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are major negative regulators of anti-tumor immunity. Identifying tumor secreting factors and signaling pathways that enhance their pro-tumorigenic activity could lead to new strategies to enhance immunotherapy efficacy. We have identified tumor-secreted epidermal growth factor-like 6 (EGFL6) as a new mediator of tumor immune suppression. In-vitro and ex-vivo analyses indicated that EGFL6 binds beta integrins to activate spleen tyrosine kinase (SYK) signaling, functioning as (i) a chemotactic factor for myeloid cell migration and (ii) a driver of their differentiation into immunosuppressive phenotypes. In syngeneic mouse models of ovarian cancer, EGFL6 expression promoted intra-tumoral accumulation of MDSCs and TAMs with high SYK, CXCL2, and IL-10 expression. In an immune ‘hot’ tumor model, EGFL6 completely abrogated the response to anti-PD-L1 therapy, whereas Egfl6 neutralization decreased the accumulation of tumor-infiltrating CD206+ TAMs and MDSCs and thereby restored the efficacy of a-PD-L1 therapy. Spatial transcriptomic datasets of human ovarian cancer tissues revealed strong correlation between tumor EGFL6 and myeloid cell SYK expression. Dual immunohistochemistry confirmed increased SYK+ macrophages in ovarian cancer compared to normal ovary. We therefore tested whether SYK inhibition could hinder EGFL6-induced signaling in myeloid cells and reprogram them from an immunosuppressive to an immunostimulatory phenotype. Treatment with the SYK inhibitor fostamatinib (R788) prolonged survival in Egfl6+/- ID8p53-/- tumor-bearing mice, reduced the number of intra-tumoral granulocytic MDSCs, and decreased VEGF, M-CSF, and CXCL5 levels in ascites. scRNA-seq revealed that SYK inhibition depleted specific CCL8+ TAM and CXCL2+ MDSC subsets, induced immunostimulatory myeloid cell populations, and reduced exhausted of TIGIT+CTL4+ CD8 T cells. These findings demonstrate that targeting the EGFL6-SYK axis, via EGFL6 blockade or SYK inhibition, can reprogram the ovarian tumor microenvironment to enhance anti-tumor immunity and restore responsiveness of “cold” tumors to immunotherapy.



 Sandra Cascio. Reprogramming tumor-associated myeloid cells to improve ovarian cancer therapies [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr IA014.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/435cc8383bb8db54f60eb41477b03e6ce3d7d946" target='_blank'>
              Abstract IA014: Reprogramming tumor-associated myeloid cells to improve ovarian cancer therapies
              </a>
            </td>
          <td>
            S. Cascio
          </td>
          <td>2025-09-19</td>
          <td>Cancer Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Obesity is characterized by a chronic low-grade inflammation and, paradoxically, is also associated with immune cells dysfunction. In this study, we analyzed peripheral blood Invariant Natural killer T cells (iNKT) in individuals with or without obesity. These unconventional T cells recognize lipid antigens presented by the monomorphic CD1d MHC I-like protein. We demonstrated an activation of iNKT cells in individuals with obesity associated with both increased apoptosis and dysfunction as assessed by the lack of responsiveness to PMA/Ionomycin stimulation. This disruption mainly affects the CD4− subset, more dedicated to pro-inflammatory cytokines release and cytotoxicity. Such impact could therefore be involved in the loss of immunosurveillance observed in obesity. Interestingly, CD1d is upregulated on intermediate and non-classical monocytes from individuals with obesity and its expression on both monocyte subsets is correlated with iNKT cell dysfunction. Both the activation and hypo-responsiveness of iNKT cells as well as CD1d modulation on monocytes are significantly reversed after bariatric surgery. Altogether, these data suggest that increased CD1d expression may enhance the presentation of endogenous lipid antigens, thereby contributing to iNKT cell activation in the context of obesity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/444e776dfdca9c2dd4f432d59055fe386c23c172" target='_blank'>
              Peripheral blood iNKT cells display an activated profile with both increased apoptosis and dysfunction in obesity
              </a>
            </td>
          <td>
            Chloé Wilkin, Nathalie Esser, Cédric Lassence, Marion Bruneteaux, Marjorie Fadeur, J. De Flines, Nicolas Paquot, Jacques Piette, S. Legrand-Poels
          </td>
          <td>2025-09-10</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Glioblastoma (GBM) is the most common and fatal primary brain malignancy in adults, and therapeutic gains have been modest despite multimodal standard care. Immunotherapy offers a promising alternative, yet its performance in GBM is constrained by a profoundly immunosuppressive neuro-immune micro-environment, the physical and functional barriers of the blood–brain interface, and adaptative resistance pathways. In this review we summarise recent progress in myeloid-reprogramming agents, immune-checkpoint modulation, adoptive cellular therapies and device-enabled delivery platforms that seek to revitalise anti-tumour surveillance within the central nervous system. We also discuss enduring challenges—including intratumoural spatial heterogeneity, limited effector lymphocyte trafficking and the scarcity of robust predictive biomarkers—that temper durable responses. By thoughtfully integrating immunologic approaches with radiotherapy, anti-angiogenic agents, metabolic modifiers and focussed-ultrasound-mediated blood–brain-barrier disruption, emerging strategies aspire to enhance immune infiltration, bolster antigen presentation and overcome region-specific barriers. Our synthesis provides an appraisal of the evolving landscape of precision immunotherapy for GBM, offering perspective on future directions and avenues for clinical translation. We hope these insights will assist researchers and clinicians as they endeavour to develop more effective and individualised treatment regimens for patients confronted with this formidable disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f7f8ea3c9ff54189d0f9412eb0fcb12fe1de1b4a" target='_blank'>
              Targeting the neuroimmune axis in glioblastoma: emerging strategies for precision immunotherapy
              </a>
            </td>
          <td>
            Xiaoling Lang, Suming Zhang, Yuhe Wang
          </td>
          <td>2025-09-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Dendritic cells (DCs) play a central role in coordinating immune responses by linking innate and adaptive immunity through their exceptional antigen-presenting capabilities. Recent studies reveal that metabolic reprogramming—especially pathways involving acetyl-coenzyme A (acetyl-CoA)—critically influences DC function in both physiological and pathological contexts. This review consolidates current knowledge on how environmental factors, tumor-derived signals, and intrinsic metabolic pathways collectively regulate DC development, subset differentiation, and functional adaptability. Acetyl-CoA emerges as a dual-function metabolite, serving not only as an energy carrier but also as an epigenetic regulator that controls DC fate via lipid biosynthesis, mitochondrial metabolism, and chromatin modification. In the tumor microenvironment (TME), DCs may experience immune suppression polarization and insufficient T cell activation due to disrupted acetyl-CoA related metabolic pathways. While existing DC-based therapies remain constrained by TME-induced metabolic limitations, emerging approaches that restore acetyl-CoA related metabolic pathways balance show enhanced antitumor efficacy. The review further examines distinct metabolic adaptations among DC subsets and their relevance to autoimmune diseases, infectious immunity, and transplant outcomes. By integrating current research on targeting DC metabolic targets, we outline strategies for developing immunotherapies that target DC metabolic flexibility. Remaining hurdles include tailoring interventions to specific subsets, refining metabolic manipulation techniques, and addressing TME heterogeneity through combination therapies. These findings position acetyl-CoA as a key therapeutic target for recalibrating immunometabolism circuits, with significant implications for DC-focused cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9f1996c0e470364b09df9398dca6e57f9bb45e1f" target='_blank'>
              Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications
              </a>
            </td>
          <td>
            Wenhao Li, Chenyu Yu, Xujian Zhang, Yunshen Gu, Xiaobo He, Rongrong Xu, Jia Xu, Ganjun Yu, Yanfeng Wu
          </td>
          <td>2025-09-08</td>
          <td>Molecular Biomedicine</td>
          <td>1</td>
          <td>6</td>
        </tr>

        <tr id="Simple Summary Acute myeloid leukemia remains difficult to treat due to its high relapse rates after standard therapies. T-cell engagers are a promising new approach that redirects the body’s own T cells to attack leukemia cells by binding both T cells and specific markers to AML cells. Targets such as CD33, CD123, and others have been studied. Several TCE formats—including BiTEs and DARTs—are being developed to improve effectiveness and reduce side effects. However, no TCEs in AML have moved beyond early-stage (Phase I/II) clinical trials, mainly due to the lack of an optimal target in AML and safety concerns with immune-related side effects like cytokine release syndrome. This review explores the current progress, key targets, and challenges in developing TCEs for AML treatment. Abstract The treatment of acute myeloid leukemia (AML) remains challenging, largely due to high relapse rates following standard therapies. T-cell engagers (TCEs) offer a promising immunotherapeutic approach by redirecting T cells to recognize and kill AML cells. These therapeutic proteins bind CD3 to T cells and a tumor-associated antigen to AML cells, facilitating targeted immune activation. While CD33 and CD123 are the most commonly targeted AML antigens, others such as CD135, CD38, and CLEC12A/CLL-1 are being evaluated in preclinical and clinical studies. In parallel, various TCE formats—including BiTEs, DuoBodies, DARTs, and DARPin-based constructs—have been developed to optimize pharmacokinetics, stability, and immune engagement. Despite the growing number of TCEs entering clinical evaluation, none have advanced beyond early Phase (I/II) trials, primarily due to the lack of optimal target antigens and challenges in balancing antileukemic activity with the risks of immune-related toxicities such as cytokine release syndrome (CRS). This review aims to summarize the current landscape of TCE development in AML, highlighting key targets, formats, and challenges.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bac31cf0d00849ef822f10610d70f5922a428ae0" target='_blank'>
              T-Cell Engagers in Acute Myeloid Leukemia: Molecular Targets, Structure, and Therapeutic Challenges
              </a>
            </td>
          <td>
            Hunter Daws, Kate Gallinero, Amanda Singh, Sanela Bilic
          </td>
          <td>2025-10-01</td>
          <td>Cancers</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Human cytomegalovirus (HCMV) establishes lifelong latency following primary infection, residing within myeloid progenitor cells and monocytes. To achieve this, the virus employs multiple immune evasion strategies. It suppresses innate immune signaling by inhibiting Toll-like receptor and cGAS-STING pathways. In addition, the virus suppresses major histocompatibility complex (MHC)-dependent antigen presentation to evade T cell recognition. As the downregulation of MHC molecules may trigger NK cell activation, the virus compensates for this by expressing proteins such as UL40 and IL-10, which engage inhibitory NK cell receptors and block activating signals, thereby suppressing NK cell immune surveillance. Viral proteins like UL36 and UL37 block host cell apoptosis and necroptosis, allowing HCMV to persist undetected and avoid clearance. In settings of profound immunosuppression, such as after allogeneic hematopoietic stem cell transplantation (allo-HSCT) or solid organ transplantation, slow immune reconstitution creates a window for viral reactivation. Likewise, immunosenescence and chronic low-grade inflammation during aging increases the risk of reactivation. Once reactivated, HCMV triggers programmed cell death, releasing viral PAMPs (pathogen-associated molecular patterns) and host-derived DAMPs (damage-associated molecular patterns). This release fuels a potent inflammatory response, promoting further viral reactivation and exacerbating tissue damage, creating a vicious cycle. This cycle of inflammation and reactivation contributes to both transplant-related complications and the decline of antiviral immunity in the elderly. Therefore, understanding the immune regulatory mechanisms that govern the switch from latency to reactivation is critical, especially within the unique immune landscapes of transplantation and aging. Elucidating these pathways is essential for developing strategies to prevent and treat HCMV-related disease in these high-risk populations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c0c843dc82ca4b27cae84bc783dc80e13ac42440" target='_blank'>
              The Immunoregulatory Mechanisms of Human Cytomegalovirus from Primary Infection to Reactivation
              </a>
            </td>
          <td>
            Xiaodan Liu, Chang Liu, Ting Zhang
          </td>
          <td>2025-10-02</td>
          <td>Pathogens</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Objectives Dendritic cells (DCs) are pivotal antigen-presenting cells capable of bridging innate and adaptive immunity, making them promising candidates for cancer immunotherapy. While canine mature DCs (cmDCs) have been successfully generated from circulating mononuclear cells (CMCs) in healthy dogs, their derivation and immunomodulatory capacity in tumor-bearing dogs (TbDs) remain poorly characterized. Methods In this study, we evaluated the efficiency of cmDC generation from peripheral blood of both healthy donors (HDs) and TbDs and investigated their functional responses to Toll-like receptor (TLR) agonists and mRNA-based genetic modification. Results CD14+ monocytes were successfully isolated from peripheral blood using immunomagnetic sorting and differentiated into cmDCs using recombinant canine GM-CSF and IL-4. The differentiation efficiency was comparable between the two groups. In both cohorts, cmDCs upregulated key maturation markers (CD1a, CD80, CD83) and restored DLA class II expression in TbDs. Stimulation with LPS and R848 significantly increased CD80 and CD83 expression and triggered IL-12/p70 and IL-8 production, confirming the acquisition of a functional immunostimulatory phenotype. To assess their amenability to genetic engineering, cmDCs were transfected using DE-DOPE/mRNA lipoplexes. These lipoplexes exhibited favorable physicochemical properties and achieved robust mRNA delivery, resulting in 100% GFP-positive cells and >60% viability, outperforming electroporation in terms of cytocompatibility. Conclusions Our findings demonstrate that cmDCs derived from both HDs and TbDs are phenotypically and functionally competent and can be efficiently transfected using a non-viral mRNA delivery system. This strategy offers a viable platform for the development of personalized, DC-based cancer vaccines in canine patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/214b1855d713559c7344f3f9c1196e520714ee7a" target='_blank'>
              Toll-like receptor activation and gene delivery efficiency in canine dendritic cells: a model for comparative oncology
              </a>
            </td>
          <td>
            S. Capellero, Raffaella De Maria, Lisa Adele Piras, L. Marconato, Lorenza Parisi, Eugenio Mazzone, C. Marchiò, E. Berrino, S. Bellomo, A. Sapino, G. P. Stola, Valeria Chiono, L. Nicoletti, Luca Aresu
          </td>
          <td>2025-10-03</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are a dominant immune component within the glioma microenvironment and are increasingly recognized as key contributors to therapeutic resistance, the major challenge in glioma management. Understanding their role is critical for developing novel therapies. This review synthesizes current knowledge on TAM-mediated chemoresistance in glioma. TAMs originate from bone marrow-derived monocytes and resident microglia, exhibiting significant heterogeneity and plasticity, particularly between pro-inflammatory (M1) and pro-tumorigenic (M2) phenotypes. M2-like TAMs drive resistance through multiple mechanisms: (1) Modulating drug metabolism/clearance (e.g., via CYP450 enzymes and P-glycoprotein); (2) Secreting protumor factors (TNF-α, ILs like IL-4/IL-6/IL-10, chemokines like CCL5/CCL22, growth factors like VEGF/EGF) that activate survival pathways, induce immunosuppression, promote angiogenesis, and enhance epithelial-mesenchymal transition (EMT); (3) Interacting with glioma stem cells (GSCs) to maintain stemness; (4) Facilitating microenvironmental adaptation (e.g., hypoxia/HIF-1α response); (5) Remodeling the extracellular matrix (ECM) via MMPs, increasing stiffness and impairing drug penetration. Targeting TAMs offers promising approaches to overcome resistance. Strategies include: (1) Reprogramming M2 to M1 phenotypes using agonists (TLR, STING, CD40) or inhibitors (STAT3/STAT6); (2) Metabolic modulation (targeting glycolysis, fatty acid oxidation, glutaminolysis); (3) Blocking recruitment axes (CCL2/CCR2, CSF-1/CSF-1R, CXCL12/CXCR4); (4) Depleting M2-TAMs (e.g., trabectedin, CAR-T cells, M2pep-drugs); (5) Enhancing phagocytosis (anti-SIRPα/CD47, anti-SIGLEC). TAMs are pivotal mediators of chemoresistance in glioma through diverse molecular and cellular mechanisms. Targeting TAM recruitment, polarization, function, or metabolism represents a promising therapeutic avenue. However, the complexity of the glioma microenvironment and blood-brain barrier necessitate combination strategies for clinical translation. Further research is needed to optimize specificity and overcome challenges like compensatory pathways and drug delivery.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/af7b44f62f9ab81285800350b0fbea1b42e0f4e9" target='_blank'>
              Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma
              </a>
            </td>
          <td>
            Xuebo Liu, Qi Yu
          </td>
          <td>2025-09-26</td>
          <td>Frontiers in Cell and Developmental Biology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Simple Summary Chimeric Antigen Receptor (CAR)-T cell therapy has shown significant success in treating hematological cancers, but commercialized autologous CAR-T therapies face challenges such as high costs, manufacturing delays, complex standardization and the risk of tumor relapses due to single-antigen targeting. To address these issues, a novel allogeneic CAR-T therapy with broader target specificity was developed, optimizing its manufacturing process. Using CRISPR/Cas9, TCR and HLA class I complex expression were eliminated from donor T cells to reduce the risk of immune rejection and graft-versus-host disease. Additionally, NKG2D CAR, targeting eight ligands upregulated in both solid and hematological tumors, was lentivirally transduced. This study optimized CAR-T cell manufacture by testing various interleukin supplements (IL-2, IL-7/IL-15, IL-7/IL-15/IL-21). Results showed that IL-7/IL-15/IL-21 supplementation produced CAR-T cells with the most suitable characteristics in terms of genetic modification efficiency, cell proliferation, antitumor activity and memory profile. This new allogeneic NKG2D CAR-T therapy represents a promising universal treatment for a variety of cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8e4e75f43da33ddda8e85ac431c369c654f5ec0" target='_blank'>
              A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid Tumors
              </a>
            </td>
          <td>
            C. Aparicio, Mónica Queipo, Marina Belver, Francisco Espeso, Julia Serna-Pérez, Lucía Enríquez-Rodríguez, Carlos Acebal, Álvaro Martín-Muñoz, A. Valeri, A. Leivas, Paula Río, Daniel J. Powell, Rosa Lobo-Valentín, David Arrabal, Joaquín Martínez-López, Ana Sánchez, Miguel Á. de la Fuente, Margarita González-Vallinas
          </td>
          <td>2025-09-30</td>
          <td>Cancers</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ea81bcddaf13d081e97df3be63dd2c84368f07c4" target='_blank'>
              mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow.
              </a>
            </td>
          <td>
            Taylor Fulton-Ward, N. Gudgeon, Isaac Thirlwell, E. Bishop, Bryan Marzullo, Hannah Giles, Graham McIlroy, Paul Ferguson, B. Kishore, Kate Rogers, Nuri Nuri Alfasi, Timothy Wong, Satnam Aytain, Daniel A. Tennant, G. Pratt, Sarah Dimeloe
          </td>
          <td>2025-09-12</td>
          <td>Blood advances</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Abstract Background Dual immune checkpoint blockade (IO/IO) has significantly improved overall survival in renal cell carcinoma (RCC), but only ∼50% of patients initially respond to treatment. Understanding the mechanisms underlying primary response and resistance is critical to improving therapeutic outcomes. Methods We developed a novel mouse model of sarcomatoid RCC (sRCC) by targeting Vhl, Bap1, and Cdkn2a/b, recapitulating the genomic and histological features and tumor microenvironment of human sRCC. Mice were treated with anti-CTLA-4 antibody. Tumor-infiltrating immune populations were analyzed using single-cell RNA sequencing and flow cytometry to evaluate T cell subsets and cytotoxic function. Results Anti-CTLA-4 treatment led to Treg depletion and an increase in activated Th1 cells. Importantly, only responder mice exhibited a selective expansion of TCF1+ CD4+ T cells. This was accompanied by increased granzyme B and perforin expression in effector CD8+ T cells, indicating enhanced cytotoxic activity. In contrast, non-responder mice lacked this TCF1+ CD4+ population and associated cytotoxic CD8+ responses. Conclusions Our findings reveal that Treg-depleting anti-CTLA-4 therapy promotes anti-tumor immunity by expanding a TCF1+ CD4+ T cell population that orchestrates CD8+ T cell responses. This mechanism offers a novel insight into immune modulation in sRCC and identifies a potential target to improve immunotherapy efficacy in RCC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3aa635a80718bf4810ef5e37204ff599497c31dc" target='_blank'>
              47TCF1+ CD4+ T cells mediate response to anti-CTLA-4 therapy in a sarcomatoid RCC mouse model
              </a>
            </td>
          <td>
            Hui Jiang, Lynda Vuong, F. Kuo, Doris Zheng, Alex Penson, Jing Zhang, Shengyu Gao, Ankur Mascareno, Yingbei Chen, Yash S. Khandwala, Daniel Barbakoff, Andrea Lopez Sanmiguel, G. Luca Gusella, Ming Li, A. Hakimi
          </td>
          <td>2025-10-01</td>
          <td>The Oncologist</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Solid tumors often suppress antitumor immune responses by promoting various dysfunctional CD8+ T cell states, which limit the effectiveness of T-cell-based immunotherapy. However, the mechanisms that promote these states have not been fully characterized. It is demonstrated that spontaneous priming responses during tumor growth can produce memory T cell reservoirs that are conducive to poor proliferative responsiveness during boosting vaccination. Surprisingly, when type I interferon (IFN-I) signaling is impeded, boosting vaccination can elicit robust proliferative responses from tumor-primed memory T cells and promote tumor control. This is observed in multiple tumor types and target antigens. In contrast to conventional memory T cells, tumor-primed memory T cells are unique in their pre-encoded responsiveness to IFN-I and show enrichment of pathways pertaining to DNA repair and cell cycle arrest. Tumor-primed memory T cells up-regulate p21 expression and blockade of either p21 or IFN-I can alleviate this effect to improve their proliferative capacity during boosting vaccination. Characterization of tumor-primed memory T cells revealed transcriptional and phenotypic features of cellular senescence, where higher senescence severity correlated with higher responsiveness to IFNα/β receptor blockade. Overall, IFN-I hyperresponsiveness may be a unique feature of senescent tumor-primed memory T cells that can exacerbate their dysfunction during cancer vaccination.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cb2455df0fef81e7cabdf5fd3952e0ae44f71bd" target='_blank'>
              Pre-Encoded IFN-I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors.
              </a>
            </td>
          <td>
            Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan
          </td>
          <td>2025-10-05</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Despite recent advances in triple-negative breast cancer (TNBC) biology and new therapies, this aggressive subtype remains difficult to treat. A key obstacle is the immunosuppressive tumor microenvironment (TME), often dominated by myeloid cells that impair anti-tumor immunity. Radiation therapy (RT), used as an in-situ vaccine, enhances tumor immunogenicity and has shown promise when combined with immune checkpoint blockade (ICB) in preclinical and clinical settings1-3. We previously found that combining RT with CTLA-4 blockade and a CD40 agonist antibody (CD40a), which activates myeloid cells, led to profound tumor regression and occasional complete responses in a rapidly metastasizing TNBC mouse model4. However, CD40a did not improve control of lung metastases beyond that achieved with RT and CTLA-4 blockade. In tumors, CD40a induced remodeling of dendritic cell and macrophage populations, along with enrichment in B cell–associated gene signatures. As CD40 signaling can promote either effector or regulatory B cell responses depending on context5, we hypothesized that triple therapy induces organ-specific B cell differentiation that may hinder systemic immune control. We first assessed systemic versus local effects of CD40a on B cells in naïve and tumor-bearing (4T1) mice. In both settings, CD40a expanded splenic B cells and increased MHC-II+ expression. In lungs, tumor implantation alone led to increased B cell infiltration, even without CD40a. However, these lung B cells showed reduced activation in untreated tumor-bearing mice, only partially restored by CD40a, suggesting a distinct, potentially immunosuppressive phenotype. To evaluate this in the context of RT + CTLA-4 blockade + CD40a, we analyzed B cells from lungs and tumors via multiparametric flow cytometry and observed that CD40a consistently shifted B cell profiles across compartments. Among B cells, we identified regulatory B cells (Breg) as expressing TIM1, CD138, CD5, CD39, and FasL. CD40a decreased Breg infiltration in tumors but significantly increased it in lungs. In both tissues, Breg marker expression correlated with tumor or lung burden. Given TIM1’s role in IL-10–producing Bregs—and its capacity to suppress T cells independently of IL-10—6-8 we tested a TIM1-blocking antibody in combination with RT + CTLA-4 blockade + CD40a. While TIM1 blockade did not enhance tumor control, it markedly reduced lung Bregs. Our data highlight organ-specific B cell responses following CD40a-based immunotherapy and suggest that lung-resident Bregs may limit systemic immune efficacy. Ongoing work focuses on defining mechanisms of Breg-mediated suppression and, in collaboration with bioengineers, on developing intra-tumoral delivery strategies to reduce systemic immunosuppressive effects of agents like CD40a. 1-PMID: 29180535 2-PMID: 33476307 3-PMID: 30397353 4-PMID: 37620372 5-PMID: 19265127 6-PMID: 25582854 7-PMID: 31511630 8-PMID: 31685302



 Maud Charpentier, David Sprott, Sandra Demaria. Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B007.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0c36421ca4c9e00ab71754a147fca0a0213794c4" target='_blank'>
              Abstract B007: Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy
              </a>
            </td>
          <td>
            M. Charpentier, David Sprott, Sandra Demaria
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Pancreatic ductal adenocarcinoma (PDA) is defined by a myeloid-enriched microenvironment and has shown remarkable resistance to immune checkpoint blockade (e.g., PD-1 and CTLA-4). Here, we sought to define the role of myeloid immunosuppression in immune resistance in PDA. We report that depletion of CSF1R+ myeloid cells in combination with anti-PD-1 and chemotherapy triggers T cell infiltration into PDA but causes compensatory remodeling of the myeloid compartment with limited tumor control. Unexpectedly, combined therapy against multiple myeloid targets including CSF1R, CCR2/5 and CXCR2 was insufficient to overcome treatment resistance. High-dimensional single cell analyses performed on T cell infiltrates in human and mouse PDA revealed upregulation of multiple immune checkpoint molecules, including PD-1, LAG-3, and CTLA-4. Combinatorial blockade of PD-1, LAG-3, and CTLA-4 along with chemotherapy and anti-CSF1R was necessary to trigger activation of peripheral CD4+ and CD8+ T cells and led to deep, durable, and complete tumor responses, with each immune checkpoint blockade agent contributing to efficacy. Our findings indicate that a comprehensive approach targeting both negative regulatory signals controlling T cell function and the myeloid compartment will be fundamental to unveiling the potential of immunotherapy in PDA.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9bac35ccda4226af90146d1a95a7c29a2bb17ae0" target='_blank'>
              Non-redundant immune checkpoints direct therapeutic resistance to chemoimmunotherapy in pancreatic ductal adenocarcinoma.
              </a>
            </td>
          <td>
            M. Stone, Veronica M. Herrera, Yan Li, Heather Coho, Yuqing Xue, Kathleen Graham, Jennifer Ratmansky, D. Delman, Shaun O'Brien, Gregory Lawrence Beatty
          </td>
          <td>2025-09-08</td>
          <td>Cancer immunology research</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Age-related accumulation of somatic mutations in hematopoietic stem and progenitor cells (HSPCs), causing clonal hematopoiesis (CH), often precedes the development of hematologic malignancies. Chronic inflammation and aberrant cytokine expression that are common in aging, contribute to clonal expansion and genomic instability. Acute myeloid leukemia (AML) is an (epi)genetically and physiologically diverse malignancy, characterized by clonal proliferation and incomplete differentiation of HSPCs. The innate immune system, with pattern recognition receptors (PRRs), plays a pivotal role in maintaining hematopoietic homeostasis. Dysregulated signaling through PRRs disrupts hematopoiesis, fostering malignant cell proliferation. In addition, cytokines and interferons exert multifaceted effects on HSPCs, impacting their proliferation, differentiation, and survival. Therapeutic approaches targeting innate immune pathways, offer promising avenues for treating hematologic malignancies. Understanding the intricate crosstalk between innate immunity and hematopoiesis would provide insights into novel therapeutic strategies for combating hematologic malignancies, offering hope for improved patient outcomes and survival. In this review, we discuss about the malfunctioning innate immune-inflammatory axes in the context of abnormal hematopoiesis and the therapeutic approaches that are utilizing/targeting these pathways with efficacy. This review delves into the derangements of innate immune and inflammatory pathways implicated in the development of AML and myelodysplastic syndromes (MDS), shedding light on the therapeutic strategies targeting these pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dde18cfb4c76b3db17292e304b00038b9b81709c" target='_blank'>
              Innate immune-inflammatory signaling milieu in myeloid leukemia and aging-associated clonal hematopoiesis pathologies
              </a>
            </td>
          <td>
            Satyaki Bhowmik, A. Bose, Amitava Sengupta
          </td>
          <td>2025-10-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Background Tertiary lymphoid structures (TLSs), ectopic lymphoid aggregates composed of immune cells, are associated with favorable clinical outcomes and increased efficacy of anti-tumor immunotherapies. However, the mechanisms underlying the formation and maturation of TLSs require further elucidation. The correlation between tumor immune microenvironment in tumor-draining lymph nodes (TDLNs) and TLSs remains inadequately studied. The study aimed to utilize multiplex immunofluorescence (mIF) to explore the relationship between TDLN and TLSs. Methods Tissue slides from 120 patients with lung adenocarcinoma (LUAD) were collected to perform for mIF staining. Panel 1 (DAPI, CD20, CD21, CD23) was used for the quantitative and qualitative analyses of TLS. Panel 2 (DAPI, CD4, CD8, CD20) was used to describe the immune microenvironment of the tumor and TDLN. Results TLS (+) patients showed better disease-free survival (DFS) (mDFS, 70.8 vs. 28.7 months; p = 0.013, HR = 0.555, 95% CI 0.352 to 0.875) and overall survival (OS) (mOS, 77.83 months vs. not reached; p = 0.028, HR = 0.512, 95% CI 0.289 to 0.907) compared to TLS (-) patients. B cells in the tumor and TDLN determined the formation of TLSs. A higher percentage of B cells in the tumor / B cells in the TDLN correlated with a higher number of TLSs (p < 0.0001, r = 0.349). In addition, a high percentage of TIM-1 + B cells /B cells in the TDLN was correlated with a reduced percentage of mature TLSs (p < 0.001, r=-0.441). Conclusion This study demonstrated that B cells in the tumor and TDLN play critical roles in the formation and maturation of TLS. TIM-1 + B cell is a unique immunosuppressive B cell subset that impedes the maturation of TLS and could be a promising target for improving the maturation of TLS and the prognosis of LUAD. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-025-14913-3.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/08cd134726e0b592d4a519f4bacd9727687a03f9" target='_blank'>
              Effect of tumor draining lymph nodes in the formation and maturation of tertiary lymphoid structure in patients with lung adenocarcinoma
              </a>
            </td>
          <td>
            Junxu Wen, Wenhua Yun, Xiaoyan Yin, Xiangjiao Meng
          </td>
          <td>2025-10-03</td>
          <td>BMC Cancer</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Cryptococcal meningitis is a fungal infection in patients with compromised CD4 T cell function. CD4 T cells provide killing signals to macrophages, principally IFNγ, to limit intracellular fungal replication. However, CD4 T cells may also drive inflammatory tissue damage. Yet, it is not fully understood how fungal-specific CD4 T cells infiltrate the brain and how they influence functional phenotypes of CNS-resident myeloid cells. In the current work, we develop a mouse model to track fungal-specific CD4 T cells and determine their influence on microglia. We found IFNγ+ fungal-specific CD4 T cells have limited TCR signalling and characterise a population of inflammatory microglia that upregulate MHCII and IFNγ-regulated genes during infection. Inflammatory microglia have poor fungicidal capacity and significantly expand during infection, a process that depends on CD4 T cell infiltration. Taken together, these data identify the early inflammatory consequences of fungal-specific CD4 T cell infiltration and identify proliferating microglia as important drivers of brain inflammation during infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/37f4633c141c3226368499b170bc53f8df43b779" target='_blank'>
              Brain-infiltrating CD4 T cells drive inflammatory microglia proliferation during cryptococcal meningitis in mice
              </a>
            </td>
          <td>
            Sofia Hain, Man Shun Fu, Lucy Wigg, Lorna S. George, D. Lecky, Alexander J Whitehead, Erin Clipston, Ko Sato, Masahiro Ono, Marcel Wuthrich, Bruce Klein, Kazuyoshi Kawakami, J. Rayes, D. Bending, Rebecca A. Drummond
          </td>
          <td>2025-10-09</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Abstract Background Despite the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC), patient outcomes vary even among those with identical EGFR mutations. This study investigates whether osimertinib, a third-generation EGFR-TKI, activates the nucleotide-binding oligomerization domain-like receptor protein-3 (NLRP3) inflammasome in macrophages to drive antitumor immunity and explores its mechanistic basis. Methods Using bone marrow-derived macrophages from wild-type and gene-deficient mice, human peripheral blood mononuclear cells, and a Lewis lung cancer murine model, we assessed osimertinib-induced NLRP3 inflammasome activation, interleukin (IL)-1β secretion, pyroptosis, and tumor microenvironment (TME) remodeling. Mechanistic studies evaluated lysosomal dysfunction, calcium overload, mitochondrial damage, and reactive oxygen species (ROS) production. Clinical correlations were analyzed in patients with NSCLC treated with EGFR-TKIs. Results Osimertinib triggered NLRP3 inflammasome activation in macrophages via lysosomal dysfunction-induced calcium overload, leading to mitochondrial damage and ROS production, which acted as damage-associated molecular patterns to activate NLRP3. This process promoted IL-1β release, pyroptosis, and CD8+ T-cell activation while suppressing regulatory T cells in the TME. In murine models, osimertinib’s antitumor effects were abrogated by NLRP3 inhibition (MCC950) and enhanced by recombinant IL-1β (rIL-1β) co-administration (p<0.01). Clinically, high NLRP3 and IL-1β expression in tumor-associated macrophages (TAMs) correlated with prolonged progression-free survival (p<0.01) and overall survival (p<0.01) in EGFR-TKI-treated patients with NSCLC. Conclusions Osimertinib exerts off-target immunomodulatory effects by activating the tumor-extrinsic NLRP3 inflammasome, linking mitochondrial-lysosomal crosstalk to antitumor immunity. NLRP3 and IL-1β in TAMs emerge as predictive biomarkers for EGFR-TKI efficacy, while rIL-1β combination therapy represents a novel strategy to enhance clinical outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/863e1cef18a3ff1f96b29c912ef92adbf59c3495" target='_blank'>
              Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity
              </a>
            </td>
          <td>
            Haiyang Yu, Xin Sun, Yan Li, Jing Pan, Xuemei Liu, Hongbin He, Haibo Wu, Yubei Sun, Yueyin Pan, Xiaojun Qian
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Immunotherapy remains ineffective in many solid tumors due to poor T-cell infiltration and a metabolically suppressive tumor microenvironment. A dual strategy combining low-level light (LLL) therapy with a nanoscale stimulator of interferon genes (STING) agonist formulation (nanoSTING@Mn) is presented to enhance immune activation and metabolic fitness for durable tumor immunity against T-cell lymphoma (EL4) model. NanoSTING@Mn, composed of ADU-S100 complexed with Mn2⁺ and encapsulated in biomimetic liposomes, potently activates the cGAS-STING pathway, induces a type I interferon response, and promotes lymphocyte infiltration. These monocytes polarize into M1 macrophages, suppressing regulatory T cells. Simultaneously, LLL photo-biomodulation reprograms mitochondrial metabolism in tumor-infiltrating CD8⁺ T and natural killer cells, restoring their durability and leading to complete local tumor eradication. This combination expands a distinct CD8⁺ T-cell subset with Tcf-1⁺ progenitor-exhausted features and elevated memory/effector gene expression, enhancing proliferation and cytotoxicity, as shown by single-cell RNA sequencing. Intranasal nanoSTING@Mn delivery mobilizes these LLL-revived T cells to the lung, where they differentiate into resident memory T cells and establish systemic antitumor immunity. Upon intravenous rechallenge, disseminated tumor cells are eliminated, preventing metastasis and ensuring long-term protection. This synergistic approach offers a scalable platform to boost immunotherapy efficacy and redefines immune-based metastasis prevention strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2e9ba5699caa736e818a9807d89458c43c8a2b62" target='_blank'>
              Light Metabolically Reprograms CD8+ T Cells to Potentiate STING-Driven Tumor Eradication and Prevent Metastasis.
              </a>
            </td>
          <td>
            Asmita Banstola, Shilin Gao, ZhengKun Zhang, Yan Dong, Prabhat Upadhyay, Quanwei Zhang, Yongli Li, Zuan-Tao Lin, Zhilong Wang, Mei X. Wu
          </td>
          <td>2025-10-23</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="The efficacy of CD19 CAR-T cells in B-cell lymphoma patients is not as good as that in B-cell acute lymphoblastic leukemia (B-ALL) patients. This might be attributed to the intricate tumor microenvironment of B-cell lymphoma, which leads to CAR-T cell exhaustion, inability to sustain function, and difficulty infiltrating into the tumor interior. We developed CD19 CAR structures that simultaneously produce membrane-bound IL-15 (mbIL-15) and CXCR5. This design aims to enhance the migration of CAR-T cells into CXCL13+ B-cell lymphomas and their long-term antitumor ability. Compared with CD19 CAR-T cells, CD19 mbIL15-CXCR5 CAR-T cells exhibited greater cytotoxicity against CD19+ tumor cell lines in vitro. In particular, when exposed to recurrent tumor antigen stimulation, CD19 mbIL15-CXCR5 CAR-T cells still exerted long-lasting antitumor effects. CD19 mbIL15-CXCR5 CAR-T cells had a greater proportion of central memory T (TCM) and effector memory T (TEM) cells, which allowed them to exhibit more long-lasting antitumor effects. Moreover, in Transwell assays and mouse models, compared with CD19 CAR-T cells, CD19 mbIL15-CXCR5-CAR-T cells exhibited significant chemotaxis toward CXCL13+ tumor cells and superior tumor infiltration ability. The Xenogram animal model demonstrated better and more persistent tumor suppression ability than did the CD19 CAR-T cells. We preliminarily demonstrated the safety of CD19 mbIL15-CXCR5-CAR-T cells in vivo by evaluating liver and kidney function and major organ morphology in mice. In summary, the use of CD19 mbIL15-CXCR5-CAR-T cells is a relatively safe and effective option for the treatment of B-cell malignancies. Supplementary Information The online version contains supplementary material available at 10.1007/s10238-025-01860-3.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/984da11ad30bb4c6e74e1f03fcaa2f86bdf7da61" target='_blank'>
              A novel fourth generation of CAR-T cells: CD19 CAR-T cells engineered to express membrane-bound interleukin-15 and CXCR5 for the treatment of lymphoma
              </a>
            </td>
          <td>
            Xinping Cao, Jile Liu, Mohan Zhao, Shujing Guo, Meng Zhang, Xiaomei Zhang, Rui Sun, Yifan Zhao, R. Guo, Yi Zhang, Mingfeng Zhao
          </td>
          <td>2025-10-25</td>
          <td>Clinical and Experimental Medicine</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="The short lifespan of polymorphonuclear neutrophils (PMNs) in vitro poses challenges, as their limited viability restricts functional assays and experimental manipulations. The HL-60 cell line serves as a valuable model for neutrophil-like differentiation, yet the functional relevance of ATRA- and DMSO-induced differentiation remains incompletely understood. In the present study, we aimed to characterize the differentiation potential of all-trans retinoic acid (ATRA) and dimethyl sulfoxide (DMSO) on HL-60 cells and compare their functionality with primary PMNs. Besides that, we performed profound immunophenotypes of the cells with multicolor cytometry, and evaluated their antitumor capabilities. Our findings indicate that both differentiation conditions yield cells resembling immature neutrophils, exhibiting promyelocyte-like morphology, lacking key maturity markers. However, ATRA-differentiated cells exhibit a more mature phenotype, with higher expression of C/EBPα and reduced proliferation rates, indicating advanced differentiation. Functionally, ATRA-dHL-60 cells displayed limited immune responses, showing minimal phagocytic activity, low ROS production, and a reduced response to LPS. In contrast, DMSO-dHL-60 cells, despite their less mature phenotype, showed enhanced NET formation, and tumor-promoting potential. Additionally, DMSO-dHL-60 cells demonstrated superior adhesion and migration abilities, likely due to increased expression of CD18 and CD31. Overall, different differentiation conditions shape the functional specialization of HL-60 cells, with ATRA promoting a more neutrophil-like maturation and moderate activation, while DMSO results in a more immature phenotype with enhanced NET formation. These distinct properties suggest that ATRA-dHL-60 cells may better model neutrophils in chronic inflammation, whereas DMSO-dHL-60 cells could be more suitable for studying NETosis-driven autoimmune, thrombotic disorders and cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ba34cc673dca45ee20b6336553f4b45cb2eec70e" target='_blank'>
              Unraveling the functional landscape of ATRA- and DMSO-differentiated HL-60 cells
              </a>
            </td>
          <td>
            S. Ghonyan, David Poghosyan, A. Martirosyan, S. Margaryan, Aida Avetisyan, Z. Khachatryan, G. Manukyan
          </td>
          <td>2025-09-08</td>
          <td>PLOS One</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Cytotoxic T lymphocytes eliminate infected or malignant cells, safeguarding surrounding tissues. Although experimental and systems-immunology studies have cataloged many molecular and cellular actors involved in an immune response, the design principles governing how the speed and magnitude of T-cell responses emerge from cellular decision-making remain elusive. Here, we recast a T-cell response as a feedback-controlled program, wherein the rates of activation, proliferation, differentiation and death are regulated through antigenic, pro- and anti-inflammatory cues. We demonstrate how the speed and magnitude of T-cell responses emerge from optimizing signal-feedback to protect against diverse infection settings. We recover an inherent trade-off: infection clearance at the cost of immunopathology. We show how this trade-off is encoded into the logic of T-cell responses by hierarchical sensitivity to different immune signals. This model explains experimentally observed patterns of T-cell effector expansion regulation in mice. Extending our model to immune-based T-cell therapies for cancer tumors, we identify a trade-off between the affinity for tumor antigens (“quality”) and the abundance (“quantity”) of infused T-cells necessary for effective treatment. Finally, we show how therapeutic efficacy can be improved by targeted genetic perturbations to T-cells. Our findings offer a unified control-logic for cytotoxic T-cell responses and point to specific regulatory programs that can be engineered for more robust T-cell therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/54671a6a3aa477ee5cd8f17387b609ce783798c9" target='_blank'>
              Design principles of the cytotoxic CD8+ T-cell response
              </a>
            </td>
          <td>
            Obinna A. Ukogu, Zachary Montague, Grégoire Altan-Bonnet, Armita Nourmohammad
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Plasma cells (PCs) possess the unique capacity to produce antibodies (Abs), effectors of the humoral response against virtually all microbes and toxins, but also against self-antigens, participating in the development of autoimmune diseases (ADs). In recent years, it has become evident that PCs contribute in more ways than just secreting Abs, as their cytokine production, such as IL-10+LAG3+ PCs or IL-35+ PCs, partial complement activation, or their interaction with other cells are critical for immune homeostasis. Thus, PCs represent a heterogeneous immune compartment composed of several subsets with different functions in immunity and immunoregulation. These findings suggest that certain characteristics, such as surface markers of disease-specific PC subsets, allow targeting pathogenic PCs with high selectivity in various ADs. Selective targeting of pathogenic PCs is a fundamental part of precision medicine in ADs such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Long-lived PCs (LLPCs) that produce high-affinity antibodies and reside in the bone marrow are essential for protection against infections but are also generated during autoimmune responses and resist current therapies. A unique subset of CD19-lacking PCs (CD19- PCs) was found enriched in human bone marrow, while almost absent from blood, tonsils, and spleen. New therapies targeting pathogenic PCs while sparing protective and regulatory ones represent an unmet medical need in ADs, replacing current depletion strategies based on antibodies against pan-PC markers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a36e52815b5b81d3027a208581b718dcebb2a4d" target='_blank'>
              Targeting Plasma Cells in Autoimmune Diseases
              </a>
            </td>
          <td>
            Andreia C. Lino
          </td>
          <td>2025-09-17</td>
          <td>Crossover Science</td>
          <td>0</td>
          <td>0</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025'],
    y: [5],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>